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CHAPTER 1. Introduction 
 
1.1 CHEMICAL STABILITY STUDIES  
Chemical stability of drug molecule is a matter of great concern as it affects the safety and 
efficacy of the drug product.  
The Food and Drug Administration (FDA) and the International Conference on 
Harmonization (ICH) guidance state the requirement of stability testing data to understand 
how the quality of a drug substance and drug product changes with time under the influence 
of various environmental factors.  
In particular, the ICH guideline entitled “Stability Testing of New Drug Substance and 
Products” (ICH Q1A(R2), 2003) states that stress testing is intended to identify the likely 
degradation products which can in turn help establish the degradation pathways and the 
intrinsic stability of the molecule and validate the stability indicating power of the analytical 
procedures used. 
Forced degradation or stress testing is undertaken to demonstrate specificity when developing 
stability-indicating methods, particularly when little information is available about potential 
degradation products. Besides these studies also provide information about the degradation 
pathways and degradation products that could form during storage. Forced degradation 
studies may help facilitate pharmaceutical development as well in areas such as formulation 
development, manufacturing, and packaging, in which knowledge of chemical behavior can 
be used to improve a drug product.  
Even if the available regulatory guidance provides useful definitions and comments about 
degradation studies nonetheless it is very general concerning the scope, timing, and best 
practices for degradation studies. In particular, the issue of how much stress is adequate in 
stress testing is not addressed specifically. Overstressing a molecule can lead to degradation 
profiles that are not representative of real storage conditions and perhaps not relevant to 
method development, hence stress-testing conditions should be realistic and not excessive 
(Reynolds et al. 2002). It is stated that the testing should include the effect of temperature, 
humidity (where appropriate), oxidation, photolysis and susceptibility to hydrolysis across a 
wide range of pH values. However no details are provided about the practical approach 




duration, extent of degradation, etc. Nevertheless some general indications on how to best 
conduct forced degradation studies can be found in literature and are here mentioned. 
1.1.1 Experimental approach  
Forced degradation studies should be conducted whenever a stability-indicating method is 
required. Studies may need to be repeated as methods, processes, or formulations change.  
Forced degradation studies of active pharmaceutical ingredient (API) and drug product (DP) 
include appropriate solid state and solution state stress conditions (e.g. acid/base hydrolysis, 
heat, oxidation, and light exposure) in accordance with ICH guidelines.   
Since it is advisable that the stress conditions should result in approximately 5–20% 
degradation of the API, the specific conditions (intensity and duration) used will depend on 
the chemical characteristics of the API. The stressed sample should be compared to the 
unstressed sample (control) and the appropriate blank. Finally, a compound may not 
necessarily degrade under a given stress conditions hence no further stressing is advised in 
these cases (Alsante et al. 2007). 
 
1.1.2 Degradation conditions 
1.1.2.1 Hydrolytic conditions 
Hydrolytic reactions are among the most common processes for drug degradation. 
Hydrochloric acid or sulfuric acid (0.1–1 mol/L solution) for acid hydrolysis and sodium 
hydroxide or potassium hydroxide (0.1–1 mol/L solution) for base hydrolysis are suggested as 
suitable reagents for hydrolysis. Studies should be carried out in the solution state. For certain 
APIs that are partially soluble or insoluble in the described acidic or basic solution, addition 
of an appropriate co-solvent, may be required to achieve dissolution. Additionally, the sample 
may be heated for a defined time/temperature to accelerate degradation, depending on the API 
sensitivity to heat. 
 
1.1.2.2 Oxidation  
Oxidation can be carried out under an oxygen atmosphere or in the presence of peroxides. The 
use of oxygen is a more realistic model. Free radical initiators may be used to accelerate 
oxidation. Generally, a free radical initiator and peroxide will produce all primary oxidation 
degradation products observed on real-time stability. Therefore, free radical and/or hydrogen 




For solution state stress conditions, dissolve the API utilizing an appropriate solvent, add 5–
20 mol% of a free radical initiator at atmospheric pressure. To increase the solubility of 
oxygen in the solution, the reaction can be performed in a reaction vessel pressurized at 50–
300 psi with molecular oxygen. Additionally, the system is heated to accelerate degradation. 
The temperature depends on the free radical initiator selected. 
For peroxide conditions, hydrogen peroxide reagent (up to 3%) can be used. As previously 
indicated, the addition of an appropriate co-solvent may be necessary, depending on API 
solubility. Hydrogen peroxide stress testing can be useful in DP studies where hydrogen 
peroxide is an impurity in an excipient. Solid-state stress conditions may be similarly 
investigated by placing the API (as is) in suitable closed containers filled with an oxygen 
headspace versus an argon or nitrogen control headspace. Additionally, the sample may be 
heated for a defined time/temperature to accelerate degradation, depending on the API 
sensitivity to heat. 
For later stage development compounds when more time and effort can be focused on 
mechanistic understanding, the following oxidation conditions can be applied. The addition of 
metal ions to solutions of API can indicate whether there is a tendency for the API to be 
catalytically oxidized; indeed iron and copper ions are routinely found, as impurities, in APIs 
and formulation excipients. Transition metal ions can also reduce peroxide to generate 
hydroxyl radicals in a Fenton-type reaction. In addition, light can also effect oxidation 
reactions. Light absorbed by a photosensitizer can react with molecular oxygen to form the 
more reactive singlet oxygen species (Alsante et al. 2007). 
 
1.1.2.3 Thermal/humidity  
Solid state stability can be evaluated utilizing accelerated storage temperatures in general 
greater than 50 °C and > 75% relative humidity. The duration of exposure is dependent on the 
API sensitivity. If the forced degradation thermal/humidity conditions produce a phase 
change, it is recommended to also run thermal/humidity conditions below the critical thermal/ 
humidity that produces the phase change. 
 
1.1.2.4 Photostability  
The studies should be performed in accordance with ICH photostability guidelines (ICH Q1B, 
1996) using Option 1 and/or Option 2. According to the ICH guideline, “the design of the 




levels should be justified. The recommended exposures for confirmatory stability studies are 
an overall illumination of not less than 1.2 million lux hours and an integrated near ultraviolet 
energy of not less than 200 W-h/m
2
. 
1.1.3 Drug product  
Drug product (DP) degradation cannot be predicted solely from the stability studies of the 
API in the solid state or solution. The non-active pharmaceutical ingredients can also react 
with the API or catalyze degradation reactions. Impurities in the excipients can also lead to 
degradation in the DP not originally observed in the API. For DP formulations, heat, light, 
and humidity are often used. The DP stress conditions should result in approximately 5–20% 
degradation of the API or represent a reasonable maximum condition achievable for a given 
formulation. The specific conditions used will depend on the chemical characteristics of the 
DP. For a solid DP, key experiments are thermal, humidity, photostability and oxidation, if 
applicable. For solution formulations, key experiments are thermal, acid/ base hydrolysis, 
oxidation and photostability. It is recommended to compare stressed samples with unstressed 
samples and an appropriate blank. For DP studies, the blank sample is an appropriate placebo. 
The stressed placebo sample will provide information about excipient compatibility. It is 
advised to take kinetic time points along the reaction pathway for API and DP degradation 
studies to determine primary degradants and a better understanding of the degradation 
pathway. 
 
1.1.4 Stability-indicating method development  
A stability-indicating method is defined as an analytical method that accurately quantitates the 
active ingredients without interference from degradation products, process impurities, 
excipients, or other potential impurities. A method that accurately quantitates significant 
degradants may also be considered stability-indicating.  
Forced degradation should be the first step in method development. If forced degradation 
studies are performed early, method development and identification of primary degradation 





1.2 METABOLIC STABILITY STUDIES  
The drug development process involves several steps, from target identification and 
screening, lead generation and optimization, preclinical and clinical studies to final 
registration of a drug (Baranczewski et al., 2006). During the preclinical screening stage the 
main pharmacokinetic, pharmacodynamic, and toxicological properties of the candidate drug 
are investigated. Accordingly, efforts are being made to reduce attrition of drug candidates 
during the various stages of their development while bringing safer compounds to market. 
Among the major reasons for new chemical entities NCEs failure, other than poor clinical 
efficacy, are serious undesired side effects, adverse drug reactions, and unfavorable drug 
metabolism and pharmacokinetics (Prakash et al., 2007).  
During the past years, pharmaceutical companies have invested and introduced a number of 
new approaches dedicated to improve the rate of success of development of new drugs. One 
of the new strategies is an in vitro approach for early determination and prediction of drug 
metabolism of NCEs. The use of in vitro methodology in drug metabolism studies has several 
advantages. First, it allows for determination of metabolic profiles of NCE early in the drug 
discovery process, and, therefore, this information can be used to guide further modifications 
of NCE in order to obtain favorable metabolic properties. Secondly, since it is possible to use 
human enzymes, cells and liver subcellular fraction the data are more relevant for the human 
in vivo situation. Finally, the in vitro approach is cost and time effective (Baranczewski et al., 
2006). 
Metabolism is a biochemical process by which endogenous compounds and xenobiotics (such 
as drugs) are converted to more hydrophilic (water soluble) entities, which enhance their 
elimination from the body. In general, metabolites are pharmacologically less active and less 
toxic than their corresponding parent compound. However, it is not uncommon that 
biotransformation reactions also lead to undesirable consequences, such as too rapid drug 
clearance, formation of pharmacologically active metabolites, drug-drug interactions via 
inhibition or induction of drug metabolizing enzymes, and/or formation of toxic metabolites. 
Therefore, determination of an NCE’s metabolic rate, biotransformation pathways in animals 
and humans, and pharmacological and toxicological consequences of its metabolites are very 
critical to pharmaceutical research and compound progression (Prakash et al., 2007). 
Biotransformation occurs in many tissues, with the liver as the most important organ, but also 




of the human body and is strategically located between the digestive tract and the other parts 
of the body (Brandon et al., 2003). 
 
1.2.1 Xenobiotics biotransformation 
Drug biotransformation is divided into two types of reactions, namely phase I 
(functionalization) and phase II (conjugation). The biotransformation pathway is mediated by 
phase I, phase II, or a combination of both.  
Phase I include: hydroxylation (aliphatic, aromatic, or nitrogen), epoxidation (aliphatic, 
aromatic), dealkylation (O-, N-, or S-), deamination, oxidation (N-, or S-), reduction (nitro, 
azo, disulfide, keto, aldehyde, olefin), and hydrolysis (amide, ester, carbamate, epoxide). 
These reactions introduce or unmask a functional group (e.g., –OH, –COOH, –NH2, or –SH) 
within a molecule to enhance its hydrophilicity. These Phase I reactions are mediated 
primarily by liver enzymes, such as cytochrome P450 (CYPs), FAD-containing mono-
oxygenases (FMOs), monoamine oxidases (MAOs), aldehyde oxidase/xanthine oxidase 
(AO/XO), alcohol dehydrogenase (ADH), aldo-ketoreductase (AKR), esterases, 
dehydropeptidase, and epoxide hydrolase (EH). 
Phase II biotransformations include: glucuronidation, sulfation, methylation, acetylation, and 
amino acid (glycine, glutamic acid, and taurine) and glutathione (GSH) conjugation. Phase II 
reactions are catalyzed by conjugative enzymes, such as UDP-glucuronyltransferase (UGT), 
sulfotransferase (SULT), glutathione S-transferase (GST), N-acetyltransferase (NAT), and 
methyl transferase (N-methyl-, thiomethyl-, and thiopurinemethyl-). Glutathione conjugates 
are further metabolized to cysteine and N-acetyl cysteine adducts (i.e., mercapturic acid 
synthesis). Most phase II reactions result in a concomitant increase in hydrophilicity and 
decrease in volume of distribution of the metabolized compounds, facilitating  their excretion 
from the body (Prakash et al., 2007). Some of the most important and common enzyme 
systems involved in drug biotransformation are presented in Figure 1. 
 




Finally it is becoming increasingly apparent that drug transporters (phase III) influence not 
only the therapeutic efficacy but also the absorption, distribution, and elimination of a drug. 
The drug transporters are located in epithelial and endothelial cells of the liver, 
gastrointestinal tract, kidney, blood–brain barrier, and other organs. They are responsible for 
the transport of most of the commonly prescribed drugs across cellular barriers and thus for 
the concentration at the target or biotransformation site. Multidrug resistance proteins (MRP; 
p-glycoprotein and others) have been shown to be important in explaining the 
pharmacokinetics of a drug in man. 
 
1.2.2 Cytochrome P450 
Among the phase I enzymatic systems the CYP system is a superfamily of membrane-bound, 
heme-containing mixed-function oxygenases that are the principal enzyme system for the 
metabolism of drugs (Figure 1). These enzymes are expressed in many tissues, but are found 
at the highest levels in liver. CYPs principally function to introduce oxygen into a molecule to 
increase the hydrophilicity of the product and hence, the ease with which the product can be 
eliminated from the body. A nomenclature for these enzymes has been developed based on 
similarities in amino acid sequences. The catalytic activities of CYPs (Figure 2) require 
molecular oxygen and reducing equivalents from NADPH as summarized by the reaction 
below reported: 
 
ROH + NADPH + O2 + H
+
  ROH + NADP
+
 + H2O 
 
The flavoprotein NADPH-cytocrome P450 reductase is associated to the CYPs catalyzing the 
electron transfer from NADPH to cytocrome P450 through the coenzymes flavin-adenine 
dicucleotide (FAD) and riboflavin 5'-phosphate (FMN) (Figure 3). In addition, another 
membrane-bound, heme-containing protein, NADPH-cytocrome b5 reductase, stimulates the 










Figure 3. Molecular components constituent of cytocrome P450 system. 
 
There are 11 xenobiotic-metabolizing CYPs that are expressed in a typical human liver 
(CYP1A2, CYP2A6, CYP2B6, CYP2C8/9/18/19, CYP2D6, CYP2E1, and CYP3A4/5). A 
relatively limited subset of these enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4) appears to be most commonly responsible for the metabolism of drugs and 
associated drug-drug interactions. The relative importance of this subset of enzymes is due to 
both the mass abundance of these enzymes (e.g., CYP3A4 is the most abundant P450 in 
human liver at ~30% of total P450) and the preference of these enzymes to bind and/or 




Human populations exhibit considerable variability in CYP activity levels. This is due to the 
fact that some human CYP enzymes are polymorphic, with a significant percentage of 
populations being deficient in a specific enzyme or having a functional enzyme with an 
altered amino acid sequence, which can change the kinetics of substrate metabolism. 
Expression levels of specific CYP enzymes vary substantially among individuals. The levels 
of other human CYP enzymes (e.g., CYP1A2 and CYP3A4) are induced by certain 
environmental exposures or drug treatments (Table 1). If an enzyme, which is polymorphic or 
subject to environmental regulation, is rate-limiting for the elimination of a drug, then 








1.2.3 In vitro models to study drug metabolism 
A key question in human drug biotransformation research is how to make reliable 
extrapolations from the in vitro or in vivo model to clinical practice. 
Several in vitro models have been developed in the past. They are used to obtain early 
information about biotransformation pathways and to predict drug-drug interactions. The 
optimal model system depends on a number of factors, such as in vivo resemblance, expense, 
availability of the model, and ethical considerations. In vitro data from human and animal 
models can be used to choose the best in vivo model (e.g., mouse, rat, dog) for further testing. 
In conclusion, it can be stated that an in vitro model is always a compromise between 
convenience and relevance. 
 
1.2.3.1 Liver microsomes 
Microsomes can easily be prepared from different tissues, most commonly from the liver of 
animals and human donors. Therefore, human liver microsomes (HLM) have become a very 
commonly and widely used in vitro model. Liver microsomes consist of vesicles of the 
hepatocyte endoplasmic reticulum and are prepared by differential centrifugation and thus 
contain almost only CYP and UGT enzymes (Figure 4).  
 
 
Figure 4. Liver fractions preparation  
 
The enzymatic activities are stable during prolonged storage of the microsomes. In order to 
reflect the standard proportion of the enzymes in human or animal livers, liver microsomes 




appropriate cofactors and other reaction components, it is possible to investigate and 
distinguish between CYPs, flavin-containing monooxygenase (FMO) and 
glucuronosyltransferase (UGT) activities.  
The major advantages of microsomes are low costs, simplicity in use, and they are one of the 
best-characterized in vitro systems for drug biotransformation research. However, some major 
drawbacks exist. It should be noted that results obtained with microsomes cannot be used for 
quantitative estimations of in vivo human biotransformation, because CYPs and UGTs are 
enriched in the microsomal fraction and there is no competition with other enzymes (e.g., 
NAT, GST, and SULT) with the consequence that metabolites formed in intact liver could be 
unnoticed. 
 
1.2.3.2 Liver cytosol fractions  
The liver cytosolic fraction contains the soluble phase II enzymes, e.g., NAT, GST, and 
SULT. It is obtained by differential centrifugation of whole-liver homogenate, like 
microsomes (Figure 4). For the catalytic activity of the phase II enzymes, addition of 
exogenous cofactors, e.g., acetyl coenzyme A (acetyl CoA), dithiothreitol (DTT), and acetyl 
CoA regenerating system for NAT, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) for 
SULT, and glutathione (GT) for GST, is necessary.  
The main advantage of cytosol fraction is the presence of only three enzymes at higher 
concentrations compared to human liver S9 fraction. The biotransformation capacity of NAT, 
SULT, and GST can be studied separately or in combination depending on the cofactors 
added. A disadvantage is that only the soluble phase II enzymes are present in the liver 
cytosol fraction and that therefore the UGTs, which are located on the endoplasmic reticulum, 
metabolic pathways cannot be investigated with this model. 
 
1.2.3.3 Liver S9 fractions 
The liver S9 fraction contains both microsomal and cytosolic fractions. Like microsomes, a 
NADPH-regenerating system or NADPH solution is required to supply the energy demand of 
the CYP enzymes, as well as for the catalytic activity of phase II enzymes, addition of 
exogenous cofactors is necessary. 
Compared with microsomes and cytosol, S9 fractions offer a more complete representation of 




S9 fractions, metabolites that are not produced by either the cytosolic fraction or the 
microsomal fraction alone are formed.  
 
1.2.3.4 Human CYP and UGT supersomes (baculovirusinsect-cell-expressed) 
Insect cells lack endogenous CYP and UGT activity and, therefore, microsomes, which 
consist of vesicles of the hepatocyte endoplasmic reticulum, of human CYP- or UGT 
transfected insect cells can be a useful tool in human biotransformation studies. Since the 
expression is baculovirus mediated, microsomes of these cells are sometimes referred to as 
baculosomes, but more often as supersomes™. The availability of specifically expressed 
human CYPs and UGTs in supersomes allows the investigation of the contribution of a single 
metabolic enzyme to the biotransformation pathway of the compound under investigation. At 
present all common human CYPs, coexpressed with NADPH-cytochrome P450 reductase and 
optionally cytochrome b5, and UGTs are offered in supersomes™. A control experiment, an 
incubation with nontransfected supersomes, must always be conducted. NADPH-regenerating 
system or NADPH is required to supply the energy demand of the CYPs as well as UDPGA 
for the UGT activity has to be added as a cofactor. A major advantage of supersomes is that 
they can be used to study not only isozyme-specific drug biotransformation, but also drug–
drug interactions. In the past few years the development of new CYP and UGT supersomes™ 
has increased considerably. The different genotypes of the CYP isozymes (e.g., CYP2C9*1, 
CYP2C9*2, and CYP2C9*3) are now also commercially available 
(https://www.corning.com). Hence, the influence of different polymorphisms on the drug 
biotransformation pattern also can be studied. 
A disadvantage is that, in UGT supersomes, the UGT active site is shielded behind a 
hydrophobic barrier, resulting in latency of glucuronidations. However, this disadvantage can 
be overcome by using a pore-forming agent, alamethicin. 
 
1.2.3.5 Hepatocytes  
Primary hepatocytes 
Primary hepatocytes are a popular in vitro system for drug biotransformation research due to 
their strong resemblance of in vivo human liver. Human liver is mainly obtained from patients 






Once isolated, hepatocytes can be held in suspension, in which case they remain viable for 
only a few hours, or they can be maintained in monolayer culture for a maximum of 4 weeks. 
Both cultured hepatocytes and suspensions of primary hepatocytes have repeatedly proven to 
be powerful tools to analyze the specific metabolic profile of a variety of drugs with good in 
vitro–in vivo correlations However, it has been widely recognized that cultured hepatocytes 
are subject to a gradual loss of liver-specific functions, with special reference to a decreased 
CYP expression. This loss is different for the specific CYP isoforms; for some isoforms it 
becomes evident after a few days of culture (CYP 2E1 and CYP 3A4), while others remain 
nearly unaffected by the isolation and culturing processes (CYP 1A2 and CYP 2C9). An 
advantage of isolated hepatocytes compared to liver slices and perfused liver is the possibility 
of cryopreservation. Indeed cryopreserved hepatocytes have been shown to retain the activity 
of most phase I and phase II enzymes. A disadvantage is the lack of liver nonhepatocyte cells. 
Although hepatocytes account for the vast majority of the liver volume (about 80%), other 
cells such as Kupffer cells may be necessary for cofactor supply. Another problem 
encountered with human hepatocytes, as with human liver microsomes, is the considerable 







1.3 PROPARGYLAMINE-CONTAINING DRUGS 
1.3.1 Neurodegenerative disorders 
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are conditions constituting part of the 
broad cluster of diseases commonly referred to as neurodegenerative disorders (ND).  
A classical feature of these diseases is the transient loss of neuronal cells in the brain due to 
apoptosis triggered by one of many factors including genetic, endogenous and environmental 
ones. Although each disease has its own molecular mechanisms and clinical manifestations, 
some general pathways might be recognized in different pathogenic cascades. They include 
protein misfolding and aggregation, oxidative stress and free radical formation, metal 
dyshomeostasis, mitochondrial dysfunction, and phosphorylation impairment, all occurring 
concurrently (Cavalli et al., 2008).  
The multifactorial nature of NDs suggests that targeting any single mechanistic site will not 
result in successful retardation of the disease progression and many “single-site-targeting” 
drugs have failed to render sufficient neuroprotective and/or neurorestorative activity. The use 
of drugs aiming to a single receptor or enzymatic system is thus insufficient for treatment of 
these multifactorial diseases (Zindo et al., 2015).  
It is now widely accepted that a more effective therapy would result from the use of 
multitarget-directed ligands (MTDLs) able to intervene in the different pathological events 
underlying the etiology of neuronal disorders. To obtain novel MTDLs, a design strategy is 
usually applied in which distinct pharmacophores of different drugs are combined in the same 
structure to afford hybrid molecules. In principle, each pharmacophore of these new drugs 
should retain the ability to interact with its specific site or sites on the target and, 
consequently, to produce specific pharmacological responses that, taken together, should slow 
or block the neurodegenerative process (Cavalli et al., 2008).  
The last few decades have seen increasing research interest and exploration of the 
neuroprotective ability of compounds bearing propargylamine function seen in selegiline and 
rasagiline. The propargylamine moiety is now known to play an important role in providing 
the neuronal and mitochondrial protective properties inherent in these compounds and other 
reported activities ascribed to this moiety in literature include antiapoptotic and amyloid-β 
(Aβ) aggregation inhibition. These features of the propargylamine moiety have led to its 
incorporation into structures of many drug-like compounds designed for neuroprotection to 
afford resultant molecules with broader therapeutic profiles that may potentially meet the 




1.3.2 Alzheimer’s Disease (AD) 
Alzheimer’s disease (AD) stands out among neurodegenerative disorders as the fourth leading 
cause of death and the most common cause of acquired dementia in the elderly population, 
afflicting more than seven million people worldwide (Cavalli et al., 2008). 
The predominant clinical manifestation is progressive memory deterioration and changes in 
brain function, including disordered behaviour and impairment in language and 
comprehension, which progressively worsen over 5–10 years. Most of these cognitive 
symptoms result from a depletion of basal forebrain cholinergic neurons leading to decreased 
cholinergic neurotransmission. Besides the cognitive deficits, patients frequently exhibit 
neuropsychiatric symptoms such as depression, psychosis and agitation.  
From the histopathological viewpoint, two characteristic hallmarks accompany these features: 
the neurofibrillary tangles (NFT) which are intracellular fibrillar deposits mainly composed of 
the microtubule-associated protein tau, and the senile plaques (SP), formed by deposition of 
the aggregated amyloid-β peptide (Aβ). Although the pathogenesis of AD is not yet fully 
understood, it is a multifactorial disease triggered by several factors, including excessive 
protein misfolding and aggregation, oxidative stress and free radical formation, mitochondrial 
dysfunction, metal dyshomeostasis, excitotoxic and neuroinflammatory processes. In addition 
to the cholinergic dysfunction, disturbances in other neurotransmitter systems such as the 
monoaminergic have also been reported to account for AD symptoms (Bolea et al., 2012). 
 
Of the above-mentioned hypotheses, the cholinergic one is the oldest and it has also had the 
strongest influence on the development of clinical treatment strategies, which led to the 
introduction of the acetylcholinesterase inhibitor (AChEI) tacrine (1), donepezil (2), 






Figure 5.  
 
These drugs have become the standard for AD therapy and, although beneficial in improving 
cognitive, behavioral, and functional impairments, they seem unable to address the molecular 
mechanisms that underlie the pathogenic processes. 
 
1.3.3 Parkinson’s disease (PD) 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Like AD, it 
is currently an incurable disease. The available pharmacological therapies are unable to arrest 
or reverse the neurodegeneration associated with PD.   
PD is characterized by the progressive loss of dopaminergic neurons in the substantia nigra 
pars compacta and other subcortical nuclei and by the presence of intraneuronal aggregates 
known as Lewy bodies (LBs), which are enriched in filamentous α-synuclein and other 
proteins that are often ubiquitinated. Depletion of dopamine (DA) causes dysregulation of the 
motor circuits that project throughout the basal ganglia, resulting in the clinical manifestations 
of PD, which include tremor, bradykinesia, rigidity, and postural instability. However, 
additional neurotransmitter systems are also involved in PD and, consequently, 
nonadrenergic, serotoninergic, and cholinergic neurons are also lost. This loss is responsible 
for nonmotor symptoms, such as cognitive decline, sleep abnormalities, and depression, 
which dominate the later stages of PD (Cavalli et al. 2008). 
The crucial molecular step of PD pathogenesis is the formation of LBs, whose key constituent 
is represented by α-synuclein, a cytoplasmic soluble protein that contains a highly 




and is converted into pathological oligomers and higher-ordered aggregates, which fibrillize 
and deposit into LBs as β-pleated sheets. Therefore, maintaining α-synuclein in the native and 
soluble random coil conformation, and consequently preventing α-synuclein-mediated neuron 
toxicity, emerges as a clear goal of innovative disease-modifying PD therapies. Moreover 
treatment with antioxidants might theoretically be of benefit in preventing neurodegeneration. 
 
Despite an increased understanding of the molecular causes of PD, current PD therapies are 
based mainly on exogenous replacement of DA within the striatum. This improves the 
symptoms but without halting the progression of the neurodegenerative process or reversing 
the neuronal degeneration. Furthermore, although PD also involves degeneration of non-
dopaminergic neurons, the treatment of the resulting predominantly non-motor features 
remains a challenge. Depletion of striatal DA from the loss of nigral projections is the main 
target for the currently available drugs. The classes of compound that still hold a prominent 
position in current anti-PD drug discovery are reported in Table 2. 
 
Mechanism of action Drugs 
DA precursor (prodrug) L-dopa 
COMT inhibition Entacapone, Tolcapone 
MAO-B inhibition Selegiline, Rasagiline 
Dopaminergic receptor agonism  
(ergot derivative) 
Bromocriptine, Pergolide, Cabergoline, 
Lisuride 
Dopaminergic receptor agonism  
(non-ergot derivative) 
Ropinirole, Pramipexole, Piribedil 
Muscarinic receptor antagonism Biperiden, Triexyphenidyl, Metixene 
Ion channel blockade Amantadine 




Levodopa (L-dopa) is the key compound in the treatment of PD, acting as a precursor of DA. 
However, besides offering only symptomatic relief for patients, this drug shows substantial 
side effects at the high doses required for therapeutic action. 
Certain other available drugs, like MAO-B (selegiline and rasagiline) and COMT (entacapone 
and tolcapone) inhibitors, are used mainly with L-dopa, since they alter the in vivo 




biperiden, triexyphenidyl) were among the first drugs used for PD therapy, since they were 
intended to correct the imbalance between DA and acetylcholine (ACh) brain levels. More 
recent therapeutic approaches to PD are represented by nicotine, anti-inflammatory agents, 
melatonin, selenium, iron chelators, and vitamins A, C, and E. 
As previously mentioned, none of these therapies are able to arrest or reverse the progression 
of PD probably because these compounds treat only the symptoms of the disease rather than 
tackling the actual molecular PD causes. Moreover, the currently available drugs have been 
shown to interact with a single molecular target, instead of confronting the multifactorial 
nature of PD neurodegeneration.  
 
1.3.4 Monoamine oxidase  
Monoamine oxidase (MAO, E.C.1.4.3.4) is a flavin-containing enzyme that catalyses the 
oxidative deamination of a wide range of biogenic and xenobiotic amines, including 
dopamine (DA), noradrenaline, adrenaline, tyramine, serotonin (5-HT). This enzyme is 
known to exist in two isoforms namely MAO-A and MAO-B, which show different 
selectivities for substrates and inhibitors. The enzyme is inserted in the outer mitochondrial 
membrane, and is widely distributed in the body tissues, with a high degree of expression in 
the gastro-intestinal tract and liver, as well as neuronal tissue, and nearly all other organs. 
Monoamine oxidase A and B catalyze the oxidation of primary, secondary, and some tertiary 
amines to their corresponding aldehyde, hydrogen peroxide and ammonia (in case of primary 
amines) or a substituted amine (in case of secondary and tertiary amines) in a reaction shown 
below: 
 
RCH2NH2 + H2O + O2  RCHO + NH3 + H2O2 
 
Selective inhibitors for MAO-A have been shown to be effective antidepressants, whereas 
MAO-B inhibitors are useful for the treatment of Parkinson’s disease. The neuroprotective 
effect of monoamine oxidase inhibitors (MAOIs) in these disorders may result not only from 
the increased amine neurotransmission, but also from prevention of neurotoxic product 
formation, which promotes reactive oxygen species (ROS) generation and may ultimately 
contribute to increased neuronal damage. Despite some disadvantages found in using MAOIs 
in clinical practice, such as hepatotoxicity and the so-called ‘‘cheese-effect’’, which describes 




MAO enzymes remain in the focus of drug design targeting neurodegenerative disorders. 
Nevertheless, it seems at present unlikely that the neuroprotective activities of MAOIs are 
exclusively related to the ability to decrease the production of free radicals and toxic 
aldehydes via the inhibition of enzymatic activity. With regard to this, several studies have 
suggested that they are rather related to the anti-apoptotic properties of the propargyl group 
present in these molecules (Bolea et al., 2014). 
 
1.3.5 Propargylamines 
Propargylamines are molecules containing a propargyl moiety that typically inhibits MAO-B 
including the well characterized compounds selegiline (l-deprenyl), rasagiline and PF9601N 
(Fig. 6).  
 
 
Figure 6. Propargylamine-derived MAOIs (the propargylamine moiety is highlighted with dotted lines) 
 
While selegiline was the first selective MAO-B inhibitor used clinically for the treatment of 
Parkinson’s disease, rasagiline and PF9601N belong to a second generation of MAO-B 
inhibitors that, unlike selegiline, do not generate amphetamine derivatives when metabolized. 
Since these compounds possess anti-apoptotic properties independent from their ability to 
inhibit MAO-B, diverse mechanisms have been suggested to be involved in the 








Figure 7. Schematic representation of the sites of action of propargylamine-derived compounds as potential 
targets for AD treatment figure taken from Bolea et al. (2014) 
 
One of these mechanisms involves a significant antioxidant potency arising from the increase 
in the activities of superoxide dismutase (SOD) and catalase (CAT) enzymes, besides the 
prevention of the MAO reaction products formation, which are potentially neurotoxic since 
they contribute to oxidative stress and the formation of ROS.  Moreover, the anti-apoptotic 
activity of these molecules has been attributed to their ability to prevent the fall in 
mitochondrial membrane potential (Ψm) and the blockade of the permeability transition pore 
(PTP) opening as a consequence of the up-regulation of Bcl-2 family protein and activation of 
protein kinase C (PKC) and mitogen-activated protein kinase (MAPK). These pathways may 
be additionally involved in the effect of propargylamines on the enhanced release of the non-
amyloidogenic α-secretase form of soluble amyloid precursor protein (sAPPα), which 
precludes the formation of amyloid derivatives promoting the non-amyloidogenic pathway of 
APP processing. Further neuroprotective effects have been related to the induced increase in 








1.3.6 Multitarget-directed ligands (MTDLs) strategy 
The advent of MTDL approach has now seen many researchers develop a number of 
compounds that can potentially confer neuroprotection by acting simultaneously on different 
receptors and target sites implicated in NDs. This approach has yielded a wide amount of 
interesting MTDLs to halt NDs: some examples of propargylamine-derived compounds as 
promising neuroprotective agents are here mentioned. 
 
1.3.6.1 MAO/AChE inhibitor  
A successful approach of combined MAO/AChE inhibition came from the combination of the 
carbamate moiety of rivastigmine (figure 5) with the indane scaffold present in the MAO-B 






Ladostigil is able to inhibit both AChE and butyrylcholinesterase (BuChE) for a longer time 
than the parent compound rivastigmine. In addition, ladostigil selectively inhibits brain MAO-
A and MAO-B resulting in an increase in noradrenaline, dopamine and serotonine levels, and 
thus exerting an antidepressant action. Ladostigil has also been shown to retain the 
neuroprotective and anti-apoptotic properties observed in the parent compound and 
propargylamine-derived rasagiline. Besides, ladostigil also possesses a cognition enhancing 
activity and is the most advanced MTDL on its category as demonstrated by the promising 
results obtained from a phase 2 clinical trial.  
 
1.3.6.2.MTDLs targeting MAO and iron 
It has been reported that iron contributes to Aβ aggregation, which in turn contributes to 
neuronal degeneration through the induction of oxidative stress. A link between high iron 





reported. To address these problems, Youdim and collaborators have developed compounds 
with a bi-functional action on iron chelation and MAO inhibition obtained by combining the 
iron-chelating and antioxidant scaffold of VK28 with the N-propargylamine moiety of 
rasagiline. The most interesting compounds obtained were M30 and HLA20 (Fig. 9) 






M30 and HLA20 possess neuroprotective properties comparable to rasagiline and potently 
inhibit the iron induced membrane lipid peroxidation features. More importantly, M30 has 
been shown to selectively inhibit brain MAO (A and B) enzymes and to increase serotonin, 
dopamine and adrenaline neurotransmission, which confers to this multipotent compound an 
antidepressant action besides preventing the potentiation of tyramine-induced cardiovascular 
activity. Interestingly, M30 inhibits the Aβ aggregation induced by metals and reduces Aβ 







The complex pathogenesis and etiology of neurodegenerative diseases make it clear that drugs 
targeting a single receptor or enzymatic system will not result in successful retardation and 
treatment of these multifactorial diseases. This is even more evident in that drugs used in the 
symptomatic treatment of these diseases fail to render sufficient neuroprotective and/or 
neurorestorative activity. The advent of MTDL approach has however seen the development 
of compounds that combine symptomatic treatment and neuroprotection in one molecule by 
acting simultaneously on different receptors and target sites implicated in NDs. 
Compound bearing the propargylamine function have received significant attention based on 
the neuroprotective ability observed for the MAO-B inhibitors selegiline and rasagiline. This 
has led to its incorporation into many drug-like compounds designed for neuroprotection and 
to afford molecules with broader therapeutic profiles to potentially meet the curative needs of 
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CHAPTER 2. Aim of the work 
 
Chemical stability studies were performed on both drug substance and drug product to 
guarantee their efficacy, quality and safety and fulfill the requirements of regulatory 
authorities. In this area, forced degradation studies provide useful data to support: the intrinsic 
stability of the drug molecule, through the identification of possible degradants and the 
corresponding degradation pathways, and the development and validation of stability-
indicating analytical procedures. 
On the other hand, metabolic stability studies were performed on drugs to identify the 
metabolites arising from phase I and phase II reactions while delineating the corresponding 
metabolic pathways; these studies have become an integral part of the drug 
discovery/development process while playing a role also in post-marketing phase. Since drug 
metabolites may have intrinsic pharmacological activity or display specific toxicity, their 
knowledge is relevant for both pharmacokinetic, pharmacodynamic and for toxicokinetics. 
Generally, in academic research, chemical and metabolic stability studies were not conducted 
in an integrated manner being preferably done from researchers having different expertise. 
However, since the intrinsic stability of drugs can be strictly related to its metabolic stability, 
the integration of both aspects of stability could be conveniently performed defining a unique 
chemical and metabolic stability space. 
In this work the chemical and metabolic stability of three propargylamine-containing drugs, 






The interest regarding this class of drugs arises from the analyses in the course of stability 
studies performed on new formulations of oxybutynin hydrochloride (Oxy), a tertiary 
propargylamine used for the management of urinary frequency, urgency and incontinence in 
neurogenic bladder disorders. During the study, a new and unprecedented degradation product 
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was identified in topical formulations, whose structure and mechanism of formation has been 
determined through a forced degradation study. These results prompted us to extend the study 
of chemical and metabolic stability to other propargylamine-containing drugs. Selegiline (SG, 
tertiary and H-terminated propargylamine) and rasagiline (RG, secondary and H-terminated 
propargylamine), MAO-B inhibitors used in the treatment of Parkinson’s Disease, were 
included in the panel of compounds to increase the chemical diversity of propargylamine 
moiety.  
To face the analytical tasks, required in performing the chemical and metabolic stability 
studies, LC-DAD-UV and LC-ESI-MS/MS techniques were employed: the analytical 
methods were developed to allow both qualitative and quantitative determination of analytes. 
Moreover, the new degradation products showing in their structure the presence of a structural 
alert were assessed for genotoxic potential evaluation; similarly, the new metabolites will be 
assessed for their potential pharmacodynamic activity. 
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CHAPTER 3. New insights in oxybutynin chemical stability: identification 




Oxybutynin hydrochloride (4-(diethylamino)but-2-ynyl (RS)-2-cyclohexyl-2-hydroxy-2-
phenyl-acetate hydrochloride, Oxy) is an antimuscarinic drug which is used for the 
management of urinary frequency, urgency and incontinence in neurogenic bladder disorders 
and in idiopathic detrusor instability (Kennelly, 2010). With Oxy being the first choice in 
treating urinary incontinence, different types of formulations are at present available on the 
market: immediate and extended release tablets, oral solutions, syrup and solution for 
intravesical administration. Alternatively, to mitigate the systemic adverse effects occurring 
during the therapy, Oxy free base was employed in topical formulations such as adhesive 
patch (Kentera
™
) and gel (Gelnique
™
) (Shaw et al., 2007). Indeed oxybutynin is associated 
with a high incidence of systemic side-effects, including dry mouth, constipation, blurred 
vision, dryness of the eyes, palpitations, drowsiness, dizziness and esophageal reflux (Lose et 
al., 2001).  
From a structural point of view Oxy is characterized by the presence of a tertiary 
propargylamine moiety and a carboxyester function; as a consequence, the chemical stability 
of Oxy has been investigated (Miyamoto et al., 1994), demonstrating the formation of a single 
hydrolytic degradation product, namely α-cyclohexylmandelic acid (CHMA). The formation 
of CHMA was also observed by Wagieh et al. (2010) and El-Gindy (2005) during the stress 
studies performed in acidic and alkaline conditions. Moreover, CHMA was the only 
degradation product included in the list of specified impurities in both the Oxy monographs of 
the European and United States Pharmacopoeias (EP 8, 2013; USP 38, 2015). In accordance 
with this scenario, a literature survey showed that the stability indicating analytical methods 
(Wagieh et al., 2010; El-Gindy, 2005; De Schutter et al., 1988) for the determination of Oxy 
in drug substance and drug product take into account CHMA as the only degradation product. 
Interestingly, even if De Shutter et al. (1988) noted the formation of several minor peaks in 
the chromatogram of Oxy treated with hydrogen peroxide in severe conditions, no 
degradation product arising from oxidation has been identified so far. At first sight this is not 
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surprising, because oxybutynin is mainly used as hydrochloride salt and the corresponding 
protonated amino group is scarcely prone to oxidation. However, due to its better 
lipophylicity and permeability, Oxy free base is used in the new topical formulations: in that 
case the unionized tertiary amine can be more easily oxidized with the potential formation of 
degradation products.  
These considerations, combined with the observation of an unknown impurity during 
oxybutynin adhesive patch analysis, prompted us to reinvestigate the Oxy chemical stability, 
focusing our attention on the oxidative degradation pathway. 
In this report, we elucidated the chemical fate of Oxy in oxidative conditions showing the 
formation of the corresponding diastereomeric N-oxides (Oxy-NO1 and Oxy-NO2) and an 
unprecedented degradation product (Oxy-EK), whose structure and mechanism of formation 
were discussed. Finally, Oxy-EK synthesis was described, allowing us to propose it as the 
indicator of stability for the oxidative degradation in stability studies and, at the same time, to 
evaluate its potential mutagenic effects. 
 
3.2 EXPERIMENTAL 
3.2.1. Reagents and chemicals 
Methanol (HPLC grade), tetrahydrofuran (THF), ammonium acetate, iron (III) trichloride 
hexahydrate, copper sulphate, pentahydrate, hydrogen peroxide solution (30% w/w), N,O-
dimethylhydroxylamine hydrochloride acetoxyacetyl chloride, ethynylmagnesium bromide 
(0.5 M in THF), 4,4ˈ-azobis-(4-cyanovaleric acid) (ACVA), α-cyclohexylmandelic acid 
(97%), ninhydrin, histidine, tryptophan, biotin, 2-nitrofluorene (2NF), 2-aminoanthracene 
(2AA), sodium azide (SA), 9-aminoacridine (9AA) and methyl methanesulfonate (MMS), 
bacteriological agar, nutrient broth, nutrient agar were supplied by Sigma-Aldrich (St. Louis, 
MO, USA). Water (HPLC grade) was obtained from Milli-Q reverse osmosis system 
(Millipore Co., Billerica MA, USA). Column chromatography was performed on silica gel 60 
(230-400 mesh ASTM Merck). TLC was carried out on plates with a layer thickness of 0.25 
mm (silica gel 60 F254; Merck); when necessary, they were visualized after spraying with 
ninhydrin reagent. Oxy (potency: 99.3%), was obtained as gift sample from Pharmafar S.r.l. 
(Torino, Italy); Kentera
™
 transdermal patches (lot n° 356861C; exp. date: 11/2013 and lot n° 
818002A exp. date: 09/2016; Nicobrand Ltd, Coleraine, Northern Ireland), were purchased 
from local pharmacy. The S9 fraction (the liver postmitochondrial supernatant of rats treated 
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with the mixture phenobarbital/β-naphthoflavone to induce the hepatic microsomal enzymes) 
was supplied and certified by Moltox (Molecular Toxicology, Boone, NC, USA). 
 
3.2.2. Instrumentation and chromatographic conditions 
3.2.2.1 LC-UV analyses 
A Shimadzu HPLC system, consisting in two LC-10AD Vp module pumps and a DGU-14-A 
on-line vacuum degasser, was used. The analyses were carried out on a Luna C18(2) (150 x 
4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) column. The isocratic mobile phase 
(flow rate 1.2 ml/min) was composed of eluant A ammonium acetate buffer (20 mM pH=5.7) 
and eluant B methanol, being the A:B ratio 25:75 (v/v). The eluants A and B were filtered 
through a 0.45 m PVDF membrane filter prior the use. A SIL-10AD Vp autosampler was 
used for the injection of samples (20µl). The SPD-M10A Vp photodiode array detector was 
used to detect Oxy and the degradation products CHMA, Oxy-NOs at 210 nm and Oxy-EK 
at 311 nm. A LCsolution 1.24 software was used to process the chromatograms. All the 
analyses were carried out at room temperature.  
 
3.2.2.2 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor PDA detector and a vacuum degasser was used for LC-
MS analysis (Thermo Electron Corporation, Waltham, MA, USA). 
The analysis were performed on a Luna C18(2) (150 x 4.6 mm I.D., 5m dp; (Phenomenex, 
Torrance, CA, USA) column maintained at 35°C. The mobile phase (flow rate 0.8 ml/min) 
was composed of eluant A: ammonium acetate buffer (pH 5.7; 10 mM) and eluant B: 
methanol, using an isocratic mode being 20:80 the ratio A:B; the sample injection volume 
was 20 l. The eluate was injected into the electrospray ion source (ESI) with a splitting of 
40% and the MS and MS/MS spectra were acquired and processed using the Xcalibur
® 
software (Thermo Electron Corporation, Waltham, MA, USA). The operating conditions of 
the ion trap mass spectrometer in positive ion mode were as follows: spray (source) voltage, 
5.30 kV; source current, 80 A; capillary temperature, 350 °C; capillary voltage, 23.00 V; 
tube lens offset, 40.0 V; multipole 1 offset, -5.75 V; multipole 2 offset, -7.00 V; sheath gas 
flow (N2), 60 Auxiliary Units; sweep gas flow (N2): 6.0 A. U. Data were acquired both full 
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scan and MS/MS product ion scan modes using mass scan range m/z 105 to 500, optimizing 
the collision energy at 30%. 
 




C experiments were performed at 298K on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05T. Chemical shifts are reported in part 
per million (ppm). FT-IR experiments were performed on AVATAR 370 FT-IR (Thermo 
Fisher Scientific, Madison WI, USA) spectrophotometers. 
 
3.2.3 Forced degradation study of Oxy 
The degradation study in solution was done at 1 mg/ml
 
Oxy concentration. For the acidic 
degradation study, Oxy was dissolved in 0.5 N HCl and the solution was left in the dark at 
50°C for 24 h. The degradation in alkaline conditions was done in 0.01 N NaOH in presence 
of methanol/water 50/50 and the solution was left in the dark at 50°C for 30 minutes.  
The oxidative degradation was studied, protecting the samples from light, using the following 
protocols:  
a) Oxy was dissolved in 3% (v/v) H2O2 in acetate buffer (pH 4.5) and the solution was left 
at room temperature (r.t.) for 24h. 
b) Oxy was dissolved in 3% (v/v) H2O2 in 50/50 water/methanol mixture (8 mL) in the 
presence of sodium hydrogen carbonate (100 mg): the solution was left at r.t. for 4h.  
c) Oxy was dissolved in acetate buffer (pH=4.5) in the presence of 1.5 mM Cu2+ or Fe3+ 
and left at r.t. for 4h. 
d) To a solution of Oxy in 50/50 methanol/water, the radical initiator ACVA, previously 
dissolved in water (1 mg/ml) in the presence of sodium hydrogen carbonate, was 
added. The mixture of reaction (ACVA: 1 mM final concentration) was stored at 60 °C 
for 24h. 
The thermal and photodegradation were studied by testing Oxy and Oxy free base. In 
particular, for thermal degradation, the samples were stored for 18 h at 60 °C in a hot air 
oven. Photodegradation was carried out, at r.t., by exposing a thin layer (10 mg) of Oxy or 
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3.2.3.1 Sample preparation 
Before LC-UV and LC-MS/MS analyses, acidic and alkaline samples were first neutralized 
by addition of a suitable amount of sodium phosphate dibasic and diluted phosphoric acid 
(8.5% w/v) respectively, and then diluted with mobile phase. The other stressed samples were 
dissolved or tenfold diluted in mobile phase only; finally, solid samples were dissolved in 
mobile phase to attain ~0.1 mg/ml concentration. For comparison purposes a freshly prepared 
aqueous solution of Oxy (~1 mg/ml) was diluted and analyzed as above. 
 
3.2.3.2 Procedure for the analysis of transdermal patch 




), the patch was transferred into 
a Falcon
™
 conical tube and extracted by sonication (SweepZone Technology Quantrex S200) 
with methanol (3x20ml). The combined methanolic extracts were evaporated to small volume 
under reduced pressure and then transferred and diluted in a 20 ml volumetric flask with 
methanol/water 75/25. The solution was analyzed with LC-UV and LC-MS/MS. To evaluate 
the role of the extraction conditions on the chemical stability of Oxy, the procedure was 
repeated on a sample of Oxy free base. 
 
3.2.3.3. Accelerated stability study of transdermal patch 
The stability study was performed in a Binder-KBF-115 constant climate chamber (Binder 
GmbH, Tuttlingen Germany). Drug product (Kentera
™
 transdermal patch) packaged in the 
container closure system used for marketing was stored using the following condition: 
40°C±2°C/75% RH±5%, t= 6 months.  
 
3.2.4. Isolation and purification of Oxy-EK  
To a solution of Oxy (500 mg, 1.27 mmol) in 5 ml of water, 240 mg of sodium hydrogen 
carbonate 5 ml of methanol and 5 ml of 30% w/w hydrogen peroxide were added. The 
mixture was reacted, under stirring at r.t., for 3h monitoring by TLC analysis (eluant: 
CH2Cl2/MeOH 9:1). At the end of the reaction, methanol was evaporated under reduced 
pressure. The aqueous residue was extracted (3x15 ml) with CH2Cl2. The pooled organic 
layers were washed with brine, dried over anhydrous sodium sulphate, filtered and evaporated 
in vacuo to dryness. The pale-yellow oily residue was left overnight at r.t. and then purified 
by column chromatography using dichloromethane/methanol 98/2 as eluant to give pure Oxy-
EK (88 mg, 19% yield; 94% purity by HPLC assay). 
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ESI-MS: calculated for C22H31NO4 M= 373.48; Found m/z = 374 [M+H]
+
 and m/z = 396 
[M+Na]
+  






C-NMR (CDCl3): for comparison purposes the spectra of Oxy-EK and Oxy 
















1 7.24 tt (7.2, 1.4) 127.4 1 7.24 tt (7.2, 1.2) 127.4 
2 7.31 tt (7.4, 1.7) 126.0 2 7.34 tt (7.4, 1.5) 126.3 
3 7.62 bd 128.0 3 7.70 dd (8.4, 1.3) 128.2 
4 --- 140.5 4 --- 140.9 
5 3.61 s (OH) 81.0 5 3.72 s (OH) 81.2 
6 --- 174.9 6 --- 175.2 













4.81 dt (15.3, 1.8) 
4.69 dt (15.3, 1.8) 
54.2 11 
4.68 d (15.3) 




12 --- 189.7 
13 --- 13 4.82 d (12.5) 89.4 
14 3.40 t (1.8) 40.9 14 7.63 d (12.6) 152.2 
15 2.44 q (7.2) 47.3 
15 
15’ 
3.23 q (7.2) 
2.92 q (7.1) 
50.5 
42.7 
16 1.01 t (7.2) 12.8 
16 
16’ 
1.16 t (7.1) 





3.2.5. Synthesis of Oxy free base 
To a solution of oxybutynin hydrochloride (600 mg, 1.5 mmol) in water, 15.5 ml of sodium 
hydroxide 0.1N were added. The aqueous layer was extracted with dichloromethane. The 
organic solution was washed with brine, dried over anhydrous sodium sulphate, filtered and 
evaporated in vacuo to dryness obtaining a pale yellow oily product (477 mg, 89% yield). 
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3.2.6 Synthesis of degradation products 
3.2.6.1 Synthesis of 4-(diethylamino)-2-oxy-but-3-enyl(RS)-2-cyclohexyl-2-hydroxy-2-
phenylacetate (Oxy-NO2) 
To a solution of Oxy (500 mg, 1.27 mmol) in 5 ml of water, 240 mg of sodium hydrogen 
carbonate 5 ml of methanol and 5 ml of 30% w/w hydrogen peroxide were added. The 
mixture was reacted and extracted following the same procedure reported in the paragraph 
3.2.4; however the purification was performed immediately after the extraction, using 
dichloromethane/methanol 90/10 as eluant, giving Oxy-NO2 (193 mg; 40% yield; purity 
~70% HPLC). 
ESI-MS: calculated for C22H31NO4 M= 373.48; Found m/z = 374 [M+H]
+





3.2.6.2 Stability of Oxy-NO2 
Two aliquots (~100 mg) of freshly prepared Oxy-NO2 were stored, separately, in a 
refrigerator at -20°C and at room temperature. The LC-UV analysis was carried out at 0, 1, 2, 
24, 48h by weighing and dissolving in 50 ml of methanol an appropriate amount of the 
samples. 
 
3.2.6.3 Synthesis of 2-[methoxy(methyl)amino]-2-oxoethyl acetate (1) 
N,O-Dimethylhydroxylamine hydrochloride (4.8 g, 49.2 mmol) was dissolved in freshly 
prepared anhydrous dichloromethane (40 ml) and acetoxyacetyl chloride (6.3 ml, 59.6 mmol) 
was added dropwise maintaining the reaction at 0°C under nitrogen. Triethylamine, (13.6 ml, 
98.1 mmol) was then added dropwise removing the gas generated from the reaction flask. The 
reaction mixture was stirred under nitrogen for 3h while the temperature rose to r.t. Finally, 
the reaction was quenched by adding 20 ml of methanol obtaining a clear solution. After 
concentration to dryness, the residue was diluted with ice-cold freshly prepared anhydrous 
THF and the white salt was filtered under vacuum and washed with dry THF. The filtrates 
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3.2.6.4 Synthesis of 2-oxobut-3-yn-1-yl acetate (2) 
To a solution of  compound 1 (2-[methoxy(methyl)amino]-2-oxoethyl acetate; 8.0 g, 
49.6mmol) in freshly prepared anhydrous THF (30 ml), ethynylmagnesium bromide (100 ml, 
0.5 M in THF) was added dropwise at -78 °C. The mixture was stirred for 7 h while the 
temperature rose to r.t. After partial concentration under reduced pressure, the reaction 
mixture was poured into 40 ml of ice-cold o-phosphoric acid (20%) and the organic phase 
diluted with diethyl ether. The aqueous layer was separated and extracted twice with diethyl 
ether. The combined organic layers were washed with brine, dried over anhydrous sodium 
sulfate, filtered and evaporated under reduced pressure obtaining a yellow oil. The crude 
product was directly used for the next step of the synthesis. 
 
3.2.6.5 Synthesis of (3E)-4-(diethylamino)-1-hydroxybut-3-en-2-one (3) 
a) To a solution of compound 2 (2-oxobut-3-yn-1-yl acetate; 6.4 g, 51 mmol) in anhydrous 
THF (30 ml), diethylamine (10.5 ml, 102 mmol) was added dropwise and the mixture was 
stirred overnight at r.t. 
Evaporation under reduced pressure of the mixture gave a yellow oil which was analyzed by 
TLC (dichloromethane/methanol 9:1, visualization with ninhydrin) obtaining two spots 
having Rf 0.70 and 0.62 respectively).  
b) The residue was suspended in a mixture of 2 ml of saturated sodium carbonate solution and 
about 50 ml of methanol and vigorously stirred for 2h at r.t. After the evaporation of methanol 
under reduced pressure, the aqueous residue was extracted three times with dichloromethane. 
The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, 
filtered and evaporated under reduced pressure. The crude residue was purified by column 
chromatography using dichloromethane–methanol 9:1 as eluant to give compound 3 as yellow 
oil (1.1 g, 6.8 mmol, 13% yield). 




H-NMR (300 MHz, CDCl3)  7.67(d, J=12.6 Hz, H-olefinic), 4.99(d, J=12.6 Hz, H-olefinic), 
4.16(s, CH2), 3.67(s, OH), 3.15(s, 2CH2), 1.17(s, 2CH3). 
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3.2.6.6 Synthesis of (3E)-4-(N,N-diethylamino)-2-oxo-3-buten-1-yl 1-cyclohexyl-1-
phenylglycolate (Oxy-EK) 
To a suspension of -cycloexylmandelic acid (801 mg, 3.4 mmol) in anhydrous toluene (30 
ml), triethylamine (1.2 ml, 8.5 mmol) was added under nitrogen. Subsequently, a solution of 
isobutyl chloroformate (532 µl, 4.1 mmol) dissolved in a few ml of anhydrous toluene, was 
added dropwise and the resultant white suspension was stirred at 60°C for 1.5h; then 
compound 3 (700 mg, 4.4 mmol) was added and the reaction mixture was stirred at 100 °C for 
3h and then at 70°C overnight. The reaction mixture was slightly diluted with ethyl acetate 
and quenched by the addition of 10% aqueous sodium hydrogen phosphate solution. The 
organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and 
evaporated under reduced pressure giving a crude oil which was first purified by column 
chromatography using dichloromethane/methanol 98:2 as eluant and then by a second column 
using petroleum ether/2-propanol 9:1 as eluant to give Oxy-EK as a pale yellow oil (389 mg, 
1.0 mmol, 29 % yield, 95% purity by HPLC assay). 
ESI-MS: calculated for C22H31NO4 M= 373.48; Found m/z = 374 [M+H]
+




(The scheme of Oxy-EK synthesis is reported in the Figure 9). 
 
3.2.7. Evaluation of the mutagenic effects of Oxy-EK and Oxy  
(This study was carried out in collaboration with the Department of Physiology and 
Pharmacology "V. Erspamer", Sapienza University, Rome) 
Experiments were carried out on different Salmonella typhimurium and Escherichia coli 
strains, according to Di Sotto et al. (2013). Taking into account that bacteria are unable to 
metabolize inactive chemicals via cytochrome P450, an exogenous metabolic activation 
system S9 was also included in the Ames test.  
 
3.2.7.1. Bacterial strains  
A set of different strains, Salmonella typhimurium TA1535 (hisG46 chl1005 rfa1001), 
TA1537 (hisC3076 chl1007 rfa1003), TA1538 (hisD3052 chl1008 rfa1004), TA98 (hisD3052 
chl1008 rfa1004 pKM101), and TA100 (hisG46 chl1005 rfa1001 pKM101), and Escherichia 
coli WP2uvrA (trpE65 uvrA155) and WP2uvrA/R (trpE65 uvrA155 pKM101), was used. The 
strains TA1535, TA1537 and TA1538 were supplied by Department of Pharmacy and 
Biotechnology, University of Bologna (Italy), while TA98, TA100, WP2uvrA and 
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WP2uvrA/R were provided by the Research Toxicological Centre (Pomezia, Rome, Italy). 
After confirmation of the genotypes by the Strain Check Assay (Di Sotto et al., 2014), the 
permanent cultures of each strain were prepared and then frozen. The working cultures, 
prepared from the permanent ones, were incubated overnight (16 h) at 37 °C, to reach a 
concentration of approximately 110
9
 bacteria/ml. In each experiment the number of viable 
cells for each strain was determined according to Ames et al. (1975). Viability of the tested 
strains TA1535, TA1537, TA1538, TA98, TA100, WP2uvrA and WP2uvrA/R, expressed as 
viable cells/plate, was of 275.18.7, 343.714.2, 236.511.7, 240.013.1, 209.09.5, 
371.512.9 and 319.015.5, respectively.  
 
3.2.7.2. Preliminary assays 
Preliminarily, the solubility of Oxy-EK and Oxy in the final mixture was assessed. 
Insolubility was defined as the formation of a precipitate of the substance in the final mixture 
under the test conditions and evident to unaided eye (Di Sotto et al., 2014). 
Starting from the highest soluble concentration, different concentrations of the substances 
(dilution factor from 1:2 to 1:5) were tested for the cytotoxicity, in order to find the highest 
concentration to study in the mutagenicity test. A cytotoxic effect was evaluated as a 
reduction (> 30%) in the number of revertant colonies and as a change in the auxotrophic 
background growth (background lawn), in comparison with the control plates (Di Sotto et al., 
2014). To perform the test, solutions of test substances (50 µl) were added to an overnight 
culture (100 µl) and S9 mixture or phosphate buffer (0.1 M; 500 µl). The mixture was pre-
incubated under shaking at 37 °C for 30 min, then it was added with top agar (2 ml) 
containing 10% of histidine/ biotin (0.5 mM) for S. typhimurium strains, and 10% of 
tryptophan (0.5 mM) for E. coli strains; finally it was poured onto a minimal agar plate. After 
incubation at 37 °C for 48 h, the plates were examined, the background lawn was observed 
and the bacterial colonies were scored. 
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3.2.7.3. Mutagenicity assay 
The mutagenicity was assayed by the pre-incubation method (Di Sotto et al., 2014), starting 
from the highest non-toxic concentration (1:1.4 dilution factor). The vehicle DMSO (2% v/v) 
was used as negative control. The mutagens SA (1 µg/plate for TA1535 and TA100), 9AA 
(50 µg/plate for TA1537), 2NF (2 µg/plate for TA1538 and TA98), MMS (500 µg/plate for 
WP2uvrA and WP2uvrA/R), 2AA (1 µg/plate for TA1538, TA98 and TA100 and 10 µg/plate 
for TA1535, TA1537, WP2uvrA and WP2uvrA/R), were used as positive controls, in order to 
verify the bacteria susceptibility to a known genotoxic damage. The experiments were 
repeated at least twice and each concentration was tested in triplicate. To perform the test, an 
overnight culture (100 µl) was added to the solutions of the samples tested (50 µl) plus S9 
mixture or phosphate buffer (0.1 M) (500 µl). The mixture was gently vortexed in a sterile 
tube then was incubated under shaking at 37 °C for 30 min. After the pre-incubation, the tubes 
were added with top agar (2 ml) containing 10% of histidine/biotin (0.5 mM) for S. 
typhimurium strains, and 10% of tryptophan (0.5 mM) for E. coli strains, then were gently 
vortexed and poured onto a minimal agar plate. The plates were incubated at 37 °C for 72 h 
and then examined. The histidine- or tryptophan-independent revertant colonies and the viable 
cells were scored and the bacterial background lawn was observed. A positive response in the 
mutagenicity assay was defined as an increase (at least two-fold above the vehicle) in the 
histidine- or tryptophan-independent revertant colonies (Di Sotto et al., 2014). 
 
3.2.7.4 Statistical analysis 
All values are expressed as mean ±SE. The one-way analysis of variance (one-way ANOVA), 
followed by Dunnett’s multiple comparison post test, was used to verify the significance of a 
positive response. A P value <0.05 was considered statistically significant. Statistical analysis 
was performed with GraphPad Prism™ (Version 4.00) software (GraphPad Software, Inc., 
San Diego, California, USA). 
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3.3 RESULTS AND DISCUSSION  
3.3.1 Forced degradation study of Oxy by LC-UV analysis  
In the course of the stability studies carried out during the development of new Oxy 
formulations and their comparison with those currently marketed, the presence of a 
degradation product in transdermal patch was observed with its structure unknown. To 
address the problem, a reinvestigation of the chemical stability of Oxy, using the stress 
conditions required by international  guidelines (ICH, 2003), was undertaken. The hydrolysis 
of Oxy in alkaline and acidic solutions has been previously reported in the literature 
(Miyamoto et al., 1994) showing the formation of CHMA as degradation product. 
Accordingly, in our protocol the formation of CHMA (tR= 2.1 min) in 0.01 N NaOH or 0.5 N 
HCl solutions as the only degradation product was observed (Figure 1a, 1b): its structure was 
confirmed by comparison of its retention time with that of CHMA reference standard (Figure 
1c).  
 
Figure 1a. LC-UV chromatogram of oxybutynin in 0.01N NaOH solution (t= 30 min at 50°C). 
 
 
Figure 1b. LC-UV chromatogram of oxybutynin in 0.5N HCl solution (t= 24h at 50°C).  








































Figure 1c. LC-UV chromatogram of CHMA solution. 
 
 
To evaluate the stability of Oxy in oxidative stress testing, four sets of experiments were 
performed. In the presence of hydrogen peroxide (pH= 4.5), demonstrating that no 
degradation occurred over 24 hours (data not shown). On the contrary, in alkaline conditions 
(pH~8), two degradation products, Oxy-NO2 (tR= 3,9 min) and Oxy-EK (tR= 6.6 min), were 
observed in the LC-UV chromatogram reported in the Fig. 2-A1. It is worth noting that, 
differently from Oxy and Oxy-NO2, the intensity of the Oxy-EK peak dramatically increases 
when the analytes were detected a higher wavelength (i.e. 311 nm) Fig. 2-A2; that feature 
indicates the presence of a new chromophoric group in its structure. Moreover, neither Oxy-
NO2 nor Oxy-EK were formed in the alkaline solution in the absence of hydrogen peroxide 
ruling out their possible formation by hydrolysis. When the oxidative degradation was studied 
in the presence of the radical initiator ACVA, the formation of the peak of Oxy-EK was 
again observed (Fig.2-B) while the peak of Oxy-NO2 was absent. Differently, Oxy did not 




 (data not shown): 
possibly, this could be due to the acidic conditions of the assay (pH= 4.5) favouring the 
protonated form of tertiary amine. The formation of Oxy-EK was also observed in thermal 
degradation of Oxy free base performed at 60 °C (Fig. 2-C) whereas Oxy in the same 
conditions did not (data not shown). Finally, the photodegradation was also studied, exposing 
Oxy or its free base to daylight and 365 nm UV-light, without observing the formation of 
degradation products (data not shown). These data showed that the assay in the presence of 
radical initiator allowed a better representation of Oxy oxidative degradation. Indeed, while 
hydrogen peroxide is a facile ‘‘two-electron’’ oxidant for amines this reaction does not 
involve peroxy radicals (Boccardi, 2005). On the other hand, it is recognized that the main 










Chemical stability study of Oxybutynin 
40 
 
oxidative pathway in pharmaceutical solid dosage forms involves free radical chain reactions 
in which peroxy radical, ROO·, is the oxidant (Boccardi, 2005).  
 
 
Figure 2. A1) LC-UV chromatogram (λa=210 nm) of Oxy in 3% H2O2 alkaline solution (t= 4h); A2) LC-UV 
chromatogram (λa=311 nm) of Oxy in 3% H2O2 alkaline solution (t= 4h). B1) LC-UV chromatogram (λa=210 
nm) of Oxy in presence of radical initiator (t= 24h); B2) LC-UV chromatogram (λa=311 nm) of Oxy in presence 
of radical initiator (t= 24h). C1) LC-UV chromatogram ( λa=210 nm) of Oxy free base in oven at 60°C (t= 18 
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3.3.2. Structural characterization of degradation products by LC-ESI-MS/MS analysis 
In order to obtain information on the structures of the degradation products, the hydrogen 
peroxide-treated sample was analyzed by LC-ESI-MS/MS. Interestingly, three degradation 
products were observed in the full mass chromatogram: Oxy-NO1, Oxy-NO2 and Oxy-EK. 
They showed the same protonated molecule at m/z 374, (+16 Da with respect to Oxy free 
base) (Fig. 3) indicating the insertion of an oxygen atom in the structure of oxybutynin. 
 
 
Figure 3. LC-MS chromatogram of Oxy in 3% H2O2 alkaline solution (t= 4h). 
 
In particular, the presence of the tertiary amine function suggested that Oxy-NO1 and Oxy-
NO2 are the diastereomeric N-oxides of oxybutynin: indeed their MS/MS spectra showed the 
same fragment ions although with different intensity pattern (Fig. 4). 
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 fragmentation patterns of Oxy-NO1, Oxy-NO2 and Oxy-EK 
 
The preparation of a synthetic standard was performed using hydrogen peroxide as oxidant 
followed by an immediate purification to avoid or at least mitigate its degradation. In any case 
the most abundant Oxy-NO2 could be only isolated, being its mass spectral and 
chromatographic properties identical to those of the degradation product found in the 
transdermal patch and in the forced degradation study. Oxy-NO2 was quite unstable 
undergoing, at room temperature, degradation leading to the formation of Oxy-EK as showed 
in the LC-UV chromatogram (Fig. 2-A). However when it was stored at -20°C the rate of 
degradation significantly decreased (Figure 5). 
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Figure 5. LC-UV chromatogram (λa= 210 nm) of a solution of Oxy-NO2 (t=0 h) D1; LC-UV chromatogram 
(λa= 311 nm) of a solution of Oxy-NO2 (t=0 h) D2. LC-UV chromatogram (λa= 210 nm) of a solution of Oxy-
NO2 at room temperature (t=24 h) E1; LC-UV chromatogram (λa= 311 nm) of a solution of Oxy-NO2 at room 
temperature (t=24 h) E2. LC-UV chromatogram (λa= 210 nm) of a solution of Oxy-NO2 at -20°C (t=48 h) F1; 
LC-UV chromatogram (λa= 311nm) of a solution of Oxy-NO2 at -20°C (t=48 h) F2. 
 
 
The assignment of the structure to Oxy-EK was challenging; the observation that Oxy-EK 
arises from the degradation of Oxy-NO2, combined with the findings of Szabo and Hermecz 
(2001) concerning the chemistry of tertiary propargylamine N-oxides, suggested that an 
intramolecular prototropic rearrangement of Oxy-NO2 occurred with the formation of an 
enamino ketone moiety. The presence of enaminoketone moiety was in accordance with the 
chromatographic and spectroscopic properties of Oxy-EK: indeed, as expected for an 
oxygenated degradation product, its retention time was lower than that of Oxy (6.6 vs 9.9 
min). Moreover, Oxy-EK showed an absorption maximum located at 311 nm, an unusually 
long wavelength, requiring the presence of a chromophore group as the enamino ketone 
(Figure 6). 
  























































































Figure 6. UV spectra of Oxy, Oxy-NO2, and the Oxy-EK. The UV spectra were recorded during the LC-UV 
analysis  (see experimental part) 
 
NMR spectra (Table 1) provided conclusive data for the structure assignment. In the 
13
C-
NMR spectrum the signal at 189.7 ppm indicates the presence of an α,β-unsaturated carbonyl 
group. This was confirmed by the signals at 152.2 and 89.4 ppm attributed to the double bond 
carbon atoms close to the carbonyl and the N,N-diethylamino groups respectively; the large 
difference in chemical shifts may be explained by the different influence of the electron-
withdrawing (C=O) and electron-donating (N(Et)2) neighbouring groups. The 
1
H-NMR 
spectrum allowed to establish the stereochemistry of double bond (C=C); indeed the observed 
coupling constant (J= 12.6 Hz) was similar to that reported for enamino ketone function (Lin 
et al., 2009; Maingot et al., 2009). Finally, no significant variations in the signal patterns of 




H-NMR spectra of 
Oxy-EK and Oxy. Based on these results, the oxidative degradation scheme of oxybutynin 
was reported in Figure 7.  
  




















































Figure 7. Oxidative degradation scheme of oxybutynin 
 
Taking into account the mechanism of Oxy-NO2 rearrangement and in particular the cyclic 
intermediate involved in (Szabò and Hermecz, 2001), it is reasonably that, initially, the Z-
enaminoketone is formed (Fig. 8); however its stereochemical integrity could be lost through 
mesomeric phenomena. Indeed the push-pull character of the central double bond would 
impose a significant presence of a mesomeric and dipolar form that would account also for 
the unusually high UV-absorption wavelength showed by Oxy-EK. Moreover, the mesomeric 
form could be characterized by a relatively low rotational barrier energy allowing the system 
to equilibrate to the more stable E-isomer: indeed the greater stability of the latter could be 





Figure 8. Mechanism of isomerization of Oxy-EK.  
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3.3.3 Synthesis of Oxy-EK  
In order to confirm the structure assigned to Oxy-EK, its synthesis (Figure 9) was performed 
in three steps starting from the Weinreb amide 1, easily obtained by reaction of N,O-
dimethylhydroxylamine hydrochloride with acetoxyacetyl chloride. The known and excellent 
acylating property of Weinreb amide for organomagnesium reagents, was exploited to obtain 
the ethynyl ketone derivative 2 through the reaction with ethynylmagnesium bromide. The 
enamino ketone side chain 3 was eventually obtained through a Michael-type addition of N,N-
diethylamine to hydrogen terminated ethynyl ketone 2. Finally, Oxy-EK was prepared by 
coupling the enamino ketone side chain with CHMA via isobutyl chloroformate. Mass 
spectral and NMR data of synthetic Oxy-EK matched with those of the degradation product 
isolated from oxidative stress assay. Contrary to Oxy-NO2, Oxy-EK was a stable compound 
and this feature, combined with its synthetic accessibility, has allowed its use as the indicator 
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3.3.4 Analysis of transdermal patches 
LC-UV and LC-MS/MS analysis of the sample arising from the extraction of transdermal 
patches arising from two different lots were reported in figures (10-11). 
 
 
Figure 10. LC-UV chromatogram of the transdermal patch sample solution (lot n° 818002A, t=0 months) 






 chromatogram of the transdermal patch sample solution (lot n° 818002A, t=0 months). 
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In the LC-UV chromatogram (Fig. 10) the presence of the impurity Oxy-EK was observed at 
311 nm (peak at tR= 6.9 min) while at lower wavelenght (210 nm) did not. The same peak, in 
the LC-MS/MS chromatogram (Fig. 11), was characterized by a protonated molecule at m/z 
374 being its fragmentation pattern
 
identical to that of Oxy-EK synthetic standard. While the 
intermediate degradation products, Oxy-NO2 and Oxy-NO1 were not detected in the LC-UV 
chromatogram, the presence of Oxy-NO2 peak was observed in the LC-MS/MS 
chromatogram (Fig. 11). Moreover, interestingly, the hydrolytic degradation product CHMA 
was also observed both in LC-UV and LC-MS chromatograms (Figure 10, 11) being its 
protonated molecule at m/z 236 (Figure 12): its formation was not further investigated.  
 
 
Figure 12. MS spectrum of degradation product CHMA found in oxybutynin transdermal patches 
 
To explain the origin of the Oxy-EK, an accelerated stability study (40°C, 6 months) on 
transdermal patches of two different lots was performed: the analysis of the samples, 
withdrawn at fixed times, showed that the impurity did not increase over a six month period 
of time Figure 13. 
 
 
Figure 13. LC-UV chromatogram of the transdermal patch sample solution (lot n° 818002A, t=6 months) 
monitored at 311 nm  
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Indeed, the availability of the synthetic standard of Oxy-EK allow us to estimate the 
concentration of Oxy-EK obtaining a value of 0.02% that does not change during the stability 
study. Finally, a sample of oxybutynin free base dissolved in triacetin, the main excipient of 
transdermal patch, and submitted to the same accelerated stability study did not show the 
formation of Oxy-EK. Possibly, these results indicate that the formation of Oxy-EK occurred 
during the preparation of the transdermal patch; alternatively, Oxy-EK is already present in 
oxybutynin free base used in the manufacturing process.  
 
3.3.5 Mutagenic activity of Oxy-EK  
The structure of Oxy-EK contains an α,β-unsaturated ketone which could behave as a 
Michael acceptor reacting with nucleophilic functions of biological macromolecules leading 
eventually to toxic effects; for this reason, α,β-unsaturated carbonyl functions are considered 
structural alert (Stepan et al., 2011). In the case of Oxy-EK, α,β-unsaturated ketone function 
is included in the enamino ketone side chain with, possibly, different electronic properties and 
reactivity. Nonetheless the mutagenic power of Oxy-EK, in term of ability to induce point 
mutations at gene level, was evaluated in vitro by the bacterial reverse mutation assay (Ames 
test).  
Both Oxy and Oxy-EK produced marked cytotoxic effects starting from the concentration of 
100 μg/plate in all the strains tested both in the absence and presence of the S9 metabolic 
activator (data not shown). Early signs of cytotoxicity, highlighted as a significant reduction 
in the number of the spontaneous revertant colonies, were observed for both substances at 
concentration of 50 μg/plate, in all the strains tested in the absence of the S9 metabolic 
activator (Appendix I). The presence of the metabolic activator seems to reduce the 
cytotoxicity of the compounds, being not cytotoxic at 50 μg/plate in all strains (Appendix I). 
At nontoxic concentrations, ranging from 9 to 36 μg/plate, both Oxy-EK and Oxy did not 
increase the number of revertant colonies in all strains tested in absence and presence of S9 
(Appendix I-II). Conversely, the known mutagens 2NF, SA, 9AA, MMS, and 2AA 
significantly increased the number of revertant colonies with respect to the vehicle (Appendix 
I-II), so confirming the ability of the bacteria to detect the DNA-damage. Present data show 
that Oxy-EK and Oxy did not induce any kind of point mutations (due to frameshift, base-
substitution, cross linking and oxidative mechanisms) so resulting not mutagenic. Further 
studies allow to better define the genotoxicity profile of the test substances at chromosomal 
level (including clastogenicity, aneuploidogenicity and DNA strand breaks).   




In this study the structure of a new and unprecedented degradation product, Oxy-EK, found 
in oxybutynin transdermal patch was elucidated. The mechanism of its formation, through the 
rearrangement of the oxybutynin N-oxide, is linked to the presence of oxybutynin in form of 
the free base; that form shows more favorable properties in term of lipophylicity and 
permeability but it results also more prone to oxidation than the corresponding protonated 
form. Overall, as expected, the oxidative degradation of Oxy is dependent on the pH of the 
assay indicating that there are no concern from this point of view as long as the 
chloride/hydrochloride salt is used in drug product manufacturing. However Oxy free base 
can undergo to oxidation suggesting that this degradation pathway should be taken into 
account in the course of stability studies. Accordingly, the synthesis of the reference standard 
of Oxy-EK allowed to propose it as the indicator of stability for the oxidative degradation of 
oxybutynin free base both in drug substance and drug product stability studies. Finally, the 
results of the Ames test highlight a lack of mutagenic effects for both the compounds and 
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CHAPTER 4. New findings in the in vitro metabolism study of oxybutynin 
4.1 INTRODUCTION 
Antimuscarinics are the mainstay of pharmacological treatment of overactive bladder (OAB), 
a complex symptom defined by the presence of urinary urgency, usually associated with 
frequency and nocturia, with or without urgency urinary incontinence. Oxybutynin 
hydrochloride (4- diethylamino) but-2-ynyl (RS)-2-cyclohexyl-2-hydroxy-2-phenyl-acetate 
hydrochloride, Oxy) is a chiral drug administered as a racemic mixture with antimuscarinic 
agent and widely prescribed to OAB patients with symptoms of urinary urge incontinence.  
However, its antimuscarinic activity resides predominantly on the (R)-enantiomer, which 
binds selectively muscarinic M1 and M3 receptors, in the detrusor muscle.  
Oxy immediate release formulation was the first treatment for OAB approved by the US FDA 
in 1975 (Arisco et al., 2009). To date, different types of Oxy formulations are available on the 
market: immediate and extended release tablets, oral solutions, syrup and solution for 
intravesical administration. Oxy is well absorbed from the gastrointestinal tract following oral 
administration, being its absolute bioavailability less than 10% due to extensive presystemic 
metabolism. The circulating primary metabolite, N-desethyloxybutynin (Oxy-DE), is present 
in plasma at concentrations approximately up tenfold those of the parent compound having 
similar anticholinergic effects to the parent compound. In therapeutic use, Oxy-DE appears to 
contribute greatly to the treatment-limiting anticholinergic side-effects associated with oral 
administration of Oxy (Zobrist et al., 2001 and Staskin et al., 2010). As a consequence, to 
mitigate the systemic adverse effects, occurring during the therapy, topical formulations, such 
as adhesive patch, were employed exploiting Oxy free base as the drug substance (Shaw et 
al., 2007).  
The first observation that Oxy undergo an extensive metabolic biotransformation in rat date 
back as early as 1965 (Lish et al., 1965). In the following decades, the metabolic fate of Oxy 
and its effect on the induction of drug metabolizing enzymes were investigated in rat, dog and 
human after oral administrations (Shinozaki et al., 1986). These authors reported the 
formation of a multitude of metabolites in dog and human urine after oral administration and 
estimated that up to ~ 30% of the administrated dose was excreted as metabolites in urine; 
they also observed the highest metabolic activity for Oxy in rat liver. Four metabolic 
pathways were identified: N-deethylation, hydrolysis of ester, hydroxylation at 3' and 4' 
positions on cyclohexan ring and the conjugation of the corresponding metabolites. In the 
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same year Yoshio et al. reported that, after Oxy oral administration, cyclohexylmandelic acid 
is the main metabolite in rat plasma and bile and its glycine conjugate the main one in urine 
(Yoshio et al, 1986). More recently carboxylesterase 1 (CES1) was identified as the major 
isozyme responsible for oxybutynin hydrolysis (Sato et al., 2012). In 1998 Yaïch and 
collaborators (Yaïch et al., 1998) demonstrated that CYP3A4 subfamily is involved in the 
formation of Oxy N-desethyl metabolite. Finally, Lindeke et al. (1981) using deuterated 
substrate and GC-MS analysis firstly reported the N-oxidation of the Oxy propargylamine 
moiety in rat liver microsomes. They were not able to reveal directly the presence of the N-
oxide metabolite (Oxy-NO) but its degradation product promoted by high temperature GC-
MS analysis. 
Indeed, based on their previous studies on pargyline N-oxide decomposition, they proposed 
the formation of propenal and Schiff base derivatives by two consecutive rearrangements of 
the Oxy-NO intermediate. 
At the best of our knowledge, over the last thirty years, no further reports addressed the 
oxidative metabolic fate of Oxy. In our previous report (Chapter 3), we elucidated the 
chemical stability of Oxy free base in oxidative conditions disclosing the role of the 
diastereomeric oxybutynin N-oxides (Oxy-NOs) in the formation of Oxy-EK, whose 
structure and mechanism of formation were elucidated. In the present report, exploiting our 
recent findings we revisited the in vitro oxidative metabolic fate of Oxy providing evidence 
for the metabolic instability of the tertiary propargylamine moiety which underwent 
enzymatic oxidation followed by chemical rearrangement to generate Oxy-EK. Besides, the 
secondary hydroxylamine Oxy-HA was formed by enzymatic oxidation of Oxy-DE.  
 
4.2 EXPERIMENTAL  
4.2.1 Reagents and chemicals 
Methanol (HPLC grade), acrylonitrile, Adenosine 3'-phosphate 5'-phosphosulfate lithium salt 
hydrate (80%), 1-chloroethyl chloroformate, m-chloroperbenzoic acid, trietylamine, were 
purchased from Sigma-Aldrich (Milano, Italy) or Alfa Aesar (Lancashire, UK). Water (HPLC 
grade) was obtained from Milli-Q reverse osmosis system (Millipore Co., Billerica MA, 
USA). Column chromatography was performed on silica gel 60 (230-400 mesh ASTM 
Merck). TLC was carried out on plates with a layer thickness of 0.25 mm (silica gel 60 F254; 
Merck); when necessary, they were visualized after spraying with ninhydrin reagent. Oxy 
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(potency: 99.3%), was obtained as gift sample from Pharmafar S.r.l. (Torino, Italy). Oxy free 
base, Oxy-NOs and Oxy-EK were prepared according to the procedures cited in the Chapter 
3. 
 
4.2.2 Instrumentation and chromatographic conditions 
4.2.2.1 LC-UV analyses 
A Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of two LC-10AD Vp 
module pumps, a SLC-10A Vp system controller, a SIL-10AD Vp autosampler and a DGU-
14-A on-line degasser, was used for the analysis. All the chromatographic separations were 
performed on a Kinetex C18 XB 150 x 4.6 mm (5 μm) core-shell column as a stationary 
phase protected by a C18-Security Guard™ (Phenomenex, Torrance, CA). The SPD-M10Avp 
photodiode array detector was used to detect the analyte at 210 and 311 nm. A LC Solution 
1.24 software was used to process the chromatograms. Aliquots (20 µl) of supernatants 
obtained from incubations were injected onto HPLC system. The isocratic mobile phase (flow 
rate 1.4 ml/min) was composed of eluant A ammonium acetate buffer (20 mM pH=5.7) and 
eluant B methanol, being the A:B ratio 35:65 (v/v) (total run time: 15 min). The eluants were 
filtered through a 0.45 µm pore size PVDF membrane filter prior to use. All the analyses were 
carried out at room temperature. 
 
4.2.2.2 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor photodiode array detector and a vacuum degasser was 
used for LC/MS analyses (Thermo Electron Corporation, Waltham, MA). All the 
chromatographic separations were performed on Kinetex C18 50 x 2.10 mm (2.6 μm) core-
shell column as a stationary phase protected by a C18-Security Guard™ (Phenomenex, 
Torrance, CA) kept at a 35 °C. Aliquots (5 μl) of supernatants obtained from incubations were 
injected onto the system and eluted with a mobile phase (flow rate 0.2 ml/min) consisting of: 
A: 10 mM ammonium acetate buffer (pH 5.70), and B: methanol. The following gradient 
elution was used: 0 to 9.5 min [A=55-20%, B=45-80%], 9.5 to 10 min [A=20-55%, B=80-
45%], 10 to 15 min [A=55%, B=45%]. The eluants were filtered through a 0.45-μm pore size 
polyvinylidene difluoride membrane filter before use. The eluate was injected into the 
electrospray ion source (ESI) and MS spectra were acquired and processed using Xcalibur
®
 
software. The operating conditions on the ion trap mass spectrometer were as follows: 
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positive mode, spray voltage, 5.00 kV; source current, 80 μA; capillary temperature, 300 °C; 
capillary voltage, 22.00 V; tube lens offset, 20.00 V; multipole 1 offset, -4.25 V; multipole 2 
offset, -8.00 V; sheath gas flow (N2), 35 Auxiliary Units. Negative mode: spray voltage, 3.30 
kV; source current, 80 μA; capillary temperature, 300 °C; capillary voltage, -34.00 V; tube 
lens offset, -35.00 V; multipole 1 offset, 6.25 V; multipole 2 offset, 10.50V; sheath gas flow 
(N2), 50 Auxiliary Units. Data was acquired in full-scan and product ion scan modes (MS
n
) 
using mass scan range m/z 105-700. The collision energy was optimized at 28-30%. 
 




C experiments were performed at 298K on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05T. Chemical shifts are reported in part 
per million (ppm).  
 
4.2.3 Synthesis of the reference compounds 
4.2.3.1 Benzeneacetic acid, α-cyclohexyl-α-hydroxy-4-(ethylamino)-2-butyn-1-yl ester (Oxy-
DE) 
 Oxybutynin free base (1.32 g, 3.70 mmol) was dissolved in freshly prepared anhydrous 
dichloromethane (30 ml) and 1-chloroethyl chloroformate (2.22 ml, 20.6 mmol) was added 
dropwise maintaining the reaction at 0°C under magnetic stirring. The reaction was further 
heated to reflux for 1.5 hours, and after cooling at room temperature, the solvent was 
evaporated and the crude residue re-dissolved in methanol (30 ml) and heated to reflux for an 
additional 1.5 hours. Evaporation under reduced pressure of the organic solvent gave a yellow 
oil which was analyzed by TLC (dichloromethane/methanol 95:5, developed with ninhydrin) 
obtaining three spots: (unreacted Oxy: Rf 0.5 red spot, Oxy-DE: Rf 0.2 yellow spot, and 
unknown product: Rf 0.1 purple spot). The residue was purified by column chromatography 
using dichloromethane/methanol 95:5 and then 9:1 as eluant to give compound Oxy-DE as 
pale yellow oil (295 mg, 0.90 mmol, 24% yield, HPLC purity at 210 nm 95.8%).  




4.2.3.2 Synthesis of benzeneacetic acid, α-cyclohexyl-α-hydroxy-4-(ethylamino)-4-
(cyanoethyl)-2-butyn-1-yl ester 
Oxy-DE (350 mg, 1.06 mmol) was dissolved in 5 ml of methanol in the presence of a 
catalytic amount of trietylamine. A small amount of water was then added to the mixture 
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without leading the solution to be opalescent. Acrylonitrile (105 mg, 2.0 mmol) was added 
dropwise and the mixture was stirred at room temperature for five hours. The reaction was 
then evaporated under reduced pressure giving a yellow oil (~300 mg) which was used 
directly without further purification. 
 
4.2.3.3 Synthesis of benzeneacetic acid, α-cyclohexyl-α-hydroxy-4-(ethylamino)-4-(hydroxy)-
2-butyn-1-yl ester (Oxy-HA) 
The crude residue (~300mg, ~0.78mmol) was dissolved in few ml of freshly prepared 
anhydrous dichloromethane and m-CPBA (270 mg, 1.29mmol) dissolved in dichloromethane 
was added dropwise maintaining the reaction at -78°C under nitrogen for 3 hours. The 
reaction was further stirred at 0°C for 2 hours. After cooling at room temperature, the reaction 
was washed with 10% aqueous sodium carbonate solution. The organic layer was dried over 
anhydrous sodium sulfate, filtered and evaporated under reduced pressure giving a crude oil 
which was first purified by column chromatography using dichloromethane/methanol 98:2 as 
eluant and then by a second column using petroleum ether/2-propanol 9:1 as eluant to give 
compound Oxy-HA as a pale yellow oil (85 mg, 0.25 mmol, 32 % yield, 97.3% purity by 
HPLC assay). 




H-NMR (300 MHz, CDCl3)  7.64-7.30(m, 5H-aromatic), 4.80(d, J=13.4 Hz, O-CH2-C≡), 
4.75(d, J=13.4 Hz, O-CH2-C≡), 3.59(s, ≡CH2-N), 2.75(q, J=7.14 Hz, N-CH2), 2.24-1.09 (m, 
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4.2.4 Human and rat Liver Preparations  
The human liver microsomes (HLM) (pooled mixed sex, fifty individual donors, protein 
concentration: 20 mg/ml, total CYP: 360 pmol/mg protein), human liver cytosol (HLC), 
(pooled mixed sex, fifty individual donors, protein concentration: 20 mg/ml, sulfotransferase: 
0.63 nmol/mg protein) and male Wistar rat liver microsomes (RLM), (protein concentration: 
25mg/ml, total P450: 0.64 nmol/mg protein) were purchased from BD Gentest™ (Woburn, 
MA) and used throughout this study. 
The incubations were all performed using a horizontal DUBNOFF shaking thermostatic bath 
(Dese Lab Research, Padova, Italy) and were protected from light. 
 
4.2.5 Phase I incubations with RLM, HLM 
The standard incubation mixture (0.5 ml final volume), was carried out in a 50 mM TRIS·HCl 
buffer (pH 7.4) containing 3.3 mM MgCl2, 1.3 mM NADPNa2, 3.3 mM glucose 6-phosphate, 
0.4 Units/ml glucose 6-phosphate dehydrogenase, 5 μl of acetonitrile (1% of total volume), 
and Oxy (200 µM). 
After pre-equilibration of the mixture, an appropriate volume of HLM/RLM suspension was 
added to give a final protein concentration of 1.0 mg/ml. The mixture was shaken for 60 
minutes at 37°C. Control incubations were carried out both without the presence of NADPH-
regenerating system or microsomes. Each incubation was stopped by addition of 0.5 ml ice-
cold acetonitrile, vortexed and centrifuged at 12,500 rpm for 10 min. The supernatants were 
analyzed by LC-UV and LC-ESI-MS. Alternatively, when the chemical reactivity of the 
metabolites  was studied, GSH (3mM) was added to the incubation mixture.  
When compounds Oxy-DE, Oxy-HA and Oxy-EK were studied as substrates, they were 
incubated following the same procedure reported above. 
 
4.2.6 Phase II incubation with HLC fraction 
4.2.6.1 Glucuronide 
The standard incubation mixture, constituted by 2 mM UDPGA cofactor, in a 50 mM 
TRIS·HCl buffer, pH 7.4, containing 5 μL of acetonitrile (1% of total volume), Oxy or Oxy-
HA (200 µM) brought to a final volume of 0.250 mL. After preequilibration of the mixture at 
37 °C, an appropriate volume of HLM suspension, previously activated by Brij 58 surfactant 
(0.5 mg/mg protein) in ice for 15 min, was added to give a final protein concentration of 1.0 
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mg/mL; the incubation mixture was shaken for 60 minutes at 37°C. Control incubation was 
carried out both in the absence of HLM or UDPGA cofactor. Incubation were stopped by 
addition of 0.250 mL ice-cold acetonitrile, vortexed and centrifuged at 11,000 r.p.m. for 5 min 
prior to LC-ESI-MS analyses of the supernatants. 
 
4.2.6.2 Sulphate 
The standard incubation mixture, constituted by 0.1 mM PAPS cofactor, in a 50 mM 
TRIS·HCl buffer, pH 7.4, containing 5 μl of acetonitrile (1% of total volume), and compound 
Oxy-HA, brought to a final volume of 0.5 ml. After pre-equilibration of the mixture at 37 °C, 
an appropriate volume of HLC suspension was added to give a final protein concentration of 
1.5 mg/ml; the incubation mixture was shaken for 60 minutes at 37°C. Control incubation was 
carried out in the absence of PAPS. Each incubation was stopped by addition of 0.5 ml ice-
cold acetonitrile, vortexed and centrifuged at 12,500 rpm for 5 min. The supernatants were 
analyzed by LC-ESI-MS. 
 
4.3 RESULTS 
The in vitro metabolic stability of Oxy was assessed through its incubation in rat and human 
liver subcellular preparations in the presence or absence of a NADPH-regenerating system 
and of the appropriate cofactors. The incubation samples were analysed by LC-UV and LC-
ESI-MS to obtain data on the metabolic stability and the structures of the metabolites 
respectively. 
When the microsomal mixed-function oxidase system was activated by the presence of 
NADPH, Oxy underwent a relevant oxidative transformation with the residual substrate 
ranging from 10% (RLM) to 56% (HLM). Similar values were obtained in incubations 
supplied with 3mM GSH ranging the residual substrate from 15% (RLM) to 62% (HLM). 
Structural characterization of Oxy metabolites was achieved by tandem mass spectrometry 
analysis. All the metabolites were characterized based on their predicted mass shift from the 
Oxy protonated molecule ([M+H]
+
= 358), and the interpretation of their MS
n
 spectra. The 
characterization of Oxy metabolites was performed using the incubations obtained with 
human liver microsomes. No further tests were carried out to assess the metabolic pattern of 
Oxy arising from RLM incubations. 
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Human liver microsomal Oxy incubation samples were analyzed by LC-ESI-MS in both 
positive full scan and product ion scan modes revealing the phase I metabolites reported in the 
chromatograms in Figure 1. As a matter of fact, incubation analyses revealed the presence of 
ten metabolite-related ions as shown in Figure 1 whose MS
2
 spectra and the proposed 
fragmentation pathways are depicted in Figures 2a and 2b.  
 
 
Figure 1. LC-MS chromatograms of Oxy incubations (HLM, 200µM) performed in positive full mass and 




Monitoring the ion at m/z 374, the LC-MS
2
 chromatogram revealed the presence of six peaks 
corresponding to the following metabolites: Oxy-NOs (N-oxide diastereoisomers) eluting at 
4.40 and 7.15 min, Oxy-EK (9.52 min), and three additional metabolites (M1-M3) eluting at 
3.87, 3.84, and 5.10 min respectively (Figure 1). Oxy-NOs product ion spectra (m/z 374) 
(Figure 2b) gave two diagnostic fragment ions at m/z 189, and 171 corresponding to the same 
ions observed in Oxy MS
2
 spectrum (Figure 2a). Moreover the presence of the fragment ions 
at m/z 356 (loss of water), and 158 (ester cleavage), both shifted of 16 Da with respect to the   
RT: 0,00 - 15,00 SM: 3G
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same ions in Oxy spectrum, clearly demonstrated that the enzymatic oxidation occurred on 
the propargylamine moiety leading to the formation of N-oxide metabolites. The structures of 
Oxy-NOs were further confirmed by comparison their mass spectral data with those arising 
from N-oxide synthetic standards (data not shown). 
Oxy-EK protonated molecule (m/z 374) generated a two-fragment MS
2
 spectrum (Figure 2a). 
The most abundant ion (m/z 356) was due to the neutral loss of water whereas the ion at m/z 
158 (generated from the ester cleavage) corresponded to the Oxy fragment ion at m/z 142 
shifted of 16 Da. Considered together, these data indicated that the structure and the 
mechanism of formation of Oxy-EK are identical to those described for the degradation 
product previously highlighted in the chemical stability study of Oxy (Chapter 3). Even if the 
structure of Oxy-EK presents an α,β-unsaturated ketone function, its formation was not 






 spectra of Oxy and the metabolites Oxy-DE, Oxy-HA, Oxy-EK formed in HLM 
incubations of Oxy (200µM)  
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Metabolites M1, M2, and M3 showed identical product ion spectra: among them, the MS
2 
spectrum of M1 is reported in figure 2b. For these metabolites, the protonated molecule at m/z 
374 gave rise to a fragmentation pathway similar to that observed for Oxy. Indeed the 
fragment ions at m/z 124, 142, and 258 are the same observed in the Oxy spectrum, whereas 
the fragment at m/z  187, 283 and 356 presented a shift of 16 Da with respect to the same ions 
found in Oxy spectrum. Overall, this set of data suggested that M1, M2, and M3 metabolites 
arose from the enzymatic oxidation on the cyclohexan ring.  
As previously reported in the literature, Oxy-DE, arising from oxidative N-deethylation was 
the main metabolite; it was characterized by a protonated molecule at m/z 330 whose 
fragmentation generated the ions at m/z 312 (loss of water) and a at m/z 230 (100 Da neutral 
fragment loss) which corresponded to the ion at m/z 258 observed in Oxy spectrum. In human 
liver microsomes Oxy-DE underwent further oxidative N-deethylation generating the primary 
propargylamine metabolite M6. The structure assignment was based on the presence of the 
protonated molecule at m/z 302, whose fragmentation generated the ions at m/z 284 (loss of 
water) and at m/z 202 (100 Da neutral fragment) which corresponded to the ion at m/z 230 
observed in Oxy-DE spectrum. Moreover, Oxy-DE underwent both N-oxidation, generating 
the hydroxylamine Oxy-HA, and the aliphatic hydroxylation of the cyclohexan ring 
(metabolites M4 and M5). In particular, metabolites M4 and M5 gave identical MS
2
 spectra 
featured by the presence of the diagnostic ions at m/z 187, 215, and 283 (the same ions were 
found in M1 spectrum), and the ion at m/z 230, resulting by the neutral loss of a 116 Da 
fragment. This fragmentation pattern indicated that the metabolites M4 and M5 arose from 
the aliphatic hydroxylation on the cyclohexan ring. Metabolite Oxy-HA gave a protonated 
molecule at m/z 346; the presence of the fragment ions at m/z 171, 229 and 246 (loss of a 100 
Da neutral fragment) indicated that oxidation on the propargyl amine moiety occurred for this 
metabolite. The structure of Oxy-HA was unequivocally confirmed by comparison of its 
retention time and MS spectrum with those of the synthetic standard.  
  






 spectra of the metabolites M1, M4, M6 and Oxy-NOs formed in HLM incubations of Oxy 
(200µM) 
 
Finally, contrary to the results of Sato et al. (2012), the formation of cyclohexylmandelic acid 
arising from the ester function hydrolysis, was never observed throughout the study. 
   
4.3.1 Phase II incubation with human liver subcellular fractions 
Glucuronidation and sulfation 
In order to assess the formation of Oxy and Oxy-HA glucuronides, HLM incubations were 
carried out in the presence of UDPGA cofactor whereas the formation of sulfates was 
assessed by incubating Oxy and Oxy-HA in the presence of human liver cytosol (HLC), with 
PAPS cofactor. All the incubations were analyzed by LC-ESI-MS in negative ionization 
mode. 
As shown in figure 3, the formation of a metabolite eluting at 4.04 min was observed in the 
Oxy-HA incubation in the presence of UDPGA, while the same peak is absent in control 
incubations. The metabolite generated a deprotonated molecule at m/z 520, corresponding to 
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the addition of 175 Da with respect to the parent compound, suggesting the formation of the 
oxybutynin hydroxylamine glucuronide. This attribution was further supported by the 
presence of the diagnostic fragment ion at 344 m/z (neutral loss of glucuronic acid) as well as 
the presence of additional fragments at m/z 502, 304
 
and 233 m/z whose structures were 
depicted in figure 4.  On the contrary, the formation of Oxy glucuronide was ruled out due to 
the lack of peaks in the LC-ESI-MS (negative ionization mode) monitoring the ion at m/z 532 
(data not shown). The absence of Oxy glucuronide indicated that the glucuronidation of Oxy 
tertiary alcohol did not occur, confirming the glucuronidation of hydroxylamine function. 
Finally the absence of peaks in LC-ESI-MS/MS chromatograms (negative ion at m/z 424) of 
Oxy-HA incubations performed in HLC fraction and in the presence of PAPS indicated that 
the sulfate metabolite was not formed (data not shown). 
 
 
Figure 3. Negative LC-ESI-MS chromatogram of HLM/UDPGA incubations of Oxy-HA a) control incubation 
with HLM; b) control incubation with UDPGA and c) with both UDPGA and HLM 
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a) HLM MS2= 520
b) UDPGA MS2= 520
c) HLM+UDPGA MS2= 520








In this work, the oxidative transformation of oxybutynin has been studied in the presence of 
human liver subcellular preparations and a metabolic scheme for in vitro metabolic fate of 
Oxy was proposed and reported in the figure 5. The metabolism showed a good degree of 
regioselectivity being oxidized the cyclohexyl and the tertiary amine moieties only. As a 
consequence, two distinct metabolic pathways were observed: the aliphatic hydroxylation and 
N-oxidation. In particular, as from literature data, Oxy is extensively metabolized and N-
desethyloxybutynin (Oxy-DE), arising from oxidative N-dealkylation is the main metabolite.  
Interestingly the formation of hydroxylated metabolites on cyclohexyl ring both on Oxy (M1-
M3) and Oxy-DE (M4-M5) was also observed for the first time; however no further 
characterization of their structures was attempted. 
The N-oxidation of Oxy to generate the diastereomeric Oxy-NOs has been previously 
proposed by Lindeke et al. (1981); however, due to the intrinsic chemical instability of Oxy-
NOs, they were not able to detect them using GC-MS analysis generally performed at high 
temperature. In this study the presence of Oxy-NOs in human liver microsomes incubations 
was detected by means of LC-MS/MS analysis. Besides, the presence of the unprecedented 
metabolite Oxy-EK was observed: its formation, through the prototropic rearrangement of 
Oxy-NOs, previously described in the Chapter 3, was proposed. Interestingly, differently 
from Oxy-NOs, Oxy-EK was a chemically and metabolically stable metabolite, which did 
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Moreover, despite the presence of an α,β-unsaturated function, no reactivity between Oxy-EK 
and GSH was observed.   
Besides, the primary metabolite Oxy-DE underwent to N-oxidation, generating the 
hydroxylamine Oxy-HA and N-deethylation to give the primary propargylamine metabolite, 
M6. The presence of Oxy-HA was confirmed by glucuronidation of hydroxylamine function 
and by means of its synthesis. It is worth of mention that the identification of Oxy-HA has not 
been reported so far. Contrary to what one might expect the formation of the metabolite 
CHMA was not detected even if the formation of this metabolite has been reported in the 
literature: this is worth of further investigation. 
 
 
Figure 5. In vitro metabolic scheme of oxybutynin 
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CHAPTER 5. Forced degradation study of selegiline  
5.1 INTRODUCTION 
Selegiline hydrochloride (SG) is an optically active compound and in its levorotatory optical 
isomer (L-deprenyl) is an irreversible inhibitor of MAO-B enzyme. Selegiline is used alone or 
in combination with levodopa in the treatment of Parkinson’s disease. Moreover clinical 
studies evaluated the use of SG as a beneficial solution to smoking addition and it may also 
have positive effects in the treatment of Alzheimer’s disease, attention deficit hyperactivity 
disorder (ADHD) and several types of depression (Riederer et al., 2004; Youdim et al., 2006). 
Selegiline, administered orally, undergoes considerably higher first pass metabolism, resulting 
in formation of amphetamine derivatives. To avoid or mitigate first pass metabolism, new 
formulations have been developed exploiting the favourable phisico-chemical properties of 
selegiline (e.g. low molecular weight (187.3) and good lipohilicity, logP: 3.4) (Chen et al. 
2011). The transdermal patches (Emsam
®
), that enable absorption through the skin, and the 
orally disintegrating tablets (Zelapar
®
), that are absorbed primarily through the buccal 
mucosa, pass directly into the bloodstream, thereby reducing the first pass metabolism. 
Moreover a thermogel was used for controlled release transdermal delivery of selegiline 
(Kalász et al., 2014). Recently Fowler et al. (2015) reported that new formulations of 
selegiline (transdermal patches and orally disintegrating tablets) also have an antidepressant 
activity at high doses, suggesting that when plasma levels of selegiline are elevated, brain 
MAO-A might also be inhibited. In fact, selegiline transdermal system (Emsam
®
) was 
approved for treating major depressive disorders.  
Two main analytical techniques have been applied to the analysis of SG in various matrices. 
HPLC-UV methods were mainly used for pharmaceutical applications (Tzanavaras et al., 
2008) and LC–MS bioanalytical assays were used for analysis of biological matrices such as 
human hair (Nishida et al., 2006) and human plasma (Slawson et al., 2002) 
In particular, to fulfil the requirements of the international guidelines (ICH, 2003), the 
analytical methods used in the field of pharmaceutical analysis should be stability-indicating. 
This aspect involves the knowledge of the intrinsic chemical stability of the drug substance 
and, as a consequence, the knowledge of the structures of degradation products and the 
corresponding degradative pathways. Moreover, in the case of selegiline the chemical 
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stability should be determined both on the free base and salt form; indeed both forms are used 
in drug product manufacturing.  
However, at the best of our knowledge, a comprehensive chemical stability study of selegiline 
was not reported so far. Hence, in the present work we have established for the first time the 
intrinsic chemical stability of SG through a forced degradation study based on LC-UV and 
LC-ESI-MS/MS analysis. In oxidative conditions, the formation of diastereomeric N-oxides 
(SG-NOs) and a novel degradation product indicator of stability, arising from rearrangement 
of tertiary propargylamine N-oxides, were identified. 
Based on these data a stability-indicating LC-UV method for simultaneous estimation of SG 
and its main degradation product was developed. The validation of the proposed method will 




5.2.1 Reagents and chemicals 
Methanol (HPLC grade), ammonium acetate, concentrated acetic acid, sodium hydroxide 
(pellets), concentrated hydrochloric acid (37%), iron (III) trichloride hexahydrate, copper 
sulphate pentahydrate, 30% w/w hydrogen peroxide solution, 4,4′-azobis-(4-cyanovaleric 
acid) (ACVA), sodium hydrogen carbonate, sodium phosphate dibasic, concentrated 
phosphoric acid,  anhydrous sodium sulphate, dichloromethane, ninhydrin, selegiline 
hydrochloride ( ≥ 99%) were purchased from Sigma-Aldrich (Milano; Italy). Water (HPLC 
grade) was obtained from Milli-Q reverse osmosis system. Propiolaldehyde diethyl acetal 
(97%) was purchased from Alfa Aesar. (+) Methamphetamine hydrochloride was purchased 
by Sigma-Aldrich (St. Louis MO; USA). Since methamphetamine is a DEA controlled item 
the purchase and the laboratory use were authorized by Ministero della Salute (Ministerial 
authorization n° UCS/SP/155). 
Column chromatography was performed on silica gel 60 (230-400 mesh ASTM Merck). TLC 
was carried out on plates with a layer thickness of 0.25 mm (silica gel 60 F254; Merck); when 
necessary, they were visualized after spraying with ninhydrin reagent. 
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5.2.2 Instrumentation and chromatographic conditions 
5.2.2.1 LC-UV analyses 
A Shimadzu HPLC system, consisting in two LC-10AD Vp module pumps and a DGU-14-A 
on-line vacuum degasser, was used. The analyses were carried out on a Luna C18(2) (150 x 
4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) column as a stationary phase. The 
isocratic mobile phase (flow rate 1.2 ml/min) was composed of eluant A ammonium acetate 
buffer (20 mM pH=5.0) and eluant B methanol, the A:B ratio being 40:60 (v/v).  
The eluants A and B were filtered through a 0.45 m PVDF membrane filter prior the use. A 
SIL-10AD Vp autosampler was used for the injection of samples (20µL). The SPD-M10A Vp 
photodiode array detector was used to detect SG and the degradation products at 210 nm and 
degradation product SG-EA at 290 nm. A LC solution 1.24 software was used to process the 
chromatograms. All the analysis were carried out at room temperature.  
 
5.2.2.2 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor PDA detector and a vacuum degasser was used for LC-
MS analysis (Thermo Electron Corporation, Waltham, MA, USA). The analysis were 
performed on a Luna C18(2) (100 x 4.6 mm I.D., 5m dp; (Phenomenex, Torrance, CA, USA) 
column as a stationary phase maintained at 35°C and protected by a Security Guard C18. The 
sample injection volume was 3 L. The mobile phase was composed of eluant A: ammonium 
acetate buffer (pH 5.0; 10 mM) and eluant B: methanol, using a gradient mode, the ratio A:B 
was set 60:40 The following gradient, at a constant flow rate of 0.2 mL/min, was used: from 0 
to 8 min, the composition was increased from 40.0 to 60.0% B. From 8 to 12 min the 
percentage of eluant B was increased again to 80.0% and then maintained 2 min. From 14 to 
14.50 the percentage of eluant B was decreased to 40.0% and then maintained 3.5 min for 
column equilibration. The eluate was injected into the electrospray ion source (ESI) and the 
MS and MS/MS spectra were acquired and processed using the Xcalibur
® 
software (Thermo 
Electron Corporation, Waltham, MA, USA).  
The operating conditions on the ion trap mass spectrometer in positive ion mode were as 
follows: spray voltage, 5.0 kV; source current, 80.0 A; capillary temperature, 350.0 °C; 
capillary voltage, 26.0 V; tube lens offset, -5.0 V; multipole 1 offset, -8.25 V; multipole 2 
offset, -9.50 V; sheath gas flow (N2), 60.0 Auxiliary Units; sweep gas flow (N2): 5.0 
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Auxiliary Units. Data were acquired both full scan and MS/MS product ion scan modes using 
mass scan range m/z 50 to 200 and m/z 80 to 600, optimizing the collision energy at 18-30%. 
 




C experiments were performed at 298K on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05T. Chemical shifts are reported in part 
per million (ppm). 
 
5.2.3 Forced degradation conditions 
Degradation studies in solution were done at a selegiline-HCl at concentration of 1 mg/mL. 
For acidic degradation study, SG was dissolved in 0.5 N HCl and the solution was left 
protected from light at 50°C for 24 h. 
The degradation in alkaline conditions was done in 0.5 N NaOH in presence of 
methanol/water 50/50 and the solution was left protected from light at 50°C for 24 hours.  
The oxidative degradation pathway was studied using four different protocols:  
a) The degradation was done in a 3% H2O2  solution (pH=5 acetate buffer); the mixture was 
left in the dark at room temperature for 24h. 
b) The degradation was done in a 1% H2O2 solution  (50/50 methanol/water) in the presence 
of sodium hydrogen carbonate; the mixture was left in the dark, at room temperature, for 
1h.  
c) To evaluate the influence of transition metals, SG solution was treated with 1.5 mM Cu2+ 
or Fe
3+
 at ambient temperature for 4h. 
d) To a solution of SG in 50/50 methanol/water, the radical iniziator ACVA, previously 
dissolved in water (1mg/ml) was added in the presence of sodium hydrogen carbonate. 
The mixture of reaction (ACVA: 1mM final concentration) was stored at 60° for 24h. 
For thermal degradation, a sample of SG was placed in a hot air oven maintained at 60°C for 
18 h.  Photodegradation studies were carried out, at room temperature, by exposing a thin 
layer (10 mg) of SG to daylight and UV-light (365 nm) for 18 days and 4 hours respectively. 
For both thermal and photodegradation tests, SG was assayed as powder. 
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5.2.4 Isolation and purification of SG-EA 
To a solution of SG (250 mg, 1.12 mmol) in 5 ml of water, 120 mg of sodium hydrogen 
carbonate 5 ml of methanol and 1 ml of 30% w/w hydrogen peroxide were added. The 
mixture was reacted, under stirring at r.t., for 16h monitoring by TLC analysis (eluant: 
CH2Cl2/MeOH 9:1). At the end of the reaction, methanol was evaporated under reduced 
pressure. The aqueous residue was extracted (3x15 ml) with CH2Cl2. The pooled organic 
layers were washed with brine, dried over anhydrous sodium sulphate, filtered and evaporated 
in vacuo to dryness. The pale-yellow oily residue was left overnight at r.t. and then purified 
by column chromatography using dichloromethane/methanol 98/2 as eluant to give pure SG-
EA (55 mg, 24% yield; 98% purity by HPLC assay at 290 nm). 
 
5.2.5 Synthesis of degradation product 
5.2.5.1 3-[methyl(1-methyl-2-phenylethyl)amino]- 2-Propenal (SG-EA)  
To a solution of propiolaldehyde, arising from propiolaldehyde diethyl acetal (90 mg, 0.7 
mmol) hydrolysis (0.2 N HCl solution, 5 mL) at 40 °C for 0.5 h, (+)-methamphetamine 
hydrochloride as free base (100 mg, 0.7 mmol) dissolved in EtOH (5 mL) was added 
dropwise. After being stirred for 2 h at 50 °C, the reaction mixture was diluted with H2O (20 
mL), and EtOH was distilled off. The pH of the aqueous phase was adjusted to 12 with 1 N 
NaOH solution, and the reaction mixture was extracted with Et2O. The ethereal solution was 
washed with H2O. The evaporation of the dried organic phase gave an oil that was purified by 
column chromatography dichloromethane/MeOH 90/10 to afford SG-EA (60 mg, 41%).  




H-NMR (300 MHz, CDCl3)  (ppm): 8.9 (d, J= 8.1 Hz, 1H), 7.26-7.19 (m, 3H), 7.07 (d, J= 
6.8 Hz; 2H), 6.86 (d, J=12.0 Hz; broad 1H), 5.03 (dd, J= 8.2 Hz, J=12.3 Hz; 1H), 3.61-3.56 
(m; 1H), 2.79(d, J=8.5 Hz; 2H), 2.69 (s, 3H), 1.29 (d, J=6.5 Hz; 3H) 
13
C-NMR (300 MHz, CDCl3)  (ppm):189.4 (CO) 158.8(C=C), 137.5 (C) 128.8 (2CH), 128.7 
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5.3 RESULTS AND DISCUSSION  
5.3.1 Forced degradation study and structural characterization of degradation products 
The chemical stability of SG was investigated following the requirements of international 
guidelines (ICH, 2003). In the Table 1 the stress conditions used in this work are summarized. 
  
Stressor  Temperature (°C) Time of the analysis 
HCl 0.5N 50 4, 24 h 
NaOH 0.5N 50 4, 24 h 
3% H2O2 pH=5 RT 4, 24 h 
1% H2O2 pH≈8 RT 1 h 
Transition metals RT 4, 24 h 
Radical initiator 60 1, 4, 24 h 
UV light RT 4 h 
Sunlight RT 18 days 
Thermal 60 18 h 
 
Table 1. Stress conditions applied in the forced degradation study of selegiline hydrochloride 
 
5.3.1.1 Degradation in acidic and basic conditions 
As expected, selegiline hydrochloride was found to be stable in acidic and alkaline conditions. 
In the presence of 0.5N NaOH and 0.5N HCl at 50°C for 24h no degradation occurred as 
showed in Figure 1a and 1b. The chromatographic peak at retention time 10.5 min is 
attributable to selegiline, no other peak corresponding to the formation of degradation 
products was observed.  
 
 
Figure 1a. LC-UV chromatogram (λa=210 nm) of SG in 0.5N NaOH solution (t= 24h at 50°C)  




















Figure 1b. LC-UV chromatogram (λa=210 nm) of SG in 0.5N HCl solution (t= 24h at 50°C) 
 
5.3.1.2 Thermal degradation and photodegradation 
For photodegradation studies, SG was exposed to daylight and 365 nm UV-light for eighteen 
days and 4h respectively; in these conditions no degradation occurred (data not shown). 
Similarly, the thermal stress test on SG was conducted without observing the formation of 
degradation product. 
 
5.3.1.3 Degradation in oxidative conditions 
The presence in selegiline of a tertiary amine aliphatic function, suggests that it could be 
oxidized to the corresponding N-oxide; in particular, since selegiline is more prone to 
oxidation in its free base form, the oxidative degradation was investigated at acidic and 
alkaline pH. Furthermore, the degradation in oxidative conditions was studied using three 
different oxidants: hydrogen peroxide, radical chain initiators and transition metal ions.  
LC-UV chromatograms reported in Figures 2-5 clearly showed the pH effect on N-oxide 
formation. In acidic pH no degradation occurred; the peak of selegiline was detected at 
tR=10.0 min, whereas the peaks appearing at tR=1.3 and 3.1 min are attributable to H2O2 and 
the solvent respectively, as evidenced by the LC-UV chromatogram of the control 
degradation (Figure 3). On the contrary, at alkaline pH, a degradation product was observed at 
tR= 2.6 min after 1h, having an absorption maximum at 210 nm (Figure 4). Moreover the 
formation of another peak at tR= 3.6 min was observed at higher wavelength (λa= 290 nm) 
(Fig.5), suggesting the presence of a new chromophore group in its structure.  
It is worth mentioning that increasing the time of degradation and/or the concentration of 
hydrogen peroxide, the intensity of the peak at 3.6 min corresponding to SG-EA increased. 
Besides, the analysis of the stress test performed at lower concentration of oxidant and/or with 
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shorter reaction time highlighted the formation of SG-NOs as the first degradation product 
followed by SG-EA. 
 
 
Figure 2. LC-UV chromatogram of SG degradation in hydrogen peroxide (pH=5, t= 4h). 
 
Figure 3. LC-UV chromatogram of control degradation in hydrogen peroxide (pH=5, t=6 h). 
 
 
Figure 4. LC-UV chromatogram (λa=210 nm) of SG in 1% H2O2 (alkaline solution, t= 1h) 
  






































Figure 5. LC-UV chromatogram (λa=290 nm) of SG in 1% H2O2 (alkaline solution, t= 1h) 
 
The oxidative degradation of selegiline was evaluated also in the presence of the radical 
initiator ACVA in slightly alkaline conditions. In the chromatogram reported in Figure 6, the 
peak at tR= 10.5 min is attributable to selegiline, whereas the formation of the peak of SG-NO 
was not detected. On the contrary, when the LC-UV analysis was performed at higher 
wavelength (λa= 290nm) the presence of a degradation product (Figure 7a) was observed, 
being its chromatographic properties identical to those of the peak SG-EA observed in Figure 
5. The presence of SG-EA was confirmed by the analysis of the synthetical standard (Figure 
7b). As previously reported regarding the chemical stability of oxybutynin hydrochloride, the 




Figure 6. LC-UV chromatogram (λa=210 nm) of SG in presence of radical initiator (t= 24h) 
  



























Figure 7a. LC-UV chromatogram (λa=290 nm) of SG in presence of radical initiator (t= 24h) 
 
 
Figure 7b. LC-UV chromatogram (λa=290 nm) of SG-EA synthetic standard 
 




, SG did 
not undergo degradation as showed in the LC-UV chromatograms reported in the Figure 8a 
and 8b. Possibly the lack of oxidative degradation in the presence of transition metal ions 
could be due to the acidic conditions used in the test  promoting the presence of the 
protonated form of selegiline.  
  




































5.3.2 Structural characterization of selegiline degradation products by LC-ESI-MS/MS 
analysis 
In order to obtain information on the structures of the degradation products formed in 
oxidative conditions, the degradation test samples were analyzed by LC-ESI-MS/MS. 
The LC-ESI-MS analysis of the H2O2/NaHCO3 sample, showed the formation of two 
degradation products (SG-NOs) in the full mass chromatogram (Figure 9, top), having the 
same protonated ion at m/z 204, and corresponding to the insertion of an oxygen atom in the 
structure of selegiline free base ([M+H]
+ 
= 188).  The presence of the tertiary amine function 
and the same fragment ion pattern in their MS/MS spectra (Fig. 10) suggested that they are 
the diastereomeric N-oxides of selegiline. Since selegiline N-oxides were the first degradation 
products detected in the stress test done in the presence of low concentration of hydrogen 
peroxide, they could represent the first step in the oxidative degradation of selegiline.   




























Figure 9. LC-MS chromatogram of SG in 1% H2O2 (alkaline solution, t= 1h) 
 
 
 Figure 10. LC-MS
2
 fragmentation patterns of SG-NOs and SG-EA  
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Selegiline N-oxides appeared rather unstable, forming, over the time, a secondary degradation 
product, SG-EA, showing a similar but not identical MS
2
 spectrum (Figure 10). In particular, 
the peak of SG-EA protonated molecule is far more intense than those of SG-NOs indicating 
the high stability of the secondary degradation product. 
The assignment of the structure to SG-EA was based on the findings of Szabó and Hermecz 
(2001), concerning the chemistry of tertiary propargylamine N-oxides, and our results about 
the chemical stability of oxybutynin hydrochloride (Chapter 3): these data suggested the 
synthesis of selegiline enaminoaldehyde through the reaction of methamphetamine with the in 
situ generated propiolaldehyde to give SG-EA standard whose mass spectral data and 
chromatographic characteristics are identical to those of the degradation product (Figure 11). 
 
 
Figure 11. LC-MS chromatogram and MS
2
 spectrum of SG-EA synthetic standard 
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Interestingly, the spectroscopic properties (Figure 12) of SG-EA were in accordance with the 
presence of enaminoaldehyde moiety in its structure; indeed the absorption maximum at 290 
nm is due to the enamino-aldehyde chromophore which was not found in selegiline and 
selegiline N-oxides whose UV-Vis spectra showed an absorption maximum at about 210 nm. 
 
 
Figure 12. UV spectra of SG, SG-NO, and the SG-EA. The UV spectra were recorded during the LC-UV 
analysis (see experimental part) 
 
A plausible mechanism of formation of SG-EA could be proposed on the basis of literature 
data (Szabó and Hermecz 2001; Szabó et al., 2004): this involves the formation of 
isoxazolinium intermediate, generated by addition of the selegiline N-oxide oxygen to the 
carbon-carbon triple bond and subsequent proton transfer from a protic solvent. Subsequently 







































































In the present work the instrinsic chemical stability of SG was evaluated by a forced 
degradation study using LC-UV and LC-MS/MS analysis. In oxidative condition the 
formation of a new and unprecedented degradation product SG-EA was identified and the 
degradation scheme for selegiline was proposed and reported in the figure 14.  
 
 
Figure 14. Oxidative degradation pathways of selegiline  
 
The formation of SG-EA take place through the rearrangement of the primary degradation 
products  selegiline N-oxides. As expected, the oxidative degradation is dependent on the pH 
and selegiline in the protonated form did not undergo N-oxidation and the subsequent 
rearrangement to SG-EA. This feature indicate that are no concern for drug products in which 
selegiline is used as hydrochloride salt. However since SG free base results more prone to 
oxidation, the oxidative degradation should be taken into account in the course of stability 
study of the drug products (e.g. transdermal system) containing selegiline free base as a drug 
substance. Though selegiline N-oxides were the primary degradation products, their instability 
prevented their use as the indicators of stability in the development of stability-indicating 
analytical methods for the determination of selegiline and its impurities. On the contrary SG-
EA was stable and synthetically accessible in pure form and it could be advantageously 
employed as the indicator of stability for oxidative stresses and included in the development 
of stability-indicating analytical methods for selegiline. Moreover the presence in the SG-EA 
structure of a α,β-unsaturated aldehydo group which could behave as a Michael acceptor 
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reacting with nucleophilic functions of biological macromolecules, suggest to test this 
compound for its potential toxicity/genotoxicity. 
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CHAPTER 6. New findings in the in vitro metabolism of selegiline  
6.1 INTRODUCTION 
Selegiline hydrochloride (SG) or L-deprenyl is a potent, irreversible and selective inhibitor of 
monoamine oxidase B (MAO-B) and is used in the treatment of Parkinson’s disease.  
Selegiline is quickly absorbed after oral administration and undergoes considerably higher 
first pass metabolism. The metabolism of selegiline has been extensively studied in literature 
in the past fifty years and it is well known that SG is predominantly metabolized into 
methamphetamine, amphetamine and N-desmethylselegiline. In addition more than 40 minor 
metabolites of selegiline have also been either detected or proposed as recently reviewed by 
Kalász et at., 2014. Among these, the formation of selegiline N-oxide as a metabolite of 
selegiline has been suggested by Wu and Ichikawa (1995) and was also identified in human 
urine (Katagi et al., 2001; Katagi et al, 2002). 
Lévai et al. (2004) described the formation of selegiline N-oxides (SG-NOs) in vitro from 
selegiline in liver microsomal preparations from different species, reporting that the extent of 
formation is species-dependent. They reported that the formation of SG-NOs was more 
intensive in dog and hamster microsomal preparations, whilst less SG-NOs were formed in 
the mouse, guinea pig and rabbit ones, and very little selegiline was metabolized to SG-NOs 
in the human preparation. Moreover they reported the synthesis of selegiline N-oxides 
hydrochloride salt (as a 1:1 mixture of the diastereomers), whose structure was confirmed by 
MS and NMR data.  
The chromatographic separation of the R,R-selegiline-NO and R,S-selegiline-NO was 
achieved by means of a HPLC method, which also allows to determine the diastereomeric 
form of selegiline-N-oxide that is preferentially originated in the different animal species. In 
particular the R,S-diastereomer is preferentially formed in the liver microsomal preparations 
of dog, rat, rabbit, mouse, guinea pig and human, whilst the R,R-selegiline-NO is the 
preferred form in the hamster microsomes. Moreover the authors suggested that the formation 
of selegiline-NOs might be catalyzed, at least partly, by the isoforms CYP2D6 and CYP3A4. 
No further metabolites were detected after incubation of the mixture of selegiline-NOs with 
rat liver microsomes. 
Interestingly, although the formation of SG-NOs has been examined in deep by Levai et al. 
(2014) and the formation of rearrangement product from tertiary propargylamine N-oxides 
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has been described in literature (Szabó and Hermecz, 2001), no rearrangement product from 
SG-NOs was reported in their study. 
The aim of this work is to achieve more insights in the metabolic fate of selegiline, focusing 
our attention on the potential formation of the rearrangement product arising from selegiline 
N-oxide. This hypothesis was suggested by the results of the chemical stability study of 
selegiline reported in chapter 5 and on the basis of the results obtained in the in vitro 
metabolism study of oxybutynin. 
 
6.2 EXPERIMENTAL 
6.2.1 Reagents and chemicals 
Methanol (HPLC grade), ammonium acetate, concentrated acetic acid, selegiline 
hydrochloride (≥ 99%), 2-mercaptoethanol were purchased from Sigma-Aldrich (Milano; 
Italy). Water (HPLC grade) was obtained from Milli-Q reverse osmosis system.  
 
6.2.2 Instrumentation and chromatographic conditions 
6.2.2.1 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor PDA detector and a vacuum degasser was used for LC-
MS analysis (Thermo Electron Corporation, Waltham, MA, USA). The analysis were 
performed on a Luna C18(2) (100 x 4.6 mm I.D., 5m dp; (Phenomenex, Torrance, CA, USA) 
column as a stationary phase maintained at 35°C and protected by a Security Guard C18. The 
sample injection volume was 3 L. The mobile phase was composed of eluant A: ammonium 
acetate buffer (pH 5.0; 10 mM) and eluant B: methanol, using a gradient mode, the ratio A:B 
was set 60:40 The following gradient, at a constant flow rate of 0.2 mL/min, was used: from 0 
to 8 min, the composition was increased from 40.0 to 60.0% B. From 8 to 12 min the 
percentage of eluant B was increased again to 80.0% and then maintained 2 min. From 14 to 
14.50 the percentage of eluant B was decreased to 40.0% and then maintained 3.5 min for 
column equilibration. The eluate was injected into the electrospray ion source (ESI) and the 
MS and MS/MS spectra were acquired and processed using the Xcalibur
® 
software (Thermo 
Electron Corporation, Waltham, MA, USA). The operating conditions on the ion trap mass 
spectrometer in positive ion mode were as follows: spray voltage, 5.0 kV; source current, 80.0 
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A; capillary temperature, 350.0 °C; capillary voltage, 26.0 V; tube lens offset, -5.0 V; 
multipole 1 offset, -8.25 V; multipole 2 offset, -9.50 V; sheath gas flow (N2), 60.0 Auxiliary 
Units; sweep gas flow (N2): 5.0 Auxiliary Units. Data were acquired both full scan and 
MS/MS product ion scan modes using mass scan range m/z 50 to 200 and m/z 80 to 600, 
optimizing the collision energy at 18-30%. 
 
6.2.3 Rat and Human liver microsomes 
Male Wistar rat liver microsomes (RLM), (protein concentration: 25mg/ml, total P450: 0.64 
nmol/mg protein) and the cryopreserved pooled human liver microsomes (HLM), (pooled 
mixed sex, ten individual donors, protein concentration: 20 mg/ml, total P450: 0.36 nmol/mg) 
were purchased from BD Gentest™ (Woburn, MA) and used throughout this study. The 
incubations were all carried out using a horizontal DUBNOFF shaking thermostatic bath 
(Dese Lab Research, Padova, Italy) and were protected from light. 
 
6.2.4 In vitro RLM and HLM incubations of selegiline 
The standard incubation mixture (500 µl final volume), in 1.5 ml Eppendorf tubes, was 
carried out in a 50 mM TRIS buffer (pH 7.4) containing 3.3 mM MgCl2, 1.3 mM NADPNa2, 
3.3 mM glucose 6-phosphate, 0.4 Units/ml glucose 6-phosphate dehydrogenase and 100 µM 
SG. After pre-equilibration of the mixture, an appropriate volume of microsomal suspension 
was added to give a final protein concentration of 1 mg/ml. The mixture was shaken for 60 
min at 37°C, and the reaction was quenched by diluting the samples with 500 µl of ice-cold 
acetonitrile. The samples were then centrifuged at 13,000 rpm for 5 min, and the supernatant 
was directly injected onto the column for analysis. Control incubations without the presence 
of substrate, NADP(H)-regenerating system, or microsomes were also carried out. 
 
6.2.5 In vitro RLM incubation of SG-EA 
The standard incubation mixture (500 µl final volume), in 1.5 ml Eppendorf tubes, was 
carried out in a 50 mM TRIS buffer (pH 7.4) containing 3.3 mM MgCl2, 1.3 mM NADPNa2, 
3.3 mM glucose 6-phosphate, 0.4 Units/ml glucose 6-phosphate dehydrogenase and 100 µM 
SG-EA. After pre-equilibration of the mixture, an appropriate volume of microsomal 
suspension was added to give a final protein concentration of 1 mg/ml. The incubation, the 
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sample preparation and the analysis of supernatants were performed following the same 
procedure described before. 
6.2.6 Incubation of selegiline in the presence of nucleophilic trapping agents 
The formation of electrophilic species in SG incubations was studied by adding 2-
mercaptoethanol (final concentration: 3mM) to the incubation mixture. The incubations were 
performed using the same conditions reported in the paragraph 6.2.4. The sample were then 
centrifuged to remove the insoluble matter and an aliquot (3µl) was analyzed by LC-ESI-MS. 
 
6.3 RESULTS AND DISCUSSION 
The oxidative metabolism of selegiline was assessed through an in vitro study performed in 
rat and human liver microsomes.  
The LC-ESI-MS analyses of the RLM and HLM incubations are reported in figures 1a and 1b 
and showed the formation of three metabolites having the same protonated molecule at m/z 
204, and corresponding to the insertion of an oxygen atom in the structure of selegiline free 
base ([M+H]
+ 
= 188). It is worth of mention that in the present study no attempt to separate 
the peaks of SG-NOs was undertaken. Nonetheless, the formation of two N-oxides may be 
inferred from the presence of a shoulder on the peak at 4.80 min; the intensity of the peak at 
4.80 min is higher in RLM than in HLM incubations, as previously highlighted in literature 
(Lévai et al., 2004). The identity of the metabolites SG-NOs, formed in RLM and HLM 
incubations, was assigned comparing the retention time and the fragmentations patterns 
(Figure 2) with those of SG-NOs synthetic standard (Figure 3) that was freshly prepared from 
the reaction of selegiline with hydrogen peroxide, as previously reported in the Chapter 5. 
  




Figure 1. LC-MS/MS chromatograms of rat and human microsomal incubations of SG (100µM) (a,b).  






 spectra of SG-NOs formed in rat and human microsomal incubations of SG (100µM).  
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spectrum of a freshly prepared sample of SG-NOs using hydrogen peroxide 
 
Besides the formation of SG-NOs, a new and more lipophilic metabolite (SG-EA) was 
observed in the chromatograms reported in figures 1a and 1b. The assignment of its structure  
was achieved by comparing its retention time with that of the authentic reference compound 
(figura 1c), whose synthesis has been reported in the Chapter 5. Moreover the evaluation of  
the fragmentation pattern in the LC-MS
2
 spectrum confirmed that the structure of the new 
metabolite SG-EA, formed in RLM and in HLM incubations, matched with that of the 





spectra of SG-EA formed in RLM and HLM incubations and LC-MS
2 
spectra of the synthetic 
SG-EA standard (SG-EA STD)  
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According to the results obtained during the chemical stability study of selegiline 
hydrochloride, as well as on the data of Szabò and Hermecz (2001), it is possible to 
hypothesize that SG-EA was formed through the chemical rearrangement of SG-NOs, as 




Figure 5. Proposed mechanism of the rearrangement of selegiline N-oxides 
 
Another hypothesis to explain the metabolic formation of SG-EA arises from the known 
reactivity of propiolaldehyde with amine derivatives to form enaminoaldehyde. Indeed, since 
propioladehyde and methamphetamine were metabolites, formed during the enzymatic N-
dealkylation of SG, they might react together giving SG-EA.  
 
 
Figure 5. LC-MS/MS chromatograms of HLM incubation (SG: 100µM) monitoring the ion at m/z 204: a) 
without 2-mercaptoethanol, b) with 2-mercaptoethanol (3mM) 
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However, this hypothesis was ruled out since the formation of SG-EA was observed, in the 
incubations carried out in the presence of 2-mercaptoethanol used as nucleophilic trapping 
agent (figure 5). This fact showed that the reaction between the propioladehyde and 2-
mercaptoethanol does not interfere with the formation of SG-EA which depends on oxidation 
of propargylamine moiety. 
Finally to evaluate the formation of other potential metabolites from further transformation of 
SG-EA, the incubation of the synthetic standard in RLM microsomes was performed: no 
metabolite could be detected by LC-ESI-MS/MS confirming the relevant stability of SG-EA 
(data not shown).  
 
6.4 CONCLUSION 
The metabolic fate of selegiline was extensively described in literature and several 
metabolites were proposed and identified so far. In this work the oxidative metabolism of 
selegiline was re-investigated focusing the attention on the potential formation of SG-EA 
through the rearrangement of SG-NOs. As expected, the presence of SG-EA was detected in 
the incubations with rat and human liver microsomes and its formation might not appear to be 
catalyzed by enzymes, but due to the prototropic rearrangement of SG-NOs. Interestingly, 
differently from SG-NOs, SG-EA was a stable metabolite which did not seem undergo to 
further oxidative and hydrolytic transformation.  
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CHAPTER 7. Forced degradation study of rasagiline: identification and 




Rasagiline mesylate ((1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate, 
RG) is a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B) enzyme.  
Rasagiline has been used for the treatment of idiopathic Parkinson’s disease (PD) both as 
monotherapy and as adjunctive therapy for levopoda in advanced disease. The recommended 
oral dosage for initial monotherapy is 1 mg once daily. When rasagiline is used as adjunctive 
therapy with levopoda, the recommended initial dose is 0.5 mg/day and may be increased to 
1mg/day if the desired clinical effect is not achieved. In patients with advanced PD and motor 
fluctuations, the maximum daily dosage could be increased to 5 mg. Rasagiline is well 
tolerated and is not associated with “cheese effect”. The “cheese effect” is the risk of a 
tyramine pressor response after ingestion of foods rich in tyramine, which normally is 
metabolized by MAO type A in the gastrointestinal tract (Lin et al., 2013). 
Tablets of rasagiline mesylate (Azilect
®
) are available on the market while transdermal 
patches are under development; the free base form of rasagiline is a promising candidate for 
delivery via the transdermal delivery system due to its relatively low-molecular weight, high 
potency and lipid solubility (Lin et al., 2013)  
A literature survey showed that several stability-indicating methods were developed for the 
determination of rasagiline in tablet dosage forms (Lakshmi et al., 2010; Narendra Kumar et 
al., 2010; Venkatesh et al., 2012) and in some papers the stability of rasagiline under different 
stress conditions was evaluated (Kathirvel et al., 2012; Shelke et al., 2014 )  
The formation of a degradation product in presence of hydrogen peroxide was reported by 
Balaji et al. (2013), revealing that rasagiline is sensitive to peroxide compared to other 
conditions, but the characterization of the unknown product was not attempted. 
In the publication of Reddy et al. (2012) a forced degradation study was performed 
identifying the impurities from synthesis, whereas not further information is available on the 
structure of the unknown product arising from stress tests.  
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Overall, these data showed that the structure(s) of the degradation product(s) of rasagiline and 
the corresponding degradation pathways were not elucidated so far. 
In this work we investigated the chemical stability of rasagiline in all the stress conditions 
required by the international guidelines. In oxidative conditions we identified two new 




7.2.1 Reagents and chemicals 
Methanol (HPLC grade), ammonium acetate, concentrated acetic acid, sodium hydroxide 
(pellets), concentrated hydrochloric acid (37%), iron (III) trichloride hexahydrate, copper 
sulphate pentahydrate, 30% w/w hydrogen peroxide solution, 4,4′-azobis-(4-cyanovaleric 
acid) (ACVA), acrylonitrile, m-chloroperbenzoic acid (m-CPBA), sodium hydrogen 
carbonate, sodium phosphate dibasic, concentrated phosphoric acid, anhydrous sodium 
sulphate, dichloromethane and ninhydrin were purchased from Sigma-Aldrich (Milano; Italy). 
Propiolaldehyde diethyl acetal (97%) was purchased from Alfa Aesar. Water (HPLC grade) 
was obtained from Milli-Q reverse osmosis system. Column chromatography was performed 
on silica gel 60 (230-400 mesh ASTM Merck). TLC was carried out on plates with a layer 
thickness of 0.25 mm (silica gel 60 F254; Merck); when necessary, they were visualized after 
spraying with ninhydrin reagent. 
Rasagiline mesylate (potency ≥ 99%), was purchased from Biovision Inc. (California, USA) 
 
7.2.2 Instrumentation and chromatographic conditions 
7.2.2.1 LC-UV analyses  
A Shimadzu HPLC system, consisting in two LC-10AD Vp module pumps and a DGU-14-A 
on-line vacuum degasser, was used. The analyses were carried out on a Luna C18(2) (150 x 
4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) column as a stationary phase, 
protected by a Security Guard C18. The isocratic mobile phase (flow rate 1.0 ml/min) was 
composed of eluant A ammonium acetate buffer (20 mM pH=5.0) and eluant B methanol, 
being the A:B ratio 42:58 (v/v). The eluants A and B were filtered through a 0.45 m PVDF 
membrane filter prior the use. A SIL-10AD Vp autosampler was used for the injection of 
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samples (20µL). The SPD-M10A Vp photodiode array detector was used to detect RG and the 
degradation product (RG-NOH) at 210 nm whereas the degradation product RG-EA was 
monitored at 285 nm. A LC solution 1.24 software was used to process the chromatograms. 
All the analysis were carried out at room temperature.  
 
7.2.2.2 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor PDA detector and a vacuum degasser was used for LC-
MS analysis (Thermo Electron Corporation, Waltham, MA, USA). The analysis were 
performed on a Luna C18(2) (100 x 4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) 
column as a stationary phase maintained at 35°C and protected by a Security Guard C18. The 
sample injection volume was 3 L. The mobile phase was composed of eluant A: ammonium 
acetate buffer (pH 4.7; 10 mM) and eluant B: acetonitrile, using a gradient elution, the ratio 
A:B was set 95:5. The following gradient, at a constant flow rate of 0.2 ml/min, was used: 
from 0 to 7 min, the composition was increased from 5.0 to 17.0% B. From 7 to 16 min the 
percentage of eluant B was increased again to 80.0% and then maintained 2 min. From 18 to 
18.50 min the percentage of eluant B was decreased to 5.0% and then maintained 4 min for 
column equilibration. When appropriate, the eluate was injected into the Surveyor PDA 
detector and the LC-UV chromatograms were acquired and processed using the Xcalibur
® 
software (Thermo Electron Corporation, Waltham, MA, USA).  
The eluate was injected into the electrospray ion source (ESI) and the MS and MS/MS spectra 
were acquired and processed using the Xcalibur
® 
software (Thermo Electron Corporation, 
Waltham, MA, USA).  
The operating conditions of the ion trap mass spectrometer in positive ion mode were as 
follows: spray voltage, 5.0 kV; source current, 80.0 A; capillary temperature, 275.0 °C; 
capillary voltage, 4.0 V; tube lens offset, -40.0 V; multipole 1 offset, -2.0 V; multipole 2 
offset, -7.0 V; sheath gas flow (N2), 60.0 Auxiliary Units; sweep gas flow (N2): 6.0 Auxiliary 
Units. Data were acquired both full scan and MS/MS product ion scan modes using mass scan 
range m/z 50 to 200 and m/z 80 to 600, optimizing the collision energy at 18-30%.  
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C experiments were performed at 298K on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05T. Chemical shifts are reported in part 
per million (ppm).  
 
7.2.3 Forced degradation conditions 
Degradation studies in solution were done at a RG concentration of 1 mg/mL. For the acidic 
degradation study, RG was dissolved in 0.5 N HCl and the solution was left protected from 
light at 50°C for 48 h. 
The degradation in alkaline conditions was done in 1 N NaOH in presence of methanol/water 
50/50 and the solution was left protected from light at 50°C for 48h.  
The oxidative degradation pathway was studied using four different protocols: 
a) The degradation was done in a 3% H2O2 solution (pH=5.0 acetate buffer); the mixture 
was left in the dark at room temperature for 24h. 
b) The degradation was prepared in a 3% H2O2 solution (50/50 methanol/water) in 
presence of sodium hydrogen carbonate and it was left in the dark at room temperature 
for 6h.  





 at ambient temperature for 4 h. 
d) To a solution of RG in 50/50 methanol/water, the radical initiator ACVA, previously 
dissolved in water (1 mg/mL) was added in presence of sodium hydrogen carbonate. 
The mixture of reaction (ACVA: 1 mM final concentration) was stored at 60° for 24h. 
For thermal degradation, a sample of RG was placed in a hot air oven maintained at 60°C for 
18 h. Photodegradation studies were carried out, at room temperature, by exposing a thin 
layer (10 mg) of RG to daylight and UV-light (365 nm) for 15 days and 4 hours respectively.  
For both the thermal and photodegradation tests, RG was assayed as powder.  
 
7.2.4 Sample preparation 
Before LC-UV and LC-MS/MS analyses, acidic and alkaline samples were first neutralized 
by addition of a suitable amount of sodium phosphate dibasic and diluted phosphoric acid 
(8.5% w/v) respectively, and then diluted with mobile phase. The other stressed samples were 
dissolved or tenfold diluted in mobile phase only; finally, solid samples were dissolved in  
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mobile phase to attain ~0.1 mg/ml concentration. For comparison purposes a freshly prepared 
aqueous solution of RG (~1 mg/ml) was diluted and analyzed as above 
 
7.2.5 Synthesis of degradation product 
7.2.5.1 Rasagiline free base (RG free base) 
1.0 g of racemic 1-aminoindan (7.50 mmol) and 1.04 g of K2CO3 (7.52 mmol) were added to 
7.5 mL of acetonitrile. The resulting suspension was heated to 60°C and 450 mg of propargyl 
chloride (6.04 mmol) were added dropwise. The mixture was stirred at 60°C overnight, after 
which most of the volatiles were removed under vacuum. The residue was partitioned 
between 2.5N aqueous sodium hydroxide and dichloromethane. The pooled organic layers 
were dried over anhydrous sodium sulphate, filtered and evaporated in vacuo to dryness. The 
pale-yellow oily residue was purified by column chromatography eluting with ethyl acetate/ 
petroleum ether 20/80 to give pure RG free base (730 mg, 57% yield; 99% purity by HPLC 
assay). 




7.2.5.2 Rasagiline hydroxylamine (RG-NOH) [2,3-Dihydro-N- hydroxy-N-2-propynyl-1H-
inden-1-amine] 
Acrylonitrile (500 mg, 9.41 mmol) was added under stirring to a solution of RG free base 
(300 mg, 1.75 mmol) in methanol (5 mL). The reaction mixture was stirred at room 
temperature for 1 month and the methanol was added during this period to compensate for 
evaporation. The reaction was constantly monitored by TLC and, at the end, the methanol was 
evaporated under reduced pressure. The resultant yellow oil was purified by flash 
chromatography on silica gel eluting with dichloromethane, yielding 0.35 g (90%) of N-




ESI-MS: calculated for C15H16N2 M= 224.30; Found m/z = 225 [M+H]
+
   




H-NMR (300 MHz, CDCl3)  (ppm): 7.43 (m; 1H), 7.25-7.21 (m, 3H), 4.54 (t, J= 7,3; 1H), 
3.49 (m; 2H), 2.93-2.79 (m; 4H), 2.52 (t, J= 7,0; 2H), 2.25-2.21 (m; 2H), 2.20-2.05 (m; 1H) 
 
A stirred solution of N-cyanoethylrasagiline (0.300g, 1.34 mmol) in dry CH2Cl2 (10 mL) was 
cooled to –78°C and m-CPBA (77%, 0.110 g, 0.49 mmol) was added. 
The reaction mixture was stirred under nitrogen atmosphere at –78°C for 3 hours, and then 
washed with ice-cold aqueous 10% K2CO3 solution (3 x 10 mL), water (3 x 10 mL), saturated 
NaCl solution (3 x 10 mL), and dried over anhydrous sodium sulfate. Evaporation of the 
solvent gave the crude product, which was purified by silica gel flash column chromatography 
eluting with ethyl acetate/petroleum ether 20/80 affording 0.185g (74% yield) of rasagiline 









H-NMR (300 MHz, CDCl3)  (ppm): 7.49 (d, J=6.9; 1H), 7.25-7.16 (m, 3H) 6.56 (broad 
1H), 4.51(dd, J=7.1; J=3.3; 1H), 3.56 (m; 2H), 3.08-3.03 (m; 1H), 2.83-2.80 (m; 1H), 2.33-
2.04 (m; 3H). 
 
7.2.5.3 3-[2,3-dihydro-1H-inden-1-yl(prop-2-yn-1-yl)amino]prop-2-enal (RG-EA) 
To a solution of propiolaldehyde, arising from propiolaldehyde diethyl acetal (230 mg, 1.8 
mmol) hydrolysis (0.2N HCl solution, 5 mL) at 40 °C for 0.5 h, RG free base (307 mg, 1.8 
mmol) dissolved in EtOH (5 mL) was added dropwise.  
After being stirred for 2 h at 50 °C, the reaction mixture was diluted with H2O (20 mL), and 
EtOH was distilled off. The pH of the aqueous phase was adjusted to 12 with 1N NaOH 
solution, and the reaction mixture was extracted with Et2O (15 mL). The pooled organic 
layers (phases) were washed with H2O. The evaporation of the solvent gave a yellow powder 
that was purified by column chromatography (ethyl acetate/ petroleum ether 20/80) to afford 
RG-EA (121 mg, 30%).  










H-NMR (300 MHz, CDCl3)  (ppm): 9.12 (d, J=7.9; 1H), 7.28-7.19 (m, 5H) 5.44 (dd, J=8.2; 
J=13.1; 1H), 5.06 (s, 1H), 3.79-3.77 (m; 2H), 3.03-2.87 (m; 2H), 2.54-2.51 (m; 1H), 2.28-
2.15 (m; 2H). 
 
7.3 RESULTS AND DISCUSSION  
7.3.1 Forced degradation study and structural characterization of degradation products 
Forced degradation studies of RG were previously reported in literature, however the 
identification of the related degradation products formed under a variety of stress conditions 
was not achieved. In the present work all the stress conditions required by ICH guidelines 
were included in order to identify the degradation products arising from stress testing and to 
establish the corresponding degradation pathways. Moreover in order to avoid unrealistic 
degradation pathways, the conditions were adjusted to obtain a 10–25% degradation of the 
parent compound.  
The structure characterization of degradation products was achieved by in LC-UV and LC–
ESI-MS/MS analysis and by means of synthesis of authentic standards. The degradation 
conditions employed in this study are summarized in the Table 1. 
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Stressor  Temperature (°C) Time of the analysis 
HCl 0.5N 50 48 h 
NaOH 1N 50 48 h 
3% H2O2 pH=5 RT 6, 24 h 
3% H2O2 pH≈8 RT 6, 24 h 
Transition metals RT 4, 24 h 
Radical initiator 60 4, 24 h 
UV light RT 4 h 
Sunlight RT 15 days 
Thermal 60 18 h 
Table 1. Stress conditions applied in the forced degradation study of rasagiline mesylate 
 
7.3.1.1 Degradation in acidic and basic conditions 
Rasagiline was found to be stable in acidic and alkaline conditions. In presence of 1N NaOH 
and 5N HCl at 50°C for 48 h no degradation occurred as showed in Figure 1a and 1b. The 
chromatographic peak at retention time 2.9 min is attributable to rasagiline; no other peak 
corresponding to the formation of degradation products was observed.  
 
Figure 1a. LC-UV chromatogram (λa=210 nm) of RG in 0.5N HCl solution (t= 48h at 50°C). 
  



















Figure 1b. LC-UV chromatogram (λa=210 nm) of RG in 1N NaOH solution (t= 48h at 50°C) 
 
7.3.1.2 Photodegradation and thermal degradation 
For photodegradation studies, RG was exposed to daylight and 365 nm UV-light for two 
weeks and 4h respectively, in these conditions no degradation occurred (data not shown).  
Similarly, the thermal stress test of RG was conducted without observing the formation of 
degradation product. 
 
7.3.1.3 Degradation in oxidative conditions 
The degradation in oxidative conditions was studied using three different protocols, in 





). Rasagiline is characterized by the presence of a secondary amine susceptible 
to oxidation to its corresponding hydroxylamine; in particular, since rasagiline is more prone 
to oxidation in its free base form, the oxidative degradation was investigated both in acidic 
and alkaline pH.  
LC-UV chromatograms reported in Figures 2-4 clearly showed the pH effect on the N-
oxidation of the secondary amine. At acidic pH no degradation occurred (Fig. 2); the peak at 
tR=2.94 min is attributable to rasagiline and the peak at tR=1.73 min is due to the hydrogen 
peroxide reagent as highlighted in the LC-UV chromatogram of the control degradation (Fig 
3). Conversely, in hydrogen peroxide at alkaline pH, the presence of a degradation product 
(RG-NOH) was observed at tR=7.48 min, having an absorption maximum at 210 nm (Figure 
4).   



















Figure 2. LC-UV chromatogram of RG degradation in hydrogen peroxide (pH=5, t=6 h). 
 
 
Figure 3. LC-UV chromatogram of control degradation in hydrogen peroxide (pH=5, t=6 h). 
 
 
Figure 4. LC-UV chromatogram (λa=210 nm) of RG in 3% H2O2 alkaline solution (t= 6h) 
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The oxidative degradation of RG was evaluated also in the presence of the radical initiator 
ACVA; in this condition the formation of the peak of RG-NOH was not detected (Fig. 5) 
whereas the presence of a degradation product at tR=5.40 min, having an absorption 
maximum at 285 nm was pointed out (Figure 6).  
 
 




Figure 6. LC-UV chromatogram (λa=285 nm) of RG in the presence of radical initiator (t= 24h) 
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, RG did not undergo degradation as 
showed in the LC-UV chromatograms reported in the Figure 7 and 8. 
Once again the lack of oxidative degradation in the presence of transition metal ions could be 
due to the acidic conditions used in the test. 
 
 




Figure 8. LC-UV chromatogram of RG degradation in the presence of Cu
2+ 
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7.3.2 Structural characterization of rasagiline degradation products by LC-ESI-MS/MS 
analysis 
In order to obtain information on the structures of the degradation products formed in 
oxidative conditions, the degradation test samples were analyzed by LC-ESI-MS/MS. 
The LC-ESI-MS/MS analysis of the H2O2/NaHCO3 sample, showed the formation of the 
degradation product RG-NOH at m/z 188 (Figure 9), corresponding to the insertion of an 
oxygen atom in the structure of rasagiline free base. The MS
2
 spectrum of RG-NOH (Fig. 9) 
showed the presence of two fragment ions at m/z 117 and m/z 72: unfortunately, they are not 
sufficiently diagnostic for the attribution of the structure of RG-NOH. 
 
 
Figura 9. LC-MS chromatogram of RG in 3% H2O2 alkaline solution (t= 6h) monitoring the ion at m/z 188 and 
LC-MS
2
 fragmentation pattern of RG-NOH  
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The presence in the RG structure of a secondary amine function, susceptible to oxidation, 
suggested the formation of the rasagiline hydroxylamine, whose synthesis starting from 
rasagiline, was performed following the procedure reported by Hanson et al. (2010); the 
procedure involved the N-alkylation of the secondary amine with acrylonitrile, followed by N-
oxidation with m-CPBA and Cope elimination of the protecting group. 
The LC-ESI-MS/MS analysis of the standard obtained by synthesis showed the presence of a 









Figura 10. LC-MS chromatogram of RG in 3% H2O2 alkaline solution (t= 6h) monitoring the ion at m/z 172 and 
m/z 188 (a); LC-MS chromatogram of RG-NOH synthetic standard monitoring the ion at m/z 172 and m/z 188 
(b) 
 
Figura 11.  MS
2
 spectrum of RG-NOH synthetic standard 
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In general, secondary hydroxylamines are not usually very stable and hence difficult to 
isolate. On the contrary what one might expect this compound was stable and was isolated 
and completely characterized.  
 
The chemical stability of RG was also evaluated in presence of the radical initiator ACVA. 
As shown in LC-UV analysis (Fig. 6), the presence of a degradation product having a higher 
retention time than RG (2.9 vs 5.4) and an absorption maximum at 285 nm was observed. 
To obtain further information regarding the structure of the degradation product a LC-MS 
analysis was performed showing the presence of a peak at tR= 16.11 min (Fig. 12), having a 
protonated molecule at m/z 226 (+54 Da more than RG). The LC-MS/MS spectrum of peak at 
m/z 226 showed a main fragment ion at m/z 109 (loss of indane scaffold) as reported in the 
figure 13. The product obtained showed the same mass spectral data and chromatographic 
characteristics of the metabolite RG-EA observed during the in vitro metabolism study of 
rasagiline (Chapter 8). The formation of RG-EA in presence of radical initiator could be 
explained exploiting the property of rasagiline to form radical species through the activation 
of propargylamine moiety rather than the addiction of propiolaldehyde to the structure of RG; 
however, this hypothesis was not confirmed and further investigation is required to assess the 






 chromatogram of RG presence of radical initiator 
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7.4 CONCLUSION 
In the present work the intrinsic chemical stability of rasagiline was investigated by a forced 
degradation study using LC-UV and LC-MS/MS analysis. In oxidative conditions the 
formation of two different degradation products RG-NOH and RG-EA was observed and the 
degradation scheme for rasagiline was proposed in the figure 14.  
As expected, the oxidative degradation is dependent on the pH and RG free base results more 
prone to oxidation; this should be taken into account in the course of stability study of the 
drug products (e.g. transdermal system) containing RG free base as a drug substance. The 
identification and the synthesis of two degradation products allowed the development of a 
stability-indicating HPLC-UV method for the determination of RG in the active ingredient 




Figure 14. Oxidative degradation pathways of rasagiline   
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CHAPTER 8. In vitro metabolism study of Rasagiline 
 
8.1 INTRODUCTION  
L-Monoamino oxidases (MAO) (EC 1.4.3.4) are a family of a flavin-containing enzymes 
responsible for the oxidative deamination of a wide range of biogenic amines (e.g., dopamine 
and noradrenaline) and which is widely distributed in most tissue of mammals (Gong et al., 
2006). Moreover, MAO are membrane-bound enzymes mainly located in mithocondria and 
two isoforms owing different selectivities for substrates and inhibitors, known as monoamine 
oxidase type A (MAO-A) and type B (MAO-B), have been characterized so far. In particular, 
MAO-B is involved in the neurodegenerative events leading to Parkinson’s disease and the 
inhibition of this enzyme system has been proposed to have a protective effect against the 
degeneration of dopaminergic neurons. Propargylamines are a class of amine compounds that 
potently and selectively inhibit MAO-A (e.g chlorgiline) or MAO-B (e.g. pargiline, selegiline 
and rasagiline), through an irreversible site-directed inhibition, forming a covalent bond with 
the N5 nitrogen of flavin, a component of the enzyme active site. 
Accordingly, rasagiline mesylate (N-propargyl-1(R)-aminoindan mesilate, RG), a selective 
and irreversible MAO-B inhibitor, has been developed for the treatment of idiopathic PD that 
is characterized by a deficiency of dopamine in nigrostriatal nerve terminals (Tabakman et al., 
2004). Rasagiline has been used both as monotherapy and as adjunctive therapy for levodopa 
in advanced disease. The recommended initial dose is 0.5 mg administered once daily. If a 
sufficient clinical response is not achieved, the dose may be increased to 1 mg administered 
once daily (Azilect
®
 package insert). Upon oral administration, RG is rapidly absorbed and 
widely distributed into body tissues and cross the blood-brain-barrier. Maximum plasma 
concentration of rasagiline is reached approximately at 5h after an oral dose of 2 mg, and the 
elimination half-life is about 0.6-2h. The absolute bioavailability is ~36%, indicating that 
rasagiline undergoes a significant first-pass metabolism, but inversely to what occurs with 
selegiline no amphetamine metabolites are formed. Indeed, selegiline, whose structure is 
based on a methamphetamine scaffold, is extensively metabolized to neurotoxic L-
methamphetamine and L-amphetamine.  
On the contrary, 1-(R)-aminoindan (AI) is the major metabolite of rasagiline. In literature, the 
data regarding the pharmacological activity of 1-(R)-aminoindan (AI), are conflicting. Some 
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authors suggested that AI is not pharmacologically active (Chen et al., 2007), whereas the 
neuroprotective properties of AI were proposed by others (Bar-Am et al., 2010). 
 
More in general, the metabolic fate of rasagiline has been previously highlighted in the 
literature by several authors. Lecht et al. (2007) stated that the main metabolic pathway is via 
N-dealkylation to form AI and by hydroxylation to form 3-hydroxy-N-propargyl-1-
aminoindan (3OH-RG). Other authors (Youdim et al., 2001; Finberg, 2010; Chen et al., 
2005) claimed that AI was the main metabolite without mentioning the hydroxylation 
pathway. Interestingly, all these statements were entirely or partially based on data found in 
the Azilect
®
 package insert in which is reported that the metabolism of rasagiline proceeds 
through two main pathways: N-dealkylation and/or hydroxylation to yield: AI, 3OH-RG and 
3-hydroxy-1-aminoindan (3OH-AI); moreover the glucuronidation of rasagiline and its 
metabolites, with subsequent urinary excretion, was also reported.  
As expected, these data were also found in the Azilect
®
 product information available from 
EMA (EMA, Azilect, Product Information, 2009); however, in the corresponding scientific 
discussion, (EMA, Azilect, Scientific Discussion 2005) while the formation of AI and 3OH-
RG was reported, the formation of metabolite 3OH-AI did not. Moreover, it was also stated 
that the sulphation or glucuronidation acid occurred during the metabolism of rasagiline.  
Overall these data appear to agree with the formation of AI as the primary metabolite but at 
the same time they do not on the formation of other metabolites. For example, although the 
presence of the metabolite 3OH-AI is mentioned in the monograph of Azilect
®
 no further 
references are available (could be found) supporting its formation.  
Finally, to the best of our knowledge no experimental data were reported in literature about in 
vitro/in vivo metabolism of rasagiline. Taken together these considerations prompted us to 
investigate the in vitro metabolism of RG in the presence of both rat and human microsomes. 
Beside the well-known AI and 3OH-RG, new metabolites arising from oxidative metabolism 
were identified by means of LC-MS and LC-UV analyses and synthesis, while their biological 
activities will be studied.  
  




8.2.1 Reagents and chemicals 
Methanol (HPLC grade), acetonitrile (HPLC grade), ammonium acetate, concentrated acetic 
acid, sodium hydrogen carbonate, semicarbazide hydrochloride, polyoxyethylene 20 cetyl 
ether (Brij 58), acrylonitrile, m-chloroperbenzoic acid (m-CPBA) were purchased from 
Sigma-Aldrich (Milano; Italy). Propiolaldehyde diethyl acetal (97%) was purchased from 
Alfa Aesar. Water (HPLC grade) was obtained from Milli-Q reverse osmosis system 
(Millipore Co., Billerica MA, USA). (±)-Aminoindan (99%), propiolaldehyde diethyl acetal 
(97%) were purchased from Alfa Aesar. Column chromatography was performed on silica gel 
60 (230-400 mesh ASTM Merck). TLC was carried out on plates with a layer thickness of 
0.25 mm (silica gel 60 F254; Merck); when necessary, they were visualized after spraying 
with ninhydrin reagent. RG (potency ≥ 99%) was purchased from Biovision Inc.(California, 
USA). The following compounds were synthetized  according to literature procedures: 3OH-
AI and 3OH-RG (Luan et al., 2013); 7OH-AI and 7OH-RG (Sterling et al., 2002).; 4OH-AI, 
4OH-RG, 6OH-AI and 6OH-RG (Herzig et al., 2005). 
 
8.2.2 Instrumentation and chromatographic conditions 
8.2.2.1 LC-UV analyses  
A Shimadzu HPLC system, consisting in two LC-10AD Vp module pumps and a DGU-14-A 
on-line vacuum degasser, was used. The analyses were carried out on a Luna C18(2) (150 x 
4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) column as a stationary phase, 
protected by a Security Guard C18. The mobile phase (flow rate 1.2 ml/min) was composed 
of eluant A, ammonium acetate buffer (20 mM pH=5), and eluant B, methanol, while the 
initial ratio A:B was set at 60:40. The elution was done using the following gradient: from 0 
to 12 min, the composition was increased from 40.0 to 90.0% B and then maintained 5 min. 
From 18 min, the percentage of eluant B was decreased to 40.0% and then maintained for 
column equilibration. The eluants A and B were filtered through a 0.45 m PVDF membrane 
filter prior the use. A SIL-10AD Vp autosampler was used for the injection of samples 
(20µL). The SPD-M10A Vp photodiode array detector was used to detect RG and the 
metabolite (RG-NOH) at 210 nm whereas the metabolites RG-EA and AI-EA were 
monitored at 285 nm. A LC solution 1.24 software was used to process the chromatograms. 
All the analysis were carried out at room temperature.   
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8.2.2.2 LC-MS/MS analyses 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, a 
Surveyor AS autosampler, a Surveyor PDA detector and a vacuum degasser was used for LC-
MS analysis (Thermo Electron Corporation, Waltham, MA, USA). The analysis were 
performed on a Luna C18(2) (100 x 4.6 mm I.D., 5m dp; Phenomenex, Torrance, CA, USA) 
column as a stationary phase maintained at 35°C and protected by a Security Guard C18. The 
sample injection volume was 3 L. The mobile phase was composed of eluant A: ammonium 
acetate buffer (pH 4.7; 10 mM) and eluant B: acetonitrile, using a gradient elution, the ratio 
A:B was set 95:5. The following gradient, at a constant flow rate of 0.2 mL/min, was used: 
from 0 to 7 min, the composition was increased from 5.0 to 17.0% B. From 7 to 16 min the 
percentage of eluant B was increased again to 80.0% and then maintained 2 min. From 18 to 
18.50 min the percentage of eluant B was decreased to 5.0% and then maintained 4 min for 
column equilibration. When appropriate, the eluate was injected into the Surveyor PDA 
detector and the LC-UV chromatograms were acquired and processed using the Xcalibur
® 
software (Thermo Electron Corporation, Waltham, MA, USA).  
The eluate was injected into the electrospray ion source (ESI) and the MS and MS/MS spectra 
were acquired and processed using the Xcalibur
® 
software (Thermo Electron Corporation, 
Waltham, MA, USA).  
The operating conditions of the ion trap mass spectrometer were as follows: positive modes 
spray voltage, 5.0 kV; source current, 80.0 A; capillary temperature, 275.0 °C; capillary 
voltage, 4.0 V; tube lens offset, -40.0 V; multipole 1 offset, -2.0 V; multipole 2 offset, -7.0 V; 
sheath gas flow (N2), 60.0 Auxiliary Units; sweep gas flow (N2): 6.0 Auxiliary Units. 
Negative mode: spray voltage, 3.4 kV; source current, 80.0 A; capillary temperature, 275.0 
°C; capillary voltage, -15.0 V; tube lens offset, -30.0 V; multipole 1 offset, 5.0 V; multipole 2 
offset, 7.0 V; sheath gas flow (N2), 60.0 Auxiliary Units; sweep gas flow (N2): 6.0 Auxiliary 
Units. Data were acquired both full scan and MS/MS product ion scan modes using mass scan 
range m/z 50 to 200 and m/z 80 to 600, optimizing the collision energy at 18-30%.  
 




C experiments were performed at 298K on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05T. Chemical shifts are reported in part 
per million (ppm).  
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8.2.3 Human intestinal and liver microsomes 
The cryopreserved Pooled Human Intestinal Microsomes (HIM), (pooled mixed sex, protein 
concentration: 10 mg/ml, total P450: 0.26 nmol/mg) and Pooled Human Liver Microsomes 
(HLM), (pooled mixed sex, ten individual donors, protein concentration: 20 mg/ml, total 
P450: 0.36 nmol/mg) were purchased from BD Gentest™ (Woburn, MA) and used 
throughout this study. 
 
8.2.4 Rat liver cytosol and microsomes 
Male Sprague-Dawley rat liver cytosol (RLC), (protein concentration: 20 mg/ml, 
sulfotransferase: 0.64 nmol/mg protein) and male Wistar rat liver microsomes (RLM), 
(protein concentration: 25mg/ml, total P450: 0.64 nmol/mg protein) were purchased from BD 
Gentest™ (Woburn, MA) and used throughout this study. 
The incubations were all carried out using a horizontal DUBNOFF shaking thermostatic bath 
(Dese Lab Research, Padova, Italy) and were protected from light. 
 
8.2.5 In vitro RLM, HLM and HIM incubations of rasagiline 
The standard incubation mixture (500-µl final volume), in 1.5-ml Eppendorf tubes, was 
carried out in a 50-mM TRIS buffer (pH 7.4) containing 3.3-mM MgCl2, 1.3-mM NADPNa2, 
3.3-mM glucose 6-phosphate, 0.4-Units/ml glucose 6-phosphate dehydrogenase and 100µM 
or 500µM RG. After pre-equilibration of the mixture, an appropriate volume of microsomal 
suspension was added to give a final protein concentration of 1 mg/ml. The mixture was 
shaken for 60 min at 37°C, and the reaction was quenched by diluting the samples with 500 µl 
of ice-cold acetonitrile. The samples were then centrifuged at 13,000 rpm for 5 min, and the 
supernatant was directly injected onto the column for analysis.  Control incubations without 
the presence of substrate, NADP(H)-regenerating system, or microsomes were also carried 
out. 
 
8.2.6 Chemical stability of RG-NOH 
The chemical stability of the freshly prepared RG-NOH synthetic standard was evaluated at 
two different temperatures protecting the samples from light. An aliquot of RG-NOH (~10 
mg) was stored as is at room temperature for 96h. A second aliquot of RG-NOH (~10 mg) 
was dissolved in a 50 mM TRIS∙HCl buffer (pH 7.4) to give a concentration of 1 mg/ml, in 
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presence of acetonitrile (1% of total volume) and left in a shaking thermostatic bath at 37°C 
for 96h. The LC-UV and LC-MS analyses were carried out at 0, 4, 8, 24, 48, 72, 96h by 
weighing and dissolving, in 50/50 (v/v) methanol/water, an appropriate amount of RG-NOH 
control sample and diluting the sample to attain ≈ 0.1 mg/ml concentration. 
 
8.2.7 Phase I metabolic stability of RG-NOH 
The standard incubation mixture (500µl final volume), in 1.5-ml Eppendorf tube, was carried 
out in a 50 mM TRIS buffer (pH 7.4) containing 3.3-mM MgCl2, 1.3-mM NADPNa2, 3.3-mM 
glucose 6-phosphate, 0.4-Units/ml glucose 6-phosphate dehydrogenase and 500µM RG-
NOH. After pre-equilibration of the mixture, an appropriate volume of microsomal 
suspension (RLM) was added to give a final protein concentration of 1 mg/ml. The 
incubation, protein precipitation and analysis of supernatants were performed following the 
same procedure described in the paragraph 8.2.5.  
 
8.2.8 Incubation of rasagiline in the presence of nucleophilic trapping agents  
The formation of electrophilic species in RG incubations was studied by adding 2-
mercaptoethanol or semicarbazide hydrochloride (final concentration: 3mM) to the incubation 
mixture. The incubations were performed using the same conditions reported in the paragraph 
8.2.5. The samples were then centrifuged to remove the insoluble matter and an aliquot (3µl) 
was analysed by LC-UV and/or LC-ESI-MS. 
 
8.2.9 Phase II incubations 
8.2.9.1 RLM glucuronidation 
The standard incubation mixture (500-µl final volume), in 1.5-ml Eppendorf tube, was carried 
out in a 50 mM TRIS∙HCl buffer (pH 7.4) containing 5 µL of acetonitrile (1% of total 
volume), 2.0 mM UDPGA and 500µM RG-NOH.  
After pre-incubation of the mixture, an appropriate volume of microsomal suspension, 
previously activated in Brij 58 surfactant (0.5 mg/mg protein) for 15 min at 0°C, was added to 
give a final protein concentration of 1 mg/ml.  
The mixture was shaken for 60 min at 37°C, and the reaction was quenched by diluting the 
samples with 500 µl of ice-cold acetonitrile. Control incubations were done without the 
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presence of UDPGA. The samples were then centrifuged at 13,000 rpm for 5 min, and the 
supernatants were analysed by LC-UV and LC-ESI-MS. 
 
8.2.9.2 Cytosol sulfation  
The standard incubation mixture, in Eppendorf tube, was carried out in a 50 mM TRIS∙HCl 
buffer (pH 7.4) containing 5 µL of acetonitrile (1% of total volume), 0.2 mM PAPS and 
500µM RG-NOH. After pre-equilibration of the mixture, an appropriate volume of cytosol 
suspension, was added to give a final protein concentration of 2 mg/ml; the mixture was 
shaken for 60 min at 37°C and the reaction was quenched by diluting the samples with 500 µl 
of ice-cold acetonitrile. Control incubations were done without the presence of PAPS. The 
samples were centrifuged and analysed as reported for glucuronidation assay. 
 
8.2.10 Synthesis of reference standards 
8.2.10.1 Rasagiline free base (RG free base) 
1.0 g of racemic 1-aminoindan (7.50 mmol) and 1.04 g of K2CO3 (7.52 mmol) were added to 
7.5 mL of acetonitrile. The resulting suspension was heated to 60°C and 450 mg of propargyl 
chloride (6.04 mmol) were added dropwise. The mixture was stirred at 60°C overnight, after 
which most of the volatiles were removed under vacuum. The residue was partitioned 
between 2.5N aqueous sodium hydroxide and dichloromethane. The pooled organic layers 
were dried over anhydrous sodium sulphate, filtered and evaporated in vacuo to dryness. The 
pale-yellow oily residue was purified by column chromatography eluting with ethyl acetate/ 
petroleum ether 20/80 to give pure RG free base (730 mg, 57% yield; 99% purity by HPLC 
assay). 




8.2.10.2 Rasagiline hydroxylamine (RG-NOH) [2,3-Dihydro-N- hydroxy-N-2-propynyl-1H-
inden-1-amine] 
Acrylonitrile (500 mg, 9.41 mmol) was added under stirring to a solution of RG free base 
(300 mg, 1.75 mmol) in methanol (5 mL). The reaction mixture was stirred at room 
temperature for 1 month and the methanol was added during this period to compensate for 
evaporation. The reaction was constantly monitored by TLC and, at the end, the methanol was 
evaporated under reduced pressure. The resultant yellow oil was purified by flash 
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chromatography on silica gel eluting with dichloromethane, yielding 0.35 g (90%) of N-








H-NMR (300 MHz, CDCl3)  (ppm): 7.43 (m; 1H), 7.25-7.21 (m, 3H), 4.54 (t, J= 7,3; 1H), 
3.49 (m; 2H), 2.93-2.79 (m; 4H), 2.52 (t, J= 7,0; 2H), 2.25-2.21 (m; 2H), 2.20-2.05 (m; 1H) 
 
A stirred solution of N-cyanoethylrasagiline (0.300g, 1.34 mmol) in dry CH2Cl2 (10 mL) was 
cooled to –78°C and m-CPBA (77%, 0.110 g, 0.49 mmol) was added. 
The reaction mixture was stirred under nitrogen atmosphere at –78°C for 3 hours, and then 
washed with ice-cold aqueous 10% K2CO3 solution (3 x 10 mL), water (3 x 10 mL), saturated 
NaCl solution (3 x 10 mL), and dried over anhydrous sodium sulfate. Evaporation of the 
solvent gave the crude product, which was purified by silica gel flash column chromatography 
eluting with ethyl acetate/petroleum ether 20/80 affording 0.185g (74% yield) of rasagiline 








H-NMR (300 MHz, CDCl3)  (ppm): 7.49 (d, J=6.9; 1H), 7.25-7.16 (m, 3H) 6.56 (broad 
1H), 4.51(dd, J=7.1; J=3.3; 1H), 3.56 (m; 2H), 3.08-3.03 (m; 1H), 2.83-2.80 (m; 1H), 2.33-
2.04 (m; 3H). 
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8.2.10.3 3-(2,3-dihydro-1H-inden-1-ylamino)prop-2-enal (AI-EA) 
To a solution of propiolaldehyde, arising from propiolaldehyde diethyl acetal (230 mg, 1.8 
mmol) hydrolysis (0.2N HCl solution, 5 mL) at 40 °C for 0.5 h, 1-aminoindan (240 mg, 1.8 
mmol), dissolved in EtOH (5 mL), was added dropwise.  
After being stirred for 2 h at 50 °C, the reaction mixture was diluted with H2O (20 mL), and 
EtOH was distilled off. The reaction mixture was extracted with Et2O. The evaporation of the 
organic phase gave an oil that was purified by column chromatography eluting with 
dichloromethane/MeOH 95/5, to afford AI-EA (50 mg, 9% yield).  
 
 





H-NMR (300 MHz, CD3OD)  (ppm): 8.91-8.79 (m; 1H) 7.62-7.44 (m; 1H), 7.25 (m; 4H), 
5.52-5.37 (m; 1H), 5.00-4.81 (m; 1H), 3.01-2.90 (m; 2H), 2.58-2.54 (m; 1H), 1.95-1.91 (m; 
1H).  
 
8.2.10.4 RG-EA 3-[2,3-dihydro-1H-inden-1-yl(prop-2-yn-1-yl)amino]prop-2-enal   
To a solution of propiolaldehyde, arising from propiolaldehyde diethyl acetal (230 mg, 1.8 
mmol) hydrolysis (0.2N HCl solution, 5 mL) at 40 °C for 0.5 h, RG free base (307 mg, 1.8 
mmol) dissolved in EtOH (5 mL) was added dropwise.  
After being stirred for 2 h at 50 °C, the reaction mixture was diluted with H2O (20 mL), and 
EtOH was distilled off. The pH of the aqueous phase was adjusted to 12 with 1N NaOH 
solution, and the reaction mixture was extracted with Et2O (15 mL). The pooled organic 
layers (phases) were washed with H2O. The evaporation of the solvent gave a yellow powder 
that was purified by column chromatography (ethyl acetate/ petroleum ether 20/80) to afford 
RG-EA (121 mg, 30%). 
  










H-NMR (300 MHz, CDCl3)  (ppm): 9.12 (d, J=7.9; 1H), 7.28-7.19 (m, 5H) 5.44 (dd, J=8.2; 
J=13.1; 1H), 5.06 (s, 1H), 3.79-3.77 (m; 2H), 3.03-2.87 (m; 2H), 2.54-2.51 (m; 1H), 2.28-
2.15 (m; 2H). 
 
8.2.10.5 MS-PROP (3-[(2-hydroxyethyl)thio]- 2-Propenal)  
To a solution of propiolaldehyde, arising from propiolaldehyde diethyl acetal (230 mg, 1.8 
mmol) hydrolysis (0.2N HCl solution, 5 mL) at 40 °C for 0.5 h, 2-mercaptoethanol (140 mg, 
1.8 mmol) dissolved in EtOH (5 mL) was added dropwise.  
After being stirred for 2 h at 50 °C, the reaction mixture was diluted with H2O (20 mL), and 
EtOH was distilled off. The pH of the aqueous phase was adjusted to 12 with 1N NaOH 
solution, and the reaction mixture was extracted with Et2O. The pooled organic phases were 
washed with H2O. The evaporation of the solvent gave MS-PROP as a yellow oil (79 mg, 
33% yield).   
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8.3 RESULTS AND DISCUSSION 
As previously highlighted in the literature, the metabolic fate of rasagiline was reported in the 
Azilect
®
 monograph only. Rasagiline is primarily metabolized by hepatic cytochrome P-450 
isoenzyme 1A2-mediated N-dealkylation followed by renal excretion of the conjugated 
rasagiline and the conjugated metabolites. The major metabolite is 1-(R)-aminoindan, a non-
amphetamine compound, lacking the deleterious activity associated with the amphetamine 
metabolites of the first generation MAO-B inhibitor selegiline. However, since no 
experimental data could be found in the rasagiline monograph as well as in literature, an in 
vitro metabolism study was undertaken to clarify, in particular, the oxidative metabolic 
pathways. Indeed, an in vivo study could not be suitable for the identification of rasagiline 
metabolites because of their very low plasma concentrations. The study was performed in the 
presence of both rat and human subcellular preparations using 500 and 100 µM rasagiline 
concentrations. In particular the higher rasagiline concentration has been employed to 
increase the formation of the metabolites allowing their structural identification. However, the 
incubations were also done at lower concentration (100 µM) to confirm the presence of the 
metabolites while avoiding the potential formation of artifacts due to the high substrate 
concentration. Ideally, an even lower rasagiline concentration (e.g. 1 µM) would have been 
more appropriate to conduct the study in conditions more similar to those in vivo. However 
the LC-MS/MS apparatus used throughout this study does not allow to detect the metabolites 
at such concentrations.  
The LC-ESI-MS analyses of the RLM and HLM incubations, performed at 500 µM, were 
reported in the figures 1 and 2, revealing that rasagiline was extensively metabolized and 
beside the well know metabolites aminoindan and 3-hydroxy-rasagiline, four (AI-EA, RG-
NOH, RG-EA, 3OH-RG-EA) new metabolites, arising from oxidative biotransformation, 
were identified.  
 




Figure 1. LC-ESI-MS chromatograms (positive mass-range screening) of RLM incubation of RG (500 µM): (a) 
m/z 134, (b) m/z 172, (c) m/z 188, (d) m/z 226, (e) m/z 242. 
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Figure 2. LC-ESI-MS chromatograms (positive mass-range screening) of HLM incubation of RG (500 µM): (a) 
m/z 134, (b) m/z 172, (c) m/z 188, (d)  m/z 226, (e) m/z 242. 
 
8.3.1 Metabolite 1-(R)-aminoindan (m/z 134) 
As expected, the known metabolite, 1-(R)-aminoindan, arising from the oxidative N-
dealkylation of RG, was detected at m/z 134 in LC-MS chromatograms of the incubations 
done in the presence of RLM and HLM preparations (Figures 1a and 2a). Moreover the 
retention time of the metabolite matched with that of the synthetic standard. According to 
literature data, AI represents, both in rat and human liver preparations, the main metabolite 
formed in in vitro incubations. 1-(R)-aminoindan, the major metabolite of rasagiline, is a non-
amphetamine metabolite, thus avoiding potent deleterious activity associated with the 
amphetamine metabolites of the first generation MAO-B inhibitor, selegiline. Various 
neuroprotective studies demonstrated that AI possess beneficial pharmacological effects in 
animal and cell culture models of PD (Bar-Am et al., 2010).   
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8.3.2 Metabolites at m/z 188 
LC-MS
2
 analysis performed at m/z 188 of RLM and HLM incubations revealed the presence 
of 3/4 metabolites (3OH-RG, AI-EA and RG-NOH) depending on the species investigated: 
the protonated molecules (m/z 188) suggest that an oxidation occurred with the insertion, for 
each metabolite, of an oxygen atom on RG structure. 
It is worth of mention that in the RLM incubations (Figure 1c) only one polar metabolite was 
formed (3OH-RG, peak at 3.28 min) while in HLM incubation (Figure 2c) a couple of 
metabolites (3OH-RG, peaks at 3.34 and 6.05 min) was observed instead. 
All the MS
2
 spectra of the metabolites 3OH-RG showed a common fragmentation pattern, 
characterized by the fragment ions at m/z 170 [M+H-18]
+
 and at m/z 133 [M+H-55]
+ 
 (Figure 
3a). These features suggest that metabolites eluting at 3.34 and 6.05 min are diastereomers. 
This hypothesis was confirmed by the synthesis of the corresponding reference standard 
compounds whose mass spectral and chromatographic data resulted identical to those of the 
metabolites. As highlighted in the introduction, the formation of 3OH-RG was already 
reported in the Azilect
®
 monograph, however no mention was done about the formation of the 








AI-EA and RG-NOH showed similar fragmentation pathways, 
being the main fragment ions at m/z 117 [M+H-71]
+
 and at m/z 72 [M+H-116]
+
 (Figure 3b,c): 
unfortunately these ions were not sufficiently diagnostic for the attribution of the structures to 
the metabolites. 






 spectra of the metabolites 3OH-RG, AI-EA and RG-NOH 
 
Taking into account the presence of a benzene ring in the structure of rasagiline, the aromatic 
hydroxylation could form the corresponding hydroxylated metabolites 4-hydroxyrasagiline 
(4OH-RG), 6-hydroxyrasagiline (6OH-RG) and 7-hydroxyrasagiline (7OH-RG). However 
this hypothesis was ruled out by the synthesis of the reference standards of these putative 
metabolites. Their mass spectra showed the fragmentation patterns not comparable (Figure 4) 
with those of AI-EA and RG-NOH. In particular the presence of the fragment ion at m/z 133 
indicated the presence of the hydroxylated benzene ring in the indane scaffold: this feature 
was not observed in the AI-EA and RG-NOH mass spectra. 
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 spectra of the putative metabolites 4OH-RG, 6OH-RG and 7OH-RG 
 
Moreover, the retention times of the synthetic standards did not match those of the 
metabolites formed in incubation (Figure 5). Possibly the higher retention time showed by 
7OH-RG (9.95 min) could be due to appreciable intramolecular H-bonding (O-H- -N) 
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 chromatograms of the putative metabolites 4OH-RG, 6OH-RG and 7OH-RG 
 
The synthesis of the potential metabolite 5OH-RG has not been attempted because of the 
elusive nature of this compound as previously reported by Herzig et al. (2006). 
The assignment of the structure to the unknown metabolites RG-NOH and AI-EA was 
performed by comparison of their mass spectral and chromatographic data with those of the 
corresponding reference standards synthetized on the basis of the following hypothesis. 
 
8.3.2.1 RG-NOH 
The presence in the RG structure of a secondary amine function, susceptible to oxidation, 
suggested the formation of rasagiline hydroxylamine whose synthesis, starting from 
rasagiline, was performed following the method reported by Hanson et al. (2010); the 
procedure involved the N-alkylation of the secondary amine with acrylonitrile, followed by N-
oxidation with m-CPBA and Cope elimination of the protecting group.  
Indeed, hydroxylamine are important metabolic products of N-oxidation of aliphatic primary 
and secondary amines. However, many are unstable in aqueous solutions in the presence of 
oxygen, especially at alkaline pH values and in the presence of metal ions (Beckett et al., 
1977).  As a consequence, the fate of hydroxylamine in vivo and in vitro conditions is still not 
well understood. Even if, in our study, RG-NOH appeared stable during the incubation, 
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sample preparation and analysis procedures, the chemical and metabolic stability of RG-
NOH were studied more in deep.  
 
Chemical stability of RG-NOH  
The chemical stability of RG-NOH was evaluated, at room temperature and at 37°C, in the 
same buffer (50 mM TRIS∙HCl, pH 7.4) used in the metabolic study; and at fixed times, 
aliquots were withdrawn and directly analyzed by the LC-UV method described above.  
As determined by LC-UV analyses, RG-NOH was stable at room temperature over the time 
course of 96h. However, when the study was performed at 37°C, RG-NOH was not stable 
forming a degradation product, increasing over the time (Figures 6 and 7) characterized by a 
retention time lower than RG-NOH (8.1 vs 10.12 min), and an absorption maximum higher 




Figure 6. LC-UV chromatogram (λa= 281 nm) of RG-NOH in 
pH=7.4 TRIS∙HCl buffer at 37°C after 1h. 
  



















Figure 7. LC-UV chromatogram (λa= 281nm) of RG-NOH in 
pH=7.4 TRIS∙HCl buffer at 37°C after 23h. 
 
To obtain further information regarding the structure of the degradation product a LC-MS 
analysis was performed showing the presence of a peak at tR= 15.02 having a protonated 
molecule at m/z 186 with a loss of 2 amu compared to RG-NOH (Fig. 9). The MS/MS 
spectrum of peak at m/z 186 showed a fragment ion at m/z 169 (loss of OH) and a main 
fragment ion at m/z 117 (indane scaffold) corresponding to the neutral loss of 69 Da (the 
enamine aldehyde moiety). On the basis of these data and of the results obtained in the 
structure assignment of AI-EA (dealing with the structure assigned to RG-EA), we 
tentatively propose for RG-NOH-DP the structure reported in the figure 8.  
 
 
Figure 8. Proposed structure for RG-NOH-DP  
 
Since the chemical reactivity of the metabolites and of the degradation products is of 
relevance in the field of drug stability studies, we evaluate the reactivity of RG-NOH-DP in 
the presence of 2-mercaptoethanol; the LC-MS analysis showed that RG-NOH-DP 
disappeared giving an adduct characterized by a protonated molecule at m/z 264 
corresponding to the addition of 2-mercaptoethanol to RG-NOH-DP.   



















 spectra of RG-NOH-DP and the corresponding 2-mercaptoethanol adduct 
 
Indeed, the mass spectrum of ion at m/z 264 (Figure 9) gave a main fragment ion at m/z 148 
and a minor one at m/z 117 both arising from N=C cleavage. Furthermore, the mass spectrum 
of RG-NOH-DP did not show the presence of the fragment ion at m/z 148. It is of relevance 
to note that, per se, RG-NOH did not form any adduct in the presence of 2-mercaptoethanol. 
A search in literature revealed that the stability of primary and secondary hydroxylamines has 
been studied. In particular, the chemical stability of amphetamine hydroxylamine and 
methamphetamine hydroxylamine was investigated in pH 8.4 potassium phosphate buffer 
(Cashman et al., 1999) showing their instability. Amphetamine hydroxylamine, a primary 
amine, was converted to the corresponding oxime with a half-life of 3.5 h, whereas the half-
life of methamphetamine hydroxylamine was significantly longer being approximately of 
13h; however the degradation product arising from methamphetamine hydroxylamine has not 
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Phase I metabolic stability of RG-NOH 
The metabolic stability of RG-NOH was assessed by its incubation in the presence of RLM 
in the same conditions (37°C, 1h) used for rasagiline metabolism. In addition, parallel 
experiment without the presence of RLM was conducted as control.  
The presence of RG-NOH-DP was observed both in the incubations with or without 
microsomes. This result confirmed that the formation of RG-NOH-DP is due to the chemical 
instability of RG-NOH. Moreover it is worth of mention that in the incubation of rasagiline in 
RLM, the formation of RG-NOH-DP was not detected over 1h period.  
This result could be explained taking into account the fact that RG-NOH was formed at low 
concentration in the incubation mixture and the presence of its degradation product was not 
detected in this condition. 
 
Phase II metabolic stability of RG-NOH 
Glucuronidation and sulfation 
To assess the formation of the potential conjugate metabolites of RG-NOH, the incubations 
were carried out in the presence of RLM with UDPGA as cofactor for the glucuronidation and 
in the presence of rat liver cytosol (RLC), with PAPS as cofactor, for sulfation. The analyses 
of all the incubations were done by a LC-ESI-MS method in full-scan negative-ion mode. As 
shown in figure 10, in the presence of RLM/UDPGA, the formation of a metabolite with 
retention time of 12.7 min was observed, which is not found in control incubations. The 
metabolite is characterized by a protonated molecule [M-H]
-
 at m/z 362, corresponding to the 
addition of 175 Da to the mass of the parent drug, suggesting the formation of the glucuronide 
of rasagiline hydroxylamine. The product ion scan spectra of peak at m/z 362 showed the 
diagnostic fragment ions at m/z and 175 [Gluc-H]
-
 and 157 [Gluc-H-H2O] whereas the ion at 
m/z
 
193 is attributable to neutral loss of glucuronic acid (Figure 10). 
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Figure 10. Negative LC-ESI-MS chromatogram of RLM/UDPGA incubation of RG-NOH and negative ESI-
MS-MS spectrum (m/z 362) of peak at tR= 12.71 minutes 
 
In the case of the incubations performed in the presence of RLC/PAPS, LC-ESI-MS analysis 
in full-scan negative-ion mode revealed that no sulphate metabolites were formed.  
 
8.3.2.2 AI-EA 
Some hypotheses were advanced to clarify the mechanism of formation of the metabolite AI-
EA (m/z 188). According to the well described mechanism of prototropic rearrangement of 
tertiary propargylamine N-oxides (Szabó and Hermecz, 2001), and taking into account the 
formation in the incubation of RG-NOH, it is possible to hypothesize that after the oxidation 
of rasagiline to RG-NOH, the latter could undergo to a rearrangement forming the enamino 
aldehyde moiety found in the structure of AI-EA (Figure 11). 
 
 
Figure 11. Hypothesis for the formation of AI-EA through the rearrangement of RG-NOH  
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However this hypothesis was not confirmed because, as reported above, RG-NOH in TRIS 
buffer (pH 7.4, 50 mM) at 37°C did not form AI-EA but the degradation product RG-NOH-
DP instead. Even if the hypothesis of the rearrangement did not appear correct, nonetheless it 
suggested the synthesis of the enaminoaldehyde derivative of AI. This was easily 
accomplished by reacting the in situ generated propiolaldehyde with AI. The product obtained 
showed the same mass spectral data and chromatographic characteristics of the metabolite AI-
EA. The reactivity of propiolaldehyde with amine derivatives to form enaminoaldehyde 
suggested also another hypothesis to explain the metabolic formation of AI-EA.  Since the 
propiolaldehyde was formed during the enzymatic N-dealkylation of RG, it could react with 
AI. This hypothesis was supported also by the high concentration (500µM) of rasagiline used 
in the incubation: indeed, in this condition, it is reasonable to postulate that propiolaldehyde 
and AI reach a sufficient concentration to react each other forming eventually AI-EA.  
However the incubation performed in the presence of 2-mercaptoethanol did not cause a 
decrease in the formation of AI-EA. Indeed 2-mercaptoethanol reacts with propiolaldehyde to 
give the corresponding addiction compound and preventing the reaction with rasagiline. 
Similarly, the incubation of rasagiline performed at lower concentration (100µM) did not 
cause the expected decrease of AI-EA formation. Interestingly this result is the opposite of 
that observed in the case of the metabolites RG-EA and 3OH-RG-EA. Taking together these 
experimental data allowed to exclude the involvement of propiolaldehyde in the metabolic 
formation of AI-EA. Further investigation is required to establish the mechanism of 
formation for the metabolite AI-EA. 
 
8.3.3 Metabolites RG-EA (m/z 226) and 3OH-RG-EA (m/z 242) 
The formation of metabolite RG-EA (m/z 226) was observed in RLM and HLM incubations 
performed at 500µM rasagiline concentration (Figura 1d,e and 2d,e), whereas at 100µM 
rasagiline concentration RG-EA was not detected.  
The protonated molecule [M+H]
+
 at m/z 226 (+54 Da more than RG) suggested the addition 
of propiolaldehyde to the structure of rasagiline. The rationale of this hypothesis was based on 
the known reactivity of propiolaldehyde with the amine derivatives to form the 
enaminoaldehyde. Indeed, since the propiolaldehyde was formed during the enzymatic N-
dealkylation of RG, it could react with another molecule of RG to give RG-EA; the high 
concentration (500µM) of rasagiline used in the incubation could favour this reaction. This 
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hypothesis was supported by the lack of RG-EA in the incubations carried out at lower 
concentration (100 µM) of rasagiline.  
To confirm our attribution, we synthetized the reference standard of RG-EA, exploiting the 
reaction of in situ generated propiolaldehyde with rasagiline; the retention time and the mass 
spectrum of the synthetic standard corresponded with those of the metabolite.  
The metabolite 3OH-RG-EA (m/z 242) was observed only in the incubations with RLM at 
higher concentration of rasagiline (500µM). The protonated molecule at [M+H]
+
 at m/z 242 
(+70 Da more than RG) and its mass spectrum (Figure 12), showing the presence of the 
diagnostic fragment ion at m/z 224 [M+H-18]
+
 (H2O loss), suggested the addiction of 





spectra of the metabolites RG-EA and 3OH-RG-EA 
 
The proposed mechanism of formation of RG-EA and 3OH-RG-EA was also confirmed by 
trapping of propiolaldehyde in RLM and HLM incubations using 2-mercaptoethanol as 
nucleophilic trapping agent; accordingly, in LC-MS
2
 chromatograms the metabolites RG-EA 
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Figure 13. Positive LC-MS
2
 chromatograms of RLM incubation (RG:500µM): (a) incubation without 2-




Figure 14. Positive LC-MS
2
 chromatograms of RLM incubation (RG:500µM): (a) incubation without 2-
mercaptoethanol, (b) incubation with 2-mercaptoethanol (3mM) monitoring the ion at m/z 242. 
 
 
Finally, in the RG incubations, done in the presence of 2-mercaptoethanol, the expected 
formation of the adduct of 2-mercaptoethanol and propiolaldehyde (MS-PROP; Figure 15) 
was observed by LC-UV analysis exploiting its absorption maximum at 291 nm (Figure 16). 
Indeed, the addiction of 2-mercaptoethanol to propioaldehyde caused a bathochromic spectral 
shift from 213 to 291 nm as previously highlighted by Demaster et.al (1982) regarding the 
glutathione-propiolaldehyde-adduct .   
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Figure 16. (a) LC-UV chromatogram (λa= 291) of RLM incubation (RG: 500µM) in the presence of 2-




Overall these data suggested that RG-EA and 3OH-RG-EA should not be considered as 
metabolites but artifacts due to the high concentration of the rasagiline substrate used in the 
incubations; as a consequence, their formation in vivo conditions could be excluded. 
Moreover, to complete the investigation, HIM incubations were performed to evaluate the 
oxidative metabolism of rasagiline: no metabolites were formed in this condition. 
  










































The metabolic scheme for the in vitro metabolism of RG was shown in Figure 17 and was 
elucidated in presence of both rat and human microsomes. The structural characterization of 
unknown metabolites was performed by means of LC-MS and LC-UV analysis. Beside the 
well-known 1-(R)-aminoindan and 3-hydroxy-rasagiline some new metabolites arising from 
oxidative metabolism were identified. Rasagiline underwent N-oxidation giving the 
corresponding hydroxylamine RG-NOH and possibly AI-EA whose mechanism of formation 
is still under investigation. The presence of RG-NOH was confirmed by glucuronidation of 
hydroxylamine function and by means of its synthesis. Moreover the metabolite AI-EA was 
observed even if the mechanism of its formation was not clarified. The metabolites RG-EA 
and 3OH-RG-EA formed by the addition of propiolaldeide were considered artifacts since 
their presence was detected in incubations performed at 500µM of RG.  
The pharmacological activity of rasagiline metabolites will be evaluated studying the 
potential activity of these compounds as MAO enzyme inhibitors. Besides, AI-EA, RG-NOH 
and RG-EA will be tested on indoleamine 2,3-dioxygenase (IDO) enzyme, since the indan 
scaffold could have a favourable role in its inhibition. This is relevant since IDO enzyme is 




Figure 17.  In vitro metabolic scheme of rasagiline. The structures in parentheses indicate the artifacts  
RG [M+H]+ = 172AI [M+H]+ = 134
RG-NOH [M+H]+ = 188
3OH-RG [M+H]+ = 188
AI-EA [M+H]+ = 188
3OH-RG-EA [M+H]+ = 242

















RG-NOH-Glu [M-H]- = 362
RLM + UDPGA






 rasagiline mesylate (package insert), 2006 Kansas City, MO: TEVA neuroscience. 
Bar-Am, O., Weinreb, O., Amit, T., and Youdim, M. B. H. (2010). The neuroprotective 
mechanism of 1-( R )-aminoindan, the major metabolite of the anti-parkinsonian drug 
rasagiline. Journal of Neurochemistry, 112, 1131–1137.  
Beckett A.H., Purkayastha A.R., Morgan P. H. (1977). Oxidation of aliphatic hydroxylamines 
in acqueos solutions. Journal of Pharmacy and Pharmacology, 29, 15–21. 
Cashman, J., Xiong, Y. N., Xu, L., & Janowsky, A. (1999). N-Oxygenation of Amphetamine 
and Methamphetamine by the Human Flavin-Containing Monooxygenase (Form 3): 
Role in Bioactivation and Detoxication. The Journal of Pharmacology and Experimental 
Therapeutics, 288(3), 1251–1260. 
Chen, J.J., Swope, D. M. (2005). Clinical Pharmacology of Rasagiline: A Novel, Second-
Generation Propargylamine for the treatment of Parkinson Disease. Therapeutic Review, 
45, 878–894. 
Chen, J. J., Swope, D. M., & Dashtipour, K. (2007). Comprehensive Review of Rasagiline, a 
Second-Generation Monoamine Oxidase Inhibitor, for the Treatment of Parkinson’s 
Disease. Clinical Therapeutics, 29(9), 1825–1849.  
Demaster Eugene G., Sumner Hatton W., Kaplan Eli, Shirota Frances N., Nagasawa H. T. 
(1982). Pargyline-induced hepatotoxicity: possible mediation by the reactive metabolite, 
propiolaldehyde. Toxicology and Applied Pharmacology, 65, 390–401. 
European Medicines Agency, Product information, 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/
human/000574/WC500030048.pdf , 2009; last accessed 28
th
 December 2015  
European Medicines Agency, Scientific discussion, 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussio
n/human/000574/WC500030046.pdf, 2005; last accessed 28
th
 December 2015 
 
Finberg, J. P. M. (2010). Pharmacology of Rasagiline , a New MAO-B Inhibitor Drug for the 
Treatment of Parkinson’s Disease with Neuroprotective Potential. Rambam Maimonides 
Medical Journal, 1(1), 1–10.  
Gong B., Boor PJ., (2006). The role of amine oxidases in xenobiotic metabolism. Expert 
Opinion on Drug Metabolism & Toxicology, 2, pp.559–71. 
Hanson, K. L., Vandenbrink, B. M., Babu, K. N., Allen, K. E., Nelson, W. L., & Kunze, K. L. 
(2010). Sequential Metabolism of Secondary Alkyl Amines to Metabolic- Intermediate 
Complexes : Opposing Roles for the Secondary Hydroxylamine and Primary Amine 
Metabolites of Desipramine, ( S )-Fluoxetine, and N- Desmethyldiltiazem. Drug 
Metabolism study of Rasagiline 
139 
 
Metabolism and Disposition, 38, 963–972. 
Herzig, Y. et al., (2006). Hydroxy-1-aminoindans and derivatives: preparation, stability, and 
reactivity. Journal of Organic Chemistry, 71(11), pp.4130–40. 
Lecht, S., Haroutiunian, S., Hoffman, A., & Lazarovici, P. (2007). Rasagiline - A novel MAO 
B inhibitor in Parkinson’s disease therapy. Therapeutics and Clinical Risk Management, 
3(3), 467–474. 
Luan, F. et al., (2013). TOPS-MODE model of multiplexing neuroprotective effects of drugs 
and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in 
neurodegenerative diseases. Bioorganic and Medicinal Chemistry, 21(7), pp.1870–1879. 
Ma, J., Chen, X., Duan, X., Deng, P., Wang, H., & Zhong, D. (2008). Validated LC–MS/MS 
method for quantitative determination of rasagiline in human plasma and its application 
to a pharmacokinetic study. Journal of Chromatography B, 873, 203–208 
Song, M., Wang, L., Zhao, H., Hang, T., Wen, A., Yang, L., & Jia, L. (2008). Rapid and 
sensitive liquid chromatography-tandem mass spectrometry: assay development, 
validation and application to a human pharmacokinetic study. Journal of 
Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 
875(2), 515–21. 
Sterling, J. et al., (2002). Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy 
Aminoindan and Phenethylamine as Potential Treatment for Alzheimer’s Disease. 
Journal of Medicinal Chemistry, 45, pp.5260–5279. 
Szabó, A. & Hermecz, I. (2001). Novel intramolecular rearrangement of tertiary 
propargylamine N-oxides. Journal of Organic Chemistry, 66(21), pp.7219–22. 
Tabakman R., Lecht S., Lazarovici, P., (2004). Neuroprotection by monoamine oxidase B 
inhibitors: a therapeutic strategy for Parkinson’s disease? Bioessays, 26, pp.80–90. 
Youdim, M.B.H., Gross, A. & Finberg, J.P.M. (2001). Rasagiline [N-propargyl-1R(+)-
aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. 






CHAPTER 9. Conclusion 
In this work, the study of the chemical and metabolic stability of oxybutynin, selegiline and 
rasagiline has been addressed and new degradation products and metabolites were identified. 
Overall, the results and, in particular, the similarity observed in the chemical and metabolic 
degradation of these drugs, confirmed the rationality in conducting the study in an integrated 
manner. Indeed, oxybutynin, selegiline and rasagiline underwent to extensive N-oxidation, 
both in chemical and metabolic stability studies. The N-oxidation of tertiary propargylamines 
(Oxy and SG) is characterized by the formation of unstable N-oxides which are involved in 
the generation of their rearrangement products, Oxy-EK and SG-EA.  
Contrary to Oxy and SG N-oxides, the stability of Oxy-EK and SG-EA allow their use as the 
indicator of stability in the development and validation of stability-indicating analytical 
methods used in drug substance and drug product stability studies. Similarly, the formation of 
N-oxides of Oxy and SG and the corresponding metabolites Oxy-EK and SG-EA were also 
observed in microsomal incubations: their mechanism of formation was the same found in the 
chemical stability study. 
The chemical oxidation of the secondary propargylamine RG give rise to the corresponding 
rasagiline hydroxylamine (RG-NOH) or the enaminoaldehyde derivative RG-EA depending 
on the stressor used (hydrogen peroxide or ACVA respectively). While the mechanism of 
formation of RG-NOH in the presence of hydrogen peroxide could be easily attributed, the 
formation of RG-EA remains to establish.  Moreover, the presence of RG-NOH and AI-EA 
was found in the in vitro metabolism: interestingly, while the enzymatic oxidation of RG to 
RG-NOH corresponds to a known metabolic pathway, the formation of AI-EA through RG 
enzymatic oxidation was not fully understood at the present time. 
As expected, the oxidative chemical degradation of propargylamines is dependent on the pH 
and the unionized form results more prone to oxidation than the protonated one. This feature 
should be taken into account in the stability study of drug products (e.g. transdermal delivery 
system) containing Oxy, SG and RG in their unionized forms.  
The presence in the structure of Oxy-EK, SG-EA and RG-EA of a α,β-unsaturated carbonyl 
function, which could behave as a Michael acceptor reacting with nucleophilic functions of 
biological macromolecules, suggest to test these compounds for their potential 
toxicity/genotoxicity. At present time, the mutagenic power of Oxy-EK was evaluated 
indicating a lack of mutagenic effects for this compound. Moreover, the potential 




(antimuscarinic activity, monoamine-oxidase (MAO) and indoleamine 2,3-dioxygenase (IDO) 
enzyme inhibition and neuroprotective activity). 
At the end of this study on chemical and metabolic stability studies of Oxy, SG and RG a 
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CHAPTER 10. In vitro phenotyping: new insights with the cocktail 
approach 
 
The following study was carried out during my PhD term abroad at the University of Geneva 
(Laboratory of Pharmaceutical Analytical Chemistry, School of Pharmaceutical Sciences) 
under the supervision of Prof. Serge Rudaz. 
  
10.1 INTRODUCTION 
Cytochromes P450 (CYPs) are the major phase I metabolic enzymes involved in the 
biotransformation of xenobiotics and endogenous compounds. The activity of CYPs is 
characterized by a high interindividual variability due to environmental factors (e.g., diet, 
drug therapy, toxic substances) and/or genetic polymorphisms, which are part of the 
individual CYP phenotype. Certain major isoforms of the CYP superfamily involved in the 
metabolism of marketed drugs (CYP2C9, CYP2C19, and CYP2D6) are recognized as highly 
polymorphic. According to the type of allelic variant affecting these CYPs, genetic 
polymorphism can significantly alter their metabolic activity, thus modifying the clinical 
response and/or increasing the risk of drug-drug interactions (DDI).  
The evaluation of genetic polymorphism can be performed by sequencing the DNA of the 
CYP genes (genotyping) or by determining the CYP expression/activity (phenotyping). In 
certain cases, owing to the genetic and epigenetic regulations, the relationship between the 
CYP gene and the enzymatic activity is not trivial, which makes the test selection (e.g., 
constitutional or functional) for predicting the drug’s clinical response difficult.  
Currently, in vitro phenotyping of CYPs has been successfully used to enhance the 
background understanding of the behavior of polymorphic CYPs involved in xenobiotic 
metabolism and DDI. The cocktail approach is an advantageous strategy used to monitor the 
activities of several cytochromes P450 (CYPs) in a single test to increase the throughput of in 
vitro phenotyping studies.  
The Geneva cocktail assay was developed with eight CYP-specific probe substrates to 
simultaneously evaluate the activity of the most important CYPs, namely, CYP1A2, 
CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and the CYP3A subfamily. 
After cocktail incubation in the presence of human liver microsomes (HLMs), the eight 
selected substrates and their specific metabolites were analyzed by ultra-high-pressure liquid 
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chromatography and electrospray ionization quadrupole time-of-flight mass spectrometry. 
The cocktail was previously tested on HLMs with different allelic variants and in presence of 
selective inhibitors. The results were in agreement with the genetic polymorphisms of the 
CYPs and the expected effect of the alterations, confirming the reliability of this cocktail 
assay for phenotyping of the microsomal CYPs (Spaggiari et al., 2014). 
In this work the cocktail was tested in presence of oxybutynin (Oxy) and oxybutynin 
metabolites (N-desethyloxybutynin (Oxy-DE) and Oxy-EK) studying the effect of these 
metabolites as potential inhibitor of CYPs. This application was suggested by considering that 




10.2.1 Materials and methods 
Methanol (MeOH), acetonitrile (ACN), and water of ultra LC–MS grade were purchased from 
Biosolve (Valkenswaard, Netherlands). Formic acid (98–100 %) was obtained from Merck 
(Darmstadt, Germany). Chlorzoxazone (98 %), 6-hydroxychlorzoxazone (97 %), (±)-4-
hydroxymephenytoin (98 %), 4′-hydroxyflurbiprofen (98 %), and hydroxybupropion (95 %) 
were purchased from Toronto Research Chemicals (Toronto ON, Canada). Potassium 
hydroxide, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt (HEPES) (99.5 
%), dextromethorphan hydrobromide (99 %), dextrorphan tartrate (98 %), bupropion 
hydrochloride (98 %), phenacetin (97 %), acetaminophen (99 %), flurbiprofen (99 %), 
coumarin (99 %), 7-hydroxycoumarin (99 %), were obtained from Sigma-Aldrich (Buchs, 
Switzerland), whereas methanolic stock solutions of midazolam and 1-hydroxymidazolam 
were purchased from Lipomed (Arlesheim, Switzerland). (S)- Mephenytoin (99 %) was 
obtained from Enzo Life Sciences (Lausen, Switzerland), reduced β-nicotinamide adenine 
dinucleotide 2′-phosphate tetrasodium salt (NADPH) (96 %) was obtained from Applichem 
(Darmstadt, Germany). Pooled HLMs from 30 donors were purchased from BD Biosciences 
(Allschwil, Switzerland). The substrate, metabolite, and inhibitor stock solutions at 1 mg/mL 
were prepared in MeOH and stored at −20 °C for 6 months or less.  
Oxybutynin, Oxy-DE and Oxy-EK were supplied by the Laboratory of Pharmaceutical and 
Analytical Chemistry, Department of Pharmaceutical Sciences (Novara).   
In vitro phenotyping: new insights with the cocktail approach 
144 
 
10.2.2 UHPLC-QTOF instrumentation 
The chromatographic analyses were performed with an Acquity UPLC system (Waters, 
Milford, MA, USA) able to deliver mobile phases at a pressure of up to 1,000 bar. The 
equipment includes a binary solvent manager with a maximum delivery flow rate of 2 
mL/min, an autosampler with a 2-μL loop operating in full-loop injection mode, and a column 
manager composed of a precolumn eluent heater and a column oven set to 40 °C. The UPLC 
system was coupled in an optimized configuration with a Xevo
®
 QTOF mass spectrometer 
(Waters, Milford, MA, USA) fitted with a Z-spray electrospray ionization (ESI) source. The 
samples were stored at 4 °C in the autosampler prior to and during the analysis. Data 
acquisition, data handling, and instrument control were performed by MassLynx version 4.1 
(Waters, Milford,MA, USA). The reversed-phase LC separations were performed on a Waters 
100 mm×2.1 mm XBridge
TM
 BEH C18 XP column with 2.5-μm particle size and a flow rate of 
400 μL/min in gradient mode (solvent A, water with 0.1 % formic acid; solvent B, ACN with 
0.1 % formic acid, 2–75 % solvent B in 15 min, up to 95 % solvent B in 0.2 min, held at 95 % 
solvent B to 0.5 min, then column reconditioning at 2 % solvent B to 18 min), with the eluate 
from the first 0.5 min diverted to waste. 
 
10.2.3 MS operating conditions 
The analysis were carried out in TOF detection mode. Regarding the MS operating 
conditions, the desolvation gas (nitrogen) flow was set to 1,000 L/h with a temperature of 500 
°C, the source temperature was 150 °C, the cone gas (nitrogen) flow rate was 20 L/h, the 
collision gas (argon) flow rate was 0.2 mL/min, and the capillary voltage was 3.0 kV in the 
positive mode and 2.4 kV in the negative mode. The cone voltage and the extraction cone 
voltage were similar in both positive and negative mode at 30 V and 4.1 V, respectively. The 
data were collected in the V-optics centroid mode over an m/z range of 100–1,000 with an 
accumulation time of 0.2 s. An independent reference lock-mass ion was infused through the 
LockSpray™ interface to ensure accuracy and to decrease acquisition variability. A solution 
of leucine-enkephalin (m/z 556.2771) at a concentration of 0.2 μg/mL in 1:1 (v/v) ACN/water 
plus 0.1 % formic acid was used as the reference compound and was infused at a flow rate of 
10 μL/min. The LockSpray frequency was set to 20 s (scan duration of 1 s) and the data were 
averaged over five spectra. 
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10.2.4 Incubation method 
All of the microsomal incubations were performed in duplicate in a final incubation volume 
of 100 μL. The reaction medium contained 50 mM HEPES (pH 7.4), excess NADPH, 0.5 mg 
protein per milliliter of HLMs, and the cocktail of substrates. The final substrate 
concentrations were obtained by adding the required volume of the cocktail solution to the 
reaction medium. These concentrations were as follows: 50 μM for phenacetin, 2 μM for 
coumarin, 5 μM for bupropion, 5 μM for flurbiprofen, 100 μM for (S)-mephenytoin, 5 μM for 
dextromethorphan, 40 μM for chlorzoxazone, and 2.5 μM for midazolam. The final organic 
solvent (MeOH) concentration was 0.5 % (v/v). After preincubation for 3 min at 37 °C, the 
CYP-dependent phase I reactions were initiated by adding excess NADPH (2.0 mM). The 
incubation proceeded for 20 min at 37 °C under agitation (400 rpm). The enzymatic reaction 
was stopped by adding 100 μL of ice-cold ACN to the reaction medium. The precipitated 
proteins were removed by centrifugation (5 min at 10,000 rpm), and an aliquot (150 μL) of 
the resulting supernatant was transferred to a vial for LC–MS analysis.  
Oxy, Oxy-DE and Oxy-EK were tested at a single concentration of 10 μM. Each reagent was 
incubated in duplicate with the cocktail of substrates and the pooled HLMs under the 
previously described incubation conditions. 
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10.3 RESULTS AND DISCUSSION 
The eight CYP probe substrates of the cocktail, namely phenacetin (CYP1A2), coumarin 
(CYP2A6), bupropion (CYP2B6), flurbiprofen (CYP2C9), (S)-mephenytoin (CYP2C19), 
dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1), and midazolam (CYP3A 
subfamily), were selected to monitor simultaneously the metabolic activities of clinically and 
toxicologically relevant cytochromes in humans.  The different substrates of the cocktail and 
their concentration in incubation are reported in the Table 1.  
After cocktail incubation in the presence of human liver microsomes (HLMs), the eight 
selected substrates and their specific metabolites were analyzed by the UHPLC-(Q)TOF 
method (Figure 1). 
 
 
Table 1. The substrates selected for the cocktail approach, with their cytochrome P450 (CYP)-specific 
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On the one hand the mixture of the cocktail was incubated as control, on the other hand the 
mixture of the cocktail was exposed to inhibitor (Oxy, Oxy-DE and Oxy-EK) to estimate the 
nature and the impact of the interference on CYP activities. The CYP activity assessment was 
based on the metabolic ratio (area of CYP-specific metabolite to area of probe substrate). 
Moreover a radar plot was used as graphical representation of the profile of activity of CYPs 
to obtain a better comparison of the different assays. For clarity, the activities of the CYPs 
obtained using the cocktail approach were considered as reference values (e.g., 100 % of 
phase I activity, red octagon). This reference profile was represented on a radar plot in which 
each axis corresponds to the relative activity of the CYP. The logarithmic scale affords 
equivalent visual variations in cases of increasing and respective decreasing activities of the 
CYPs (Figure 2). For example, an activity increased by a factor of 2 (i.e. 200%) presents the 




CYPs Oxy Oxy-EK Oxy-DE 
1A2 74% 104% 67% 
2A6 61% 43% 60% 
2B6 61% 59% 27% 
2C9 72% 76% 84% 
2C19 63% 105% 61% 
2D6 73% 108% 72% 
2E1 96% 89% 85% 
3A subfamily 44% 45% 40% 
 
Figure 2. Radar plot obtained after incubation of Oxy, Oxy-EK and Oxy-DE in presence of the cocktail. 
CYP metabolic ratios are expressed as a percentage of the metabolic ratios  
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The addition of Oxy, Oxy-EK and Oxy-DE at a concentration of 10µM reduced the CYP3A4 
activity for each compound, in addition Oxy-EK and Oxy-DE reduced the activity of 
CYP2A6 and CYP 2B6 respectively, whereas the activities of the other CYPs monitored were 
not modified compared with the original profile. These data are to be confirmed in presence 
of different inhibitor concentrations. 
These results allowed us to obtain further information regarding the potential activity of Oxy 
and oxybutynin metabolites as inhibitor of CYP isoforms. Moreover oxybutynin is recognized 
in literature as inhibitor of isoenzyme 2C8 (Walsky et al., 2005), suggesting to test these 
compounds in presence of a new cocktail assay in which the isoform 2C8 will be included.  
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Appendix I. Effect of Oxy and Oxy-EK on the number of spontaneous revertant colonies of Salmonella typhimurium TA1535, TA1537, TA1538, TA98 and 
TA100, and of Escherichia coli WP2uvrA and WP2uvrA/R in the absence of the metabolic activator S9. Values are expressed as means ± SEM (n = 6 replicates). 
 
Substance [μg/plate] 
Number of revertant colonies 
TA1535 TA1537 TA1538 TA98 TA100 WP2uvrA WP2uvrA/R 
Oxybutynin 9 149.0 ± 5.8 39.3 ± 2.3 38.7 ± 2.3 47.7 ± 2.2 150.3 ± 9.3 50.5 ± 3.5 151.0 ± 4.5 
         
 13 150.4 ± 7.5 39.7 ± 1.9 39.5 ± 1.7 49.3 ± 2.6 147.7 ± 6.2 49.5 ± 2.6 149.7 ± 7.6 
 18 153.2 ± 4.5 42.0 ± 1.7 41.5 ± 1.4 47.0 ± 2.1 147.0 ± 4.1 51.8 ± 3.7 149.4 ± 5.5 
 25 153.7 ± 6.4 41.1 ± 3.1 40.8 ± 2.9 49.3 ± 1.8 153.1 ± 7.7 50.5 ± 2.8 153.1 ± 8.6 
 36 151.3 ± 8.0 40.1 ± 2.2 40.7 ± 1.6 49.7 ± 2.9 149.7 ± 8.9 50.7 ± 3.1 151.5 ± 6.0 
 50    107.5 ± 11.3~t   31.3 ± 3.5~t   37.8 ± 1.8~t   40.0 ± 2.5~t    121.8 ± 12.9~t   41.4 ± 5.5~t   139.1 ± 9.7~t 
         
Oxy-EK 9  153.8 ± 3.6 39.1 ± 2.6 41.3 ± 1.5 48.7 ± 2.3 152.0 ± 6.1 51.3 ± 1.7 152.2 ± 7.3 
 13 154.8 ± 5.6 39.6 ± 2.0 39.4 ± 2.0 48.3 ± 1.8 153.3 ± 4.4 49.4 ± 2.0 153.1 ± 9.8 
 18 153.8 ± 7.9 41.2 ± 1.7 40.8 ± 1.7 48.3 ± 3.2 153.5 ± 7.5 50.7 ± 1.5 152.8 ± 8.3 
 25 156.0 ± 4.3 41.7 ± 1.5 41.8 ± 1.6 48.0 ± 2.7 154.0 ± 8.5 51.4 ± 1.2 153.4 ± 6.4 
 36 152.5 ± 7.4 40.8 ± 2.2 40.7 ± 1.4 49.0 ± 3.2 149.0 ± 5.2 49.9 ± 1.5 150.2 ± 5.8 
 50  132.0 ± 9.5~t   28.7 ± 2.0~t   32.7 ± 1.4~t   42.7 ± 1.8~t   129.4 ± 5.8~t   44.7 ± 1.4~t   135.9 ± 6.0~t 
Vehicle   150.7 ± 9.4 39.0 ± 2.1   39.7 ± 1.8 48.0 ± 2.3 148.0 ± 7.3   50.4 ± 1.3   152.0 ± 6.9 
2NF 2     164.3 ± 15.3 112.0 ± 9.5    
SA 1 513.7 ± 23.1    512.0 ± 42.6   
MMS 500      223.3 ± 12.5 529.0 ± 11.5 
9AA 50  156.0 ± 17.3      
a 
DMSO 50 µl/plate. 
~t






Appendix II. Effect of Oxy and Oxy-EK on the number of spontaneous revertant colonies of Salmonella typhimurium TA1535, TA1537, TA1538, TA98 and 




Number of revertant colonies 
TA1535 TA1537 TA1538 TA98 TA100 WP2uvrA WP2uvrA/R 
Oxybutynin 9 153.2 ± 9.2 42.5 ± 2.4 41.2 ± 2.2 49.7 ± 1.8 149.7 ± 6.8 51.0 ± 3.0 151.7 ± 5.5 
 13 153.0 ± 6.4 42.7 ± 2.0 41.9 ± 3.5 49.0 ± 2.1 150.0 ± 4.1 51.7 ± 2.3 152.0 ± 3.4 
 18 153.2 ± 3.2 41.9 ± 2.1 42.2 ± 2.1 48.3 ± 2.3 148.3 ± 5.3 51.9 ± 2.0 153.3 ± 4.5 
 25 154.8 ± 5.8 43.8 ± 3.4 42.4 ± 1.7 49.7 ± 2.5 149.8 ± 7.6 50.0 ± 1.6 152.2 ± 6.8 
 36 153.2 ± 8.5 42.5 ± 2.5 42.6 ± 1.8 49.0 ± 3.2 150.3 ± 3.3 53.2 ± 1.8 152.9 ± 3.9 
 50 152.4 ± 7.7 43.2 ± 1.5 41.7 ± 2.9 50.0 ± 3.2 148.8 ± 7.1 51.7 ± 2.2 153.8 ± 3.5 
         
Oxy-EK 9 153.0 ± 5.3 42.2 ± 2.6 41.3 ± 1.5 49.0 ± 1.7 149.0 ± 6.7 50.6 ± 4.1 152.5 ± 4.3 
 13 152.5 ± 7.1 42.4 ± 3.5 41.1 ± 2.8 49.5 ± 2.2 149.5 ± 5.2 51.2 ± 5.7 151.9 ± 6.2 
 18 154.6 ± 9.5 43.0 ± 2.2 42.4 ± 3.5 49.7 ± 2.3 149.7 ± 3.3 52.4 ± 2.5 151.5 ± 4.4 
 25 153.9 ± 8.3 43.7 ± 2.9 42.2 ± 2.6 49.4 ± 3.0 149.3 ± 3.7 52.2 ± 2.6 153.7 ± 5.1 
 36 154.7 ± 5.3 43.0 ± 2.7 41.7 ± 1.9 48.2 ± 2.6 149.8 ± 4.9 51.5 ± 1.9 153.1 ± 6.6 
 50 153.3 ± 6.0 41.4 ± 2.2 42.6 ± 2.2 50.1 ± 2.7 150.2 ± 6.4 49.5 ± 2.2 149.1 ± 5.2 
Vehicle  152.0 ± 5.1 42.0 ± 3.7   40.8 ± 2.9 49.3 ± 2.9 149.2 ± 5.3   51.5 ± 3.7   151.0 ± 4.6 
2AA 10  434.8 ± 19.3 423.7 ± 18.5    236.7 ± 9.6     380.3 ± 23.2 
2AA 1    438.3 ± 23.5 121.3 ± 11.1   334.8 ± 14.1   
         
a 
DMSO 50 µl/plate. 
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